



Clinical trial results:

A Dose Escalation (Phase 1), and Dose Expansion (Phase 2/3) Clinical Trial of Retinal Gene Therapy for X-linked Retinitis Pigmentosa Using an Adeno-Associated Viral Vector (AAV8) Encoding Retinitis Pigmentosa GTPase Regulator (RPGR)

Summary

EudraCT number	2016-003852-60
Trial protocol	GB
Global end of trial date	18 November 2020

Results information

Result version number	v1
This version publication date	02 June 2021
First version publication date	02 June 2021

Trial information

Trial identification

Sponsor protocol code	274RP101 (NSR-RPGR-01)
-----------------------	------------------------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT03116113
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Biogen
Sponsor organisation address	225 Binney Street, Cambridge, United States, 02142
Public contact	Biogen Study Medical Director, Biogen, clinicaltrials@biogen.com
Scientific contact	Biogen Study Medical Director, Biogen, clinicaltrials@biogen.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	Yes
EMA paediatric investigation plan number(s)	EMA-002601-PIP01-19
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	Yes

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	24 March 2021
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	18 November 2020
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

The objective of the study is to evaluate the safety, tolerability and efficacy of a single sub-retinal injection of BIIB112 in subjects with X-linked retinitis pigmentosa (XLRP).

Protection of trial subjects:

Written informed consent was obtained from each subject or subject's legally authorized representative (e.g., legal guardian), as applicable, prior to evaluations performed for eligibility. Subjects or the subject's legally authorized representative were given adequate time to review the information in the informed consent/assent and were allowed to ask, and have answered, questions concerning all portions of the conduct of the study.

Background therapy:

In Part I, all subjects were prescribed to take 1 milligram per kilogram per day (mg/kg/day) prednisone/prednisolone for a total of 10 days (beginning 2 days before the vector injection, on the day of injection, and then for 7 days); followed by 0.5 mg/kg/day for 7 days; 0.25 mg/kg/day for 2 days; and 0.125 mg/kg/day for 2 days (21 days in total). In Part II subjects in treated groups were given a 9-week course of oral prednisone/prednisolone and instructed to start taking the drug 3 days before Visit 2.

Evidence for comparator: -

Actual start date of recruitment	16 March 2017
Long term follow-up planned	Yes
Long term follow-up rationale	Efficacy, Safety
Long term follow-up duration	5 Years
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	United Kingdom: 25
Country: Number of subjects enrolled	United States: 25
Worldwide total number of subjects	50
EEA total number of subjects	0

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0

Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	1
Adults (18-64 years)	49
From 65 to 84 years	0
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

Subjects were enrolled at investigational sites in the United Kingdom (UK) and the United States (US) from 16 March, 2017 to 18 November, 2020.

Pre-assignment

Screening details:

A total of 50 subjects with X-Linked Retinitis Pigmentosa (XLRP) were randomised in the study and received treatment (18 subjects in Part 1 and 32 subjects in Part 2). Of these, 47 subjects completed the study (18 subjects in Part 1 and 29 in Part 2).

Period 1

Period 1 title	Overall Period (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Monitor, Carer, Data analyst, Assessor

Blinding implementation details:

Part 1 of the study was open label and Part II was double-masked to the assigned dose, and open-label with respect to the treatment procedure. Primary efficacy endpoint data for Part 2 was also masked.

Arms

Are arms mutually exclusive?	Yes
Arm title	Part 1: BIIB112 Dose 1

Arm description:

Followed by vitrectomy and retinal detachment in the study eye, subjects received a single Dose 1 (5×10^9 vector genomes {vg}) of BIIB112 by sub-retinal injection on Day 0 (surgery day).

Arm type	Experimental
Investigational medicinal product name	BIIB112
Investigational medicinal product code	
Other name	AAV8-RPGR
Pharmaceutical forms	Suspension for injection
Routes of administration	Intraocular use

Dosage and administration details:

Single, subretinal injection, Day 0.

Arm title	Part 1: BIIB112 Dose 2
------------------	------------------------

Arm description:

Followed by vitrectomy and retinal detachment in the study eye, subjects received a single Dose 2 (1×10^{10} vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).

Arm type	Experimental
Investigational medicinal product name	BIIB112
Investigational medicinal product code	
Other name	AAV8-RPGR
Pharmaceutical forms	Suspension for injection
Routes of administration	Intraocular use

Dosage and administration details:

Single, subretinal injection, Day 0.

Arm title	Part 1: BIIB112 Dose 3
------------------	------------------------

Arm description:

Followed by vitrectomy and retinal detachment in the study eye, subjects received a single Dose 3 (5×10^{10} vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).

Arm type	Experimental
Investigational medicinal product name	BIIB112
Investigational medicinal product code	
Other name	AAV8-RPGR
Pharmaceutical forms	Suspension for injection
Routes of administration	Intraocular use
Dosage and administration details: Single, subretinal injection, Day 0.	
Arm title	Part 1: BIIB112 Dose 4
Arm description: Followed by vitrectomy and retinal detachment in the study eye, subjects received a single Dose 4 (1×10^{11} vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).	
Arm type	Experimental
Investigational medicinal product name	BIIB112
Investigational medicinal product code	
Other name	AAV8-RPGR
Pharmaceutical forms	Suspension for injection
Routes of administration	Intraocular use
Dosage and administration details: Single, subretinal injection, Day 0.	
Arm title	Part 1: BIIB112 Dose 5
Arm description: Followed by vitrectomy and retinal detachment in the study eye, subjects received a single Dose 5 (2.5×10^{11} vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).	
Arm type	Experimental
Investigational medicinal product name	BIIB112
Investigational medicinal product code	
Other name	AAV8-RPGR
Pharmaceutical forms	Suspension for injection
Routes of administration	Intraocular use
Dosage and administration details: Single, subretinal injection, Day 0.	
Arm title	Part 1: BIIB112 Dose 6
Arm description: Followed by vitrectomy and retinal detachment in the study eye, subjects received a single Dose 6 (5×10^{11} vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).	
Arm type	Experimental
Investigational medicinal product name	BIIB112
Investigational medicinal product code	
Other name	AAV8-RPGR
Pharmaceutical forms	Suspension for injection
Routes of administration	Intraocular use
Dosage and administration details: Single, subretinal injection, Day 0.	
Arm title	Part 2: Untreated Group
Arm description: Subjects received no intervention to allow for a controlled comparison.	
Arm type	No intervention
No investigational medicinal product assigned in this arm	
Arm title	Part 2: BIIB112 Low Dose

Arm description:

Followed by vitrectomy and retinal detachment in study eye, subjects received a single low dose (5×10^{10} vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).

Arm type	Experimental
Investigational medicinal product name	BIIB112
Investigational medicinal product code	
Other name	AAV8-RPGR
Pharmaceutical forms	Suspension for injection
Routes of administration	Intraocular use

Dosage and administration details:

Single, subretinal injection, Day 0.

Arm title	Part 2: BIIB112 High Dose
------------------	---------------------------

Arm description:

Followed by vitrectomy and retinal detachment in study eye, subjects received a single high dose (2.5×10^{11} vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).

Arm type	Experimental
Investigational medicinal product name	BIIB112
Investigational medicinal product code	
Other name	AAV8-RPGR
Pharmaceutical forms	Suspension for injection
Routes of administration	Intraocular use

Dosage and administration details:

Single, subretinal injection, Day 0.

Number of subjects in period 1	Part 1: BIIB112 Dose 1	Part 1: BIIB112 Dose 2	Part 1: BIIB112 Dose 3
Started	3	3	3
Completed	3	3	3
Not completed	0	0	0
Withdrew due to COVID-19	-	-	-

Number of subjects in period 1	Part 1: BIIB112 Dose 4	Part 1: BIIB112 Dose 5	Part 1: BIIB112 Dose 6
Started	3	3	3
Completed	3	3	3
Not completed	0	0	0
Withdrew due to COVID-19	-	-	-

Number of subjects in period 1	Part 2: Untreated Group	Part 2: BIIB112 Low Dose	Part 2: BIIB112 High Dose
Started	9	11	12
Completed	9	10	10
Not completed	0	1	2
Withdrew due to COVID-19	-	1	2

Baseline characteristics

Reporting groups

Reporting group title	Part 1: BIIB112 Dose 1
Reporting group description: Followed by vitrectomy and retinal detachment in the study eye, subjects received a single Dose 1 (5×10^9 vector genomes {vg}) of BIIB112 by sub-retinal injection on Day 0 (surgery day).	
Reporting group title	Part 1: BIIB112 Dose 2
Reporting group description: Followed by vitrectomy and retinal detachment in the study eye, subjects received a single Dose 2 (1×10^{10} vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).	
Reporting group title	Part 1: BIIB112 Dose 3
Reporting group description: Followed by vitrectomy and retinal detachment in the study eye, subjects received a single Dose 3 (5×10^{10} vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).	
Reporting group title	Part 1: BIIB112 Dose 4
Reporting group description: Followed by vitrectomy and retinal detachment in the study eye, subjects received a single Dose 4 (1×10^{11} vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).	
Reporting group title	Part 1: BIIB112 Dose 5
Reporting group description: Followed by vitrectomy and retinal detachment in the study eye, subjects received a single Dose 5 (2.5×10^{11} vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).	
Reporting group title	Part 1: BIIB112 Dose 6
Reporting group description: Followed by vitrectomy and retinal detachment in the study eye, subjects received a single Dose 6 (5×10^{11} vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).	
Reporting group title	Part 2: Untreated Group
Reporting group description: Subjects received no intervention to allow for a controlled comparison.	
Reporting group title	Part 2: BIIB112 Low Dose
Reporting group description: Followed by vitrectomy and retinal detachment in study eye, subjects received a single low dose (5×10^{10} vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).	
Reporting group title	Part 2: BIIB112 High Dose
Reporting group description: Followed by vitrectomy and retinal detachment in study eye, subjects received a single high dose (2.5×10^{11} vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).	

Reporting group values	Part 1: BIIB112 Dose 1	Part 1: BIIB112 Dose 2	Part 1: BIIB112 Dose 3
Number of subjects	3	3	3
Age Categorical Units: subjects			
Age Continuous Units: years arithmetic mean standard deviation	36.3 ± 6.35	34.3 ± 10.69	30.0 ± 2.65
Gender Categorical Units: subjects			
Female	0	0	0

Male	3	3	3
------	---	---	---

Ethnicity			
Units: Subjects			
Hispanic or Latino	0	0	0
Not Hispanic or Latino	3	3	3
Race			
Units: Subjects			
White	3	3	3
Black, of African Heritage	0	0	0
Asian	0	0	0
Multiple	0	0	0
Other	0	0	0

Reporting group values	Part 1: BIIB112 Dose 4	Part 1: BIIB112 Dose 5	Part 1: BIIB112 Dose 6
Number of subjects	3	3	3
Age Categorical			
Units: subjects			

Age Continuous			
Units: years			
arithmetic mean	33.3	25.0	32.3
standard deviation	± 14.57	± 5.00	± 15.31
Gender Categorical			
Units: subjects			
Female	0	0	0
Male	3	3	3
Ethnicity			
Units: Subjects			
Hispanic or Latino	0	0	1
Not Hispanic or Latino	3	3	2
Race			
Units: Subjects			
White	3	3	3
Black, of African Heritage	0	0	0
Asian	0	0	0
Multiple	0	0	0
Other	0	0	0

Reporting group values	Part 2: Untreated Group	Part 2: BIIB112 Low Dose	Part 2: BIIB112 High Dose
Number of subjects	9	11	12
Age Categorical			
Units: subjects			

Age Continuous			
Units: years			
arithmetic mean	33.7	30.6	26.8
standard deviation	± 13.83	± 8.83	± 7.11

Gender Categorical Units: subjects			
Female	0	0	0
Male	9	11	12
Ethnicity Units: Subjects			
Hispanic or Latino	2	3	5
Not Hispanic or Latino	7	8	7
Race Units: Subjects			
White	6	9	12
Black, of African Heritage	0	1	0
Asian	0	1	0
Multiple	1	0	0
Other	2	0	0

Reporting group values	Total		
Number of subjects	50		
Age Categorical Units: subjects			

Age Continuous Units: years arithmetic mean standard deviation	-		
Gender Categorical Units: subjects			
Female	0		
Male	50		
Ethnicity Units: Subjects			
Hispanic or Latino	11		
Not Hispanic or Latino	39		
Race Units: Subjects			
White	45		
Black, of African Heritage	1		
Asian	1		
Multiple	1		
Other	2		

End points

End points reporting groups

Reporting group title	Part 1: BIIB112 Dose 1
Reporting group description: Followed by vitrectomy and retinal detachment in the study eye, subjects received a single Dose 1 (5×10^9 vector genomes {vg}) of BIIB112 by sub-retinal injection on Day 0 (surgery day).	
Reporting group title	Part 1: BIIB112 Dose 2
Reporting group description: Followed by vitrectomy and retinal detachment in the study eye, subjects received a single Dose 2 (1×10^{10} vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).	
Reporting group title	Part 1: BIIB112 Dose 3
Reporting group description: Followed by vitrectomy and retinal detachment in the study eye, subjects received a single Dose 3 (5×10^{10} vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).	
Reporting group title	Part 1: BIIB112 Dose 4
Reporting group description: Followed by vitrectomy and retinal detachment in the study eye, subjects received a single Dose 4 (1×10^{11} vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).	
Reporting group title	Part 1: BIIB112 Dose 5
Reporting group description: Followed by vitrectomy and retinal detachment in the study eye, subjects received a single Dose 5 (2.5×10^{11} vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).	
Reporting group title	Part 1: BIIB112 Dose 6
Reporting group description: Followed by vitrectomy and retinal detachment in the study eye, subjects received a single Dose 6 (5×10^{11} vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).	
Reporting group title	Part 2: Untreated Group
Reporting group description: Subjects received no intervention to allow for a controlled comparison.	
Reporting group title	Part 2: BIIB112 Low Dose
Reporting group description: Followed by vitrectomy and retinal detachment in study eye, subjects received a single low dose (5×10^{10} vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).	
Reporting group title	Part 2: BIIB112 High Dose
Reporting group description: Followed by vitrectomy and retinal detachment in study eye, subjects received a single high dose (2.5×10^{11} vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).	

Primary: Part 1: Number of Subjects with Dose-Limiting Toxicities (DLTs)

End point title	Part 1: Number of Subjects with Dose-Limiting Toxicities (DLTs) ^{[1][2]}
End point description: DLTs are defined as any of the following events considered to be related to AAV8-RPGR: Sustained decrease in best-corrected visual acuity (BCVA) of ≥ 30 letters on the Early Treatment of Diabetic Retinopathy Study (ETDRS) chart compared to baseline (sustained is defined as lasting 48 hours or more until recovery, with recovery defined as visual acuity (VA) returning to within 10 letters of baseline VA. An exception is made for surgery-related events occurring in close temporal association {within <24 hours} of the surgery); Vitreous inflammation, vitritis (>Grade 3 using standardised Nussenblatt vitreous inflammation scale grading); Any clinically significant retinal damage observed that is not directly attributed to complications of surgery; Any clinically relevant suspected unexpected serious adverse reaction, with the exception of vision loss or vision threatening. Safety analysis set included all subjects who received study treatment (vitrectomy/AAV8-RPGR).	
End point type	Primary

End point timeframe:

Up to Month 24

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive analysis was planned for this endpoint.

[2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was for Part 2, hence data was reported for Part 2 reporting arm groups only.

End point values	Part 1: BIIB112 Dose 1	Part 1: BIIB112 Dose 2	Part 1: BIIB112 Dose 3	Part 1: BIIB112 Dose 4
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	3	3	3
Units: subjects	0	0	0	0

End point values	Part 1: BIIB112 Dose 5	Part 1: BIIB112 Dose 6		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	3	3		
Units: subjects	0	0		

Statistical analyses

No statistical analyses for this end point

Primary: Part 1: Number of Subjects with Treatment-Emergent Adverse Events (TEAEs)

End point title	Part 1: Number of Subjects with Treatment-Emergent Adverse Events (TEAEs) ^{[3][4]}
-----------------	---

End point description:

An AE is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. Safety analysis set included all subjects who received study treatment (vitrectomy/AAV8-RPGR).

End point type	Primary
----------------	---------

End point timeframe:

Up to Month 24

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive analysis was planned for this endpoint.

[4] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was for Part 2, hence data was reported for Part 2 reporting arm groups only.

End point values	Part 1: BIIB112 Dose 1	Part 1: BIIB112 Dose 2	Part 1: BIIB112 Dose 3	Part 1: BIIB112 Dose 4
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	3	3	3
Units: subjects	3	3	3	3

End point values	Part 1: BIIB112 Dose 5	Part 1: BIIB112 Dose 6		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	3	3		
Units: subjects	3	3		

Statistical analyses

No statistical analyses for this end point

Primary: Part 2: Percentage of Study Eyes with ≥ 7 Decibels (dB) Improvement from Baseline at ≥ 5 of the 16 Central Loci of the 10-2 Grid Assessed by Macular Integrity Assessment (MAIA) Microperimetry

End point title	Part 2: Percentage of Study Eyes with ≥ 7 Decibels (dB) Improvement from Baseline at ≥ 5 of the 16 Central Loci of the 10-2 Grid Assessed by Macular Integrity Assessment (MAIA) Microperimetry ^[5]
-----------------	--

End point description:

MAIA microperimetry assessment was measured in dB using a 10-2 grid of 68 points. Each point was labelled as '< 0', '0', or a positive integer. The point labelled as '< 0' was assigned a value of '-1' by MAIA in the calculation. Improvement in Retinal Sensitivity in center grid was defined as an increase from baseline of 7 or more decibels in any 5 or more points out of the 16 central points. Intent-to-treat (ITT) analysis set included all subjects that were randomised under the 3-arm randomisation schedules.

End point type	Primary
----------------	---------

End point timeframe:

Month 12

Notes:

[5] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: This endpoint was for Part 2, hence data was reported for Part 2 reporting arm groups only.

End point values	Part 2: Untreated Group	Part 2: BIIB112 Low Dose	Part 2: BIIB112 High Dose	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	9 ^[6]	8 ^[7]	8 ^[8]	
Units: percentage of study eyes				
number (confidence interval 80%)	22.2 (6.1 to 49.0)	37.5 (14.7 to 65.5)	25.0 (6.9 to 53.8)	

Notes:

[6] - 'Number of subjects analysed' signifies number of subjects analysed in this endpoint.

[7] - 'Number of subjects analysed' signifies number of subjects analysed in this endpoint.

Statistical analyses

Statistical analysis title	Untreated Group Vs BIIB112 Low Dose
Comparison groups	Part 2: Untreated Group v Part 2: BIIB112 Low Dose
Number of subjects included in analysis	17
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.3181
Method	Fisher's Exact-Boschloo test
Parameter estimate	Difference from Untreated Group
Confidence interval	
level	Other: 80 %
sides	2-sided
lower limit	-13.9
upper limit	43

Statistical analysis title	Untreated Group Vs BIIB112 High Dose
Comparison groups	Part 2: Untreated Group v Part 2: BIIB112 High Dose
Number of subjects included in analysis	17
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.5177
Method	Fisher's Exact-Boschloo test
Parameter estimate	Difference from Untreated Group
Confidence interval	
level	Other: 80 %
sides	2-sided
lower limit	-24.4
upper limit	30.5

Primary: Part 2: Number of Subjects with TEAEs

End point title	Part 2: Number of Subjects with TEAEs ^{[9][10]}
End point description:	
An AE is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. Safety analysis set included all subjects who received study treatment (vitrectomy/AAV8-RPGR).	
End point type	Primary

End point timeframe:

Up to Month 12

Notes:

[9] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive analysis was planned for this endpoint.

[10] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was for Part 2, hence data was reported for Part 2 reporting arm groups only.

End point values	Part 2: Untreated Group	Part 2: BIIB112 Low Dose	Part 2: BIIB112 High Dose	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	9	11	12	
Units: subjects	5	11	12	

Statistical analyses

No statistical analyses for this end point

Secondary: Part 1: Percentage of Study Eyes with ≥ 7 dB Improvement from Baseline at ≥ 5 out of the 16 Central Loci in Microperimetry

End point title	Part 1: Percentage of Study Eyes with ≥ 7 dB Improvement from Baseline at ≥ 5 out of the 16 Central Loci in Microperimetry ^[11]
-----------------	--

End point description:

MAIA microperimetry assessment was measured in dB using a 10-2 grid of 68 points. Each point was labelled as '< 0', '0' or a positive integer. The point labelled as '< 0' was assigned a value of '-1' by MAIA in the calculation. Improvement in Retinal Sensitivity in center grid was defined as an increase from baseline of 7 or more decibels in any 5 or more points out of the 16 central points. Safety analysis set consists of all subjects who received study treatment (vitrectomy/AAV8-RPGR). n=number of subjects analysed at specific timepoint.

End point type	Secondary
----------------	-----------

End point timeframe:

Month 1, 3, 6, 9, 12, 18 and 24

Notes:

[11] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was for Part 1, hence data was reported for Part 1 reporting arm groups only.

End point values	Part 1: BIIB112 Dose 1	Part 1: BIIB112 Dose 2	Part 1: BIIB112 Dose 3	Part 1: BIIB112 Dose 4
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3 ^[12]	2 ^[13]	3 ^[14]	3 ^[15]
Units: percentage of study eyes				
number (confidence interval 95%)				
Month 1 (n=3,2,3,3,3,3)	0.0 (0.0 to 70.8)	0.0 (0.0 to 84.2)	100.0 (29.2 to 100.0)	33.3 (0.8 to 90.6)
Month 3 (n=3,2,3,3,3,3)	0.0 (0.0 to 70.8)	0.0 (0.0 to 84.2)	66.7 (9.4 to 99.2)	33.3 (0.8 to 90.6)

Month 6 (n=3,2,3,3,3,3)	0.0 (0.0 to 70.8)	0.0 (0.0 to 84.2)	66.7 (9.4 to 99.2)	33.3 (0.8 to 90.6)
Month 9 (n=3,2,3,3,3,3)	0.0 (0.0 to 70.8)	0.0 (0.0 to 84.2)	66.7 (9.4 to 99.2)	33.3 (0.8 to 90.6)
Month 12 (n=3,2,3,3,2,3)	0.0 (0.0 to 70.8)	0.0 (0.0 to 84.2)	33.3 (0.8 to 90.6)	33.3 (0.8 to 90.6)
Month 18 (n=3,2,3,3,3,2)	0.0 (0.0 to 70.8)	0.0 (0.0 to 84.2)	66.7 (9.4 to 99.2)	33.3 (0.8 to 90.6)
Month 24 (n=3,1,3,3,3,3)	0.0 (0.0 to 70.8)	0.0 (0.0 to 97.5)	33.3 (0.8 to 90.6)	33.3 (0.8 to 90.6)

Notes:

[12] - 'Number of subjects analysed' signifies number of subjects analysed in this endpoint.

[13] - 'Number of subjects analysed' signifies number of subjects analysed in this endpoint.

[14] - 'Number of subjects analysed' signifies number of subjects analysed in this endpoint.

[15] - 'Number of subjects analysed' signifies number of subjects analysed in this endpoint.

End point values	Part 1: BIIB112 Dose 5	Part 1: BIIB112 Dose 6		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	3 ^[16]	3 ^[17]		
Units: percentage of study eyes				
number (confidence interval 95%)				
Month 1 (n=3,2,3,3,3,3)	33.3 (0.8 to 90.6)	33.3 (0.8 to 90.6)		
Month 3 (n=3,2,3,3,3,3)	33.3 (0.8 to 90.6)	0.0 (0.0 to 70.8)		
Month 6 (n=3,2,3,3,3,3)	0.0 (0.0 to 70.8)	33.3 (0.8 to 90.6)		
Month 9 (n=3,2,3,3,3,3)	0.0 (0.0 to 70.8)	33.3 (0.8 to 90.6)		
Month 12 (n=3,2,3,3,2,3)	50.0 (1.3 to 98.7)	33.3 (0.8 to 90.6)		
Month 18 (n=3,2,3,3,3,2)	0.0 (0.0 to 70.8)	0.0 (0.0 to 84.2)		
Month 24 (n=3,1,3,3,3,3)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)		

Notes:

[16] - 'Number of subjects analysed' signifies number of subjects analysed in this endpoint.

[17] - 'Number of subjects analysed' signifies number of subjects analysed in this endpoint.

Statistical analyses

No statistical analyses for this end point

Secondary: Part 1: Percentage of Study Eyes with ≥ 7 dB Improvement from Baseline at ≥ 5 Out of the 68 Loci in Microperimetry

End point title	Part 1: Percentage of Study Eyes with ≥ 7 dB Improvement from Baseline at ≥ 5 Out of the 68 Loci in Microperimetry ^[18]
-----------------	--

End point description:

MAIA microperimetry assessment was measured in dB using a 10-2 grid of 68 points. Each point was labelled as '< 0', '0' or a positive integer. The point labelled as '< 0' was assigned a value of '-1' by MAIA in the calculation. Improvement in Retinal Sensitivity in whole grid was defined as an increase from baseline of 7 or more decibels in any 5 or more points of the grid as a whole (68 points). Safety analysis set consists of all subjects who received study treatment (vitrectomy/AAV8-RPGR). n=number of subjects analysed at specific timepoint.

End point type	Secondary
----------------	-----------

End point timeframe:

Month 1, 3, 6, 9, 12, 18 and 24

Notes:

[18] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was for Part 1, hence data was reported for Part 1 reporting arm groups only.

End point values	Part 1: BIIB112 Dose 1	Part 1: BIIB112 Dose 2	Part 1: BIIB112 Dose 3	Part 1: BIIB112 Dose 4
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3 ^[19]	2 ^[20]	3 ^[21]	3 ^[22]
Units: percentage of study eyes				
number (confidence interval 95%)				
Month 1 (n=3,2,3,3,3,3)	0.0 (0.0 to 70.8)	0.0 (0.0 to 84.2)	100.0 (29.2 to 100.0)	33.3 (0.8 to 90.6)
Month 3 (n=3,2,3,3,3,3)	0.0 (0.0 to 70.8)	0.0 (0.0 to 84.2)	66.7 (9.4 to 99.2)	33.3 (0.8 to 90.6)
Month 6 (n=3,2,3,3,3,3)	0.0 (0.0 to 70.8)	0.0 (0.0 to 84.2)	100.0 (29.2 to 100.0)	33.3 (0.8 to 90.6)
Month 9 (n=3,2,3,3,3,3)	0.0 (0.0 to 70.8)	0.0 (0.0 to 84.2)	66.7 (9.4 to 99.2)	33.3 (0.8 to 90.6)
Month 12 (n=3,2,3,3,2,3)	0.0 (0.0 to 70.8)	50.0 (1.3 to 98.7)	66.7 (9.4 to 99.2)	66.7 (9.4 to 99.2)
Month 18 (n=3,2,3,3,3,2)	0.0 (0.0 to 70.8)	50.0 (1.3 to 98.7)	66.7 (9.4 to 99.2)	33.3 (0.8 to 90.6)
Month 24 (n=3,1,3,3,3,3)	0.0 (0.0 to 70.8)	0.0 (0.0 to 97.5)	33.3 (0.8 to 90.6)	66.7 (9.4 to 99.2)

Notes:

[19] - 'Number of subjects analysed' signifies number of subjects analysed in this endpoint.

[20] - 'Number of subjects analysed' signifies number of subjects analysed in this endpoint.

[21] - 'Number of subjects analysed' signifies number of subjects analysed in this endpoint.

[22] - 'Number of subjects analysed' signifies number of subjects analysed in this endpoint.

End point values	Part 1: BIIB112 Dose 5	Part 1: BIIB112 Dose 6		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	3 ^[23]	3 ^[24]		
Units: percentage of study eyes				
number (confidence interval 95%)				
Month 1 (n=3,2,3,3,3,3)	33.3 (0.8 to 90.6)	33.3 (0.8 to 90.6)		
Month 3 (n=3,2,3,3,3,3)	33.3 (0.8 to 90.6)	66.7 (9.4 to 99.2)		
Month 6 (n=3,2,3,3,3,3)	66.7 (9.4 to 99.2)	100.0 (29.2 to 100.0)		
Month 9 (n=3,2,3,3,3,3)	66.7 (9.4 to 99.2)	66.7 (9.4 to 99.2)		
Month 12 (n=3,2,3,3,2,3)	50.0 (1.3 to 98.7)	66.7 (9.4 to 99.2)		
Month 18 (n=3,2,3,3,3,2)	66.7 (9.4 to 99.2)	50.0 (1.3 to 98.7)		
Month 24 (n=3,1,3,3,3,3)	33.3 (0.8 to 90.6)	33.3 (0.8 to 90.6)		

Notes:

[23] - 'Number of subjects analysed' signifies number of subjects analysed in this endpoint.

[24] - 'Number of subjects analysed' signifies number of subjects analysed in this endpoint.

Statistical analyses

No statistical analyses for this end point

Secondary: Part 1: Change from Baseline in Mean Sensitivity of the 16 Central Loci

End point title	Part 1: Change from Baseline in Mean Sensitivity of the 16 Central Loci ^[25]
-----------------	---

End point description:

MAIA microperimetry assessment was measured in dB using a 10-2 grid of 68 points. Each point was labelled as '< 0', '0' or a positive integer. The point labelled as '< 0' is assigned a value of '-1' by MAIA in the calculation. Improvement in Retinal Sensitivity in center grid was defined as an increase from baseline of 7 or more decibels in any 5 or more points out of the 16 central points. Here negative values indicate a decline in retinal sensitivity. Safety analysis set included all subjects who received study treatment (vitrectomy/AAV8-RPGR). 99999 indicates that standard deviation was not evaluable as there was only 1 subject. n=number of subjects analysed at specific timepoint.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Month 1, 3, 6, 9, 12, 18 and 24

Notes:

[25] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was for Part 1, hence data was reported for Part 1 reporting arm groups only.

End point values	Part 1: BIIB112 Dose 1	Part 1: BIIB112 Dose 2	Part 1: BIIB112 Dose 3	Part 1: BIIB112 Dose 4
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3 ^[26]	2 ^[27]	3 ^[28]	3 ^[29]
Units: decibel				
arithmetic mean (standard deviation)				
Baseline: Study Eye (n=3,2,3,3,3,3)	0.33 (± 1.748)	1.78 (± 1.282)	3.35 (± 0.911)	6.52 (± 3.398)
Baseline: Non-Study Eye (n=3,2,3,3,3,3)	0.23 (± 1.358)	3.31 (± 2.563)	6.92 (± 2.221)	8.21 (± 5.570)
Change at Month 1: Study Eye (n=3,2,3,3,3,3)	0.52 (± 0.477)	-0.09 (± 0.928)	6.10 (± 0.844)	1.19 (± 6.094)
Change at Month 1: Non-Study Eye (n=3,2,3,3,3,3)	0.42 (± 1.122)	-0.81 (± 1.768)	-0.98 (± 1.531)	-0.19 (± 0.272)
Change at Month 3: Study Eye (n=3,2,3,3,3,3)	0.40 (± 0.407)	0.47 (± 1.282)	5.63 (± 2.394)	1.73 (± 8.714)
Change at Month 3: Non-Study Eye (n=3,2,3,3,3,3)	-0.06 (± 0.534)	-0.91 (± 0.575)	-1.15 (± 2.094)	0.33 (± 1.134)
Change at Month 6: Study Eye (n=3,2,3,3,3,3)	0.54 (± 0.485)	-0.06 (± 0.265)	5.10 (± 1.890)	3.25 (± 8.199)
Change at Month 6: Non-Study Eye (n=3,2,3,3,3,3)	-0.17 (± 0.344)	-0.34 (± 2.607)	-1.19 (± 1.535)	2.10 (± 3.437)
Change at Month 9: Study Eye (n=3,2,3,3,3,3)	0.21 (± 0.219)	0.09 (± 1.282)	4.65 (± 3.851)	3.69 (± 6.308)
Change at Month 9: Non-Study Eye (n=3,2,3,3,3,3)	-0.35 (± 0.509)	0.19 (± 2.210)	0.20 (± 2.751)	-0.06 (± 1.789)

Change at Month 12: Study Eye (n=3,2,3,3,2,3)	0.19 (± 0.272)	0.13 (± 1.945)	4.10 (± 2.908)	3.98 (± 5.090)
Change at Month 12: Non-Study Eye (n=3,2,3,3,2,3)	-0.10 (± 0.355)	-1.09 (± 1.370)	-1.02 (± 0.581)	0.42 (± 1.951)
Change at Month 18: Study Eye (n=3,2,3,3,3,2)	0.21 (± 0.473)	-1.13 (± 0.177)	2.69 (± 2.507)	2.92 (± 5.550)
Change at Month 18: Non-Study Eye (n=3,2,3,3,3,2)	-0.33 (± 0.577)	-1.09 (± 1.282)	0.02 (± 0.940)	-0.67 (± 0.806)
Change at Month 24: Study Eye (n=3,1,3,3,3,3)	0.04 (± 0.253)	-1.88 (± 99999)	2.75 (± 2.683)	1.48 (± 5.236)
Month 24: Non-Study Eye (n=3,1,3,3,3,3)	-0.46 (± 0.469)	-1.63 (± 99999)	-0.33 (± 1.347)	-0.56 (± 1.207)

Notes:

[26] - 'Number of subjects analysed' signifies number of subjects analysed in this endpoint.

[27] - 'Number of subjects analysed' signifies number of subjects analysed in this endpoint.

[28] - 'Number of subjects analysed' signifies number of subjects analysed in this endpoint.

[29] - 'Number of subjects analysed' signifies number of subjects analysed in this endpoint.

End point values	Part 1: BIIB112 Dose 5	Part 1: BIIB112 Dose 6		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	3 ^[30]	3 ^[31]		
Units: decibel				
arithmetic mean (standard deviation)				
Baseline: Study Eye (n=3,2,3,3,3,3)	13.46 (± 6.316)	7.75 (± 7.742)		
Baseline: Non-Study Eye (n=3,2,3,3,3,3)	13.71 (± 8.447)	7.54 (± 7.542)		
Change at Month 1: Study Eye (n=3,2,3,3,3,3)	-0.63 (± 4.154)	-1.90 (± 7.686)		
Change at Month 1: Non-Study Eye (n=3,2,3,3,3,3)	1.40 (± 2.690)	0.19 (± 2.063)		
Change at Month 3: Study Eye (n=3,2,3,3,3,3)	-3.58 (± 7.476)	-3.35 (± 2.894)		
Change at Month 3: Non-Study Eye (n=3,2,3,3,3,3)	2.06 (± 1.137)	-0.42 (± 0.289)		
Change at Month 6: Study Eye (n=3,2,3,3,3,3)	-2.38 (± 5.177)	0.85 (± 5.105)		
Change at Month 6: Non-Study Eye (n=3,2,3,3,3,3)	2.19 (± 0.933)	-0.65 (± 1.156)		
Change at Month 9: Study Eye (n=3,2,3,3,3,3)	-2.50 (± 5.314)	0.77 (± 7.096)		
Change at Month 9: Non-Study Eye (n=3,2,3,3,3,3)	2.52 (± 1.714)	0.40 (± 2.032)		
Change at Month 12: Study Eye (n=3,2,3,3,2,3)	2.25 (± 2.121)	0.56 (± 5.590)		
Change at Month 12: Non-Study Eye (n=3,2,3,3,2,3)	2.31 (± 2.990)	-0.29 (± 1.835)		
Change at Month 18: Study Eye (n=3,2,3,3,3,2)	-2.79 (± 6.733)	-1.09 (± 5.436)		
Change at Month 18: Non-Study Eye (n=3,2,3,3,3,2)	1.92 (± 3.085)	-0.59 (± 2.607)		
Change at Month 24: Study Eye (n=3,1,3,3,3,3)	-4.90 (± 5.250)	-1.88 (± 5.862)		
Month 24: Non-Study Eye (n=3,1,3,3,3,3)	0.71 (± 3.263)	-2.19 (± 2.189)		

Notes:

[30] - 'Number of subjects analysed' signifies number of subjects analysed in this endpoint.

[31] - 'Number of subjects analysed' signifies number of subjects analysed in this endpoint.

Statistical analyses

No statistical analyses for this end point

Secondary: Part 1: Change from Baseline in Mean Sensitivity of the 68 Central Loci

End point title	Part 1: Change from Baseline in Mean Sensitivity of the 68 Central Loci ^[32]
-----------------	---

End point description:

MAIA microperimetry assessment was measured in dB using a 10-2 grid of 68 points. Each point was labelled as '< 0', '0' or a positive integer. The point labelled as '< 0' is assigned a value of '-1' by MAIA in the calculation. Improvement in Retinal Sensitivity in whole grid was defined as an increase from baseline of 7 or more decibels in any 5 or more points of the grid as a whole (68 points). Here negative values indicate a decline in retinal sensitivity. Safety analysis set included all subjects who received study treatment (vitrectomy/AAV8-RPGR). 99999 indicates that standard deviation was not evaluable as there was only 1 subject. n=number of subjects analysed at specific timepoint.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Month 1, 3, 6, 9, 12, 18 and 24

Notes:

[32] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was for Part 1, hence data was reported for Part 1 reporting arm groups only.

End point values	Part 1: BIIB112 Dose 1	Part 1: BIIB112 Dose 2	Part 1: BIIB112 Dose 3	Part 1: BIIB112 Dose 4
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3 ^[33]	2 ^[34]	3 ^[35]	3 ^[36]
Units: decibel				
arithmetic mean (standard deviation)				
Baseline: Study Eye (n=3,2,3,3,3,3)	-0.19 (± 0.690)	0.20 (± 0.281)	0.21 (± 0.435)	2.22 (± 1.536)
Baseline: Non-Study Eye (n=3,2,3,3,3,3)	-0.38 (± 0.540)	1.47 (± 1.061)	1.50 (± 1.419)	2.30 (± 1.559)
Change at Month 1: Study Eye (n=3,2,3,3,3,3)	0.12 (± 0.309)	0.24 (± 1.185)	2.42 (± 0.283)	0.08 (± 2.436)
Change at Month 1: Non-Study Eye (n=3,2,3,3,3,3)	0.18 (± 0.481)	-0.76 (± 1.165)	-0.08 (± 0.938)	-0.11 (± 0.111)
Change at Month 3: Study Eye (n=3,2,3,3,3,3)	0.14 (± 0.137)	0.74 (± 1.820)	2.44 (± 1.564)	0.58 (± 5.061)
Change at Month 3: Non-Study Eye (n=3,2,3,3,3,3)	-0.06 (± 0.292)	-0.29 (± 1.549)	-0.29 (± 1.351)	0.68 (± 1.223)
Change at Month 6: Study Eye (n=3,2,3,3,3,3)	0.04 (± 0.334)	0.19 (± 0.957)	2.28 (± 1.534)	0.90 (± 5.011)
Change at Month 6: Non-Study Eye (n=3,2,3,3,3,3)	-0.24 (± 0.331)	-0.32 (± 1.872)	-0.51 (± 0.773)	3.86 (± 5.648)
Change at Month 9: Study Eye (n=3,2,3,3,3,3)	-0.18 (± 0.145)	0.31 (± 1.456)	2.02 (± 2.177)	0.90 (± 4.233)
Change at Month 9: Non-Study Eye (n=3,2,3,3,3,3)	-0.37 (± 0.467)	-0.12 (± 1.830)	1.66 (± 1.790)	0.77 (± 1.405)

Change at Month 12: Study Eye (n=3,2,3,3,2,3)	-0.16 (± 0.165)	0.30 (± 1.612)	1.72 (± 1.892)	1.28 (± 3.541)
Change at Month 12: Non-Study Eye (n=3,2,3,3,2,3)	-0.30 (± 0.417)	-0.46 (± 1.633)	-0.24 (± 0.153)	0.76 (± 1.345)
Change at Month 18: Study Eye (n=3,2,3,3,3,2)	-0.23 (± 0.213)	-0.50 (± 0.458)	1.16 (± 1.144)	1.37 (± 4.233)
Change at Month 18: Non-Study Eye (n=3,2,3,3,3,2)	-0.33 (± 0.412)	-0.57 (± 1.435)	0.07 (± 0.509)	0.18 (± 0.191)
Change at Month 24: Study Eye (n=3,1,3,3,3,3)	-0.40 (± 0.382)	-0.96 (± 99999)	1.17 (± 1.190)	0.98 (± 3.510)
Change at Month 24: Non-Study Eye (n=3,1,3,3,3,3)	-0.37 (± 0.427)	-1.44 (± 99999)	0.14 (± 0.221)	0.24 (± 0.153)

Notes:

[33] - 'Number of subjects analysed' signifies number of subjects analysed in this endpoint.

[34] - 'Number of subjects analysed' signifies number of subjects analysed in this endpoint.

[35] - 'Number of subjects analysed' signifies number of subjects analysed in this endpoint.

[36] - 'Number of subjects analysed' signifies number of subjects analysed in this endpoint.

End point values	Part 1: BIIB112 Dose 5	Part 1: BIIB112 Dose 6		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	3 ^[37]	3 ^[38]		
Units: decibel				
arithmetic mean (standard deviation)				
Baseline: Study Eye (n=3,2,3,3,3,3)	8.87 (± 10.784)	4.26 (± 6.732)		
Baseline: Non-Study Eye (n=3,2,3,3,3,3)	9.11 (± 12.466)	5.35 (± 8.579)		
Change at Month 1: Study Eye (n=3,2,3,3,3,3)	0.56 (± 3.243)	-1.69 (± 4.341)		
Change at Month 1: Non-Study Eye (n=3,2,3,3,3,3)	1.24 (± 1.639)	-0.66 (± 1.474)		
Change at Month 3: Study Eye (n=3,2,3,3,3,3)	-1.87 (± 4.073)	-0.60 (± 1.383)		
Change at Month 3: Non-Study Eye (n=3,2,3,3,3,3)	1.38 (± 1.005)	-0.65 (± 0.407)		
Change at Month 6: Study Eye (n=3,2,3,3,3,3)	-0.60 (± 1.596)	0.51 (± 2.154)		
Change at Month 6: Non-Study Eye (n=3,2,3,3,3,3)	1.76 (± 0.470)	-0.84 (± 1.101)		
Change at Month 9: Study Eye (n=3,2,3,3,3,3)	-0.87 (± 2.229)	-0.13 (± 4.044)		
Change at Month 9: Non-Study Eye (n=3,2,3,3,3,3)	2.05 (± 0.816)	-0.41 (± 1.157)		
Change at Month 12: Study Eye (n=3,2,3,3,2,3)	-0.22 (± 2.600)	-0.41 (± 4.208)		
Change at Month 12: Non-Study Eye (n=3,2,3,3,2,3)	1.72 (± 1.144)	-0.82 (± 1.248)		
Change at Month 18: Study Eye (n=3,2,3,3,3,2)	-0.72 (± 1.253)	-1.32 (± 4.721)		
Change at Month 18: Non-Study Eye (n=3,2,3,3,3,2)	1.24 (± 1.265)	-1.19 (± 2.267)		
Change at Month 24: Study Eye (n=3,1,3,3,3,3)	-2.37 (± 1.225)	-2.26 (± 6.009)		
Change at Month 24: Non-Study Eye (n=3,1,3,3,3,3)	0.75 (± 1.427)	-1.73 (± 2.481)		

Notes:

[37] - 'Number of subjects analysed' signifies number of subjects analysed in this endpoint.

[38] - 'Number of subjects analysed' signifies number of subjects analysed in this endpoint.

Statistical analyses

No statistical analyses for this end point

Secondary: Part 1: Change from Baseline in Best Corrected Visual Acuity (BCVA) Score

End point title	Part 1: Change from Baseline in Best Corrected Visual Acuity (BCVA) Score ^[39]
-----------------	---

End point description:

BCVA was assessed using the ETDRS VA chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. BCVA was to be reported as number of letters read correctly by the subject. An increase in the number of letters read correctly means that vision has improved. Here negative values indicate decline in BCVA. Safety analysis set included all subjects who received study treatment (vitrectomy/AAV8-RPGR).

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Month 1, 3, 6, 9, 12, 18 and 24

Notes:

[39] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was for Part 1, hence data was reported for Part 1 reporting arm groups only.

End point values	Part 1: BIIB112 Dose 1	Part 1: BIIB112 Dose 2	Part 1: BIIB112 Dose 3	Part 1: BIIB112 Dose 4
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	3	3	3
Units: letters				
arithmetic mean (standard deviation)				
Baseline: Study Eye	27.67 (± 8.145)	49.67 (± 9.452)	64.33 (± 7.095)	63.67 (± 20.551)
Baseline: Non-Study Eye	60.67 (± 2.082)	57.33 (± 5.686)	66.33 (± 2.517)	62.67 (± 22.279)
Change at Month 1: Study Eye	3.67 (± 3.055)	0.33 (± 2.517)	-1.00 (± 1.732)	-1.33 (± 6.506)
Change at Month 1: Non-Study Eye	3.00 (± 3.000)	1.00 (± 4.359)	1.00 (± 1.000)	0.33 (± 0.577)
Change at Month 3: Study Eye	6.33 (± 2.309)	0.00 (± 3.606)	0.67 (± 2.082)	1.67 (± 4.726)
Change at Month 3: Non-Study Eye	3.00 (± 1.000)	1.67 (± 1.528)	-1.67 (± 1.528)	2.33 (± 2.309)
Change at Month 6: Study Eye	5.00 (± 1.000)	-3.67 (± 3.786)	0.33 (± 0.577)	3.67 (± 5.686)
Change at Month 6: Non-Study Eye	-1.00 (± 7.211)	-0.67 (± 4.726)	-0.33 (± 3.215)	3.67 (± 3.055)
Change at Month 9: Study Eye	1.33 (± 4.619)	-0.67 (± 0.577)	1.33 (± 4.509)	4.00 (± 5.292)
Change at Month 9: Non-Study Eye	-5.00 (± 5.292)	-0.67 (± 5.033)	1.00 (± 1.000)	3.00 (± 3.606)
Change at Month 12: Study Eye	4.67 (± 4.509)	-2.00 (± 3.464)	0.67 (± 5.132)	4.33 (± 4.933)

Change at Month 12: Non-Study Eye	-1.67 (± 2.309)	-0.33 (± 3.215)	-0.33 (± 0.577)	2.00 (± 4.359)
Change at Month 18: Study Eye	3.00 (± 8.718)	-2.00 (± 3.606)	-3.33 (± 5.132)	3.33 (± 3.786)
Change at Month 18: Non-Study Eye	-4.00 (± 6.245)	0.00 (± 5.000)	-0.33 (± 2.517)	1.33 (± 2.517)
Change at Month 24: Study Eye	-2.00 (± 15.588)	-2.00 (± 5.292)	-3.33 (± 3.215)	5.00 (± 7.000)
Change at Month 24: Non-Study Eye	-3.67 (± 5.508)	0.67 (± 0.577)	-2.33 (± 1.528)	2.33 (± 4.509)

End point values	Part 1: BIIB112 Dose 5	Part 1: BIIB112 Dose 6		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	3	3		
Units: letters				
arithmetic mean (standard deviation)				
Baseline: Study Eye	70.67 (± 4.163)	67.33 (± 15.044)		
Baseline: Non-Study Eye	73.33 (± 4.163)	75.00 (± 4.583)		
Change at Month 1: Study Eye	-0.67 (± 4.041)	-0.67 (± 10.693)		
Change at Month 1: Non-Study Eye	2.00 (± 4.583)	-2.67 (± 1.155)		
Change at Month 3: Study Eye	0.33 (± 6.028)	0.67 (± 6.506)		
Change at Month 3: Non-Study Eye	4.67 (± 4.509)	-0.33 (± 0.577)		
Change at Month 6: Study Eye	-3.67 (± 8.737)	-0.67 (± 5.033)		
Change at Month 6: Non-Study Eye	4.00 (± 4.359)	-0.67 (± 1.528)		
Change at Month 9: Study Eye	-3.67 (± 16.073)	-2.33 (± 9.074)		
Change at Month 9: Non-Study Eye	5.67 (± 8.622)	2.00 (± 4.359)		
Change at Month 12: Study Eye	-15.00 (± 40.286)	-2.33 (± 8.327)		
Change at Month 12: Non-Study Eye	6.67 (± 6.429)	1.00 (± 2.000)		
Change at Month 18: Study Eye	-9.33 (± 28.919)	-5.00 (± 8.544)		
Change at Month 18: Non-Study Eye	5.00 (± 7.810)	-0.33 (± 5.508)		
Change at Month 24: Study Eye	-13.33 (± 32.747)	-5.67 (± 6.110)		
Change at Month 24: Non-Study Eye	2.00 (± 7.810)	-2.00 (± 3.000)		

Statistical analyses

No statistical analyses for this end point

Secondary: Part 1: Change from Baseline in Low Luminance Visual Acuity (LLVA)

Score

End point title	Part 1: Change from Baseline in Low Luminance Visual Acuity (LLVA) Score ^[40]
-----------------	--

End point description:

LLVA was measured by placing a 2.0-log-unit neutral density filter over the front of each eye and having the subject read the normally illuminated ETDRS chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. LLVA was reported as number of letters read correctly by the subject. Here negative values indicate decline in LLVA. Safety analysis set included all subjects who received study treatment (vitrectomy/AAV8-RPGR).

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Month 1, 3, 6, 9, 12, 18 and 24

Notes:

[40] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was for Part 1, hence data was reported for Part 1 reporting arm groups only.

End point values	Part 1: BIIB112 Dose 1	Part 1: BIIB112 Dose 2	Part 1: BIIB112 Dose 3	Part 1: BIIB112 Dose 4
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	0 ^[41]	0 ^[42]	2 ^[43]	3 ^[44]
Units: letters				
arithmetic mean (standard deviation)				
Baseline: Study Eye	()	()	41.00 (± 18.385)	34.33 (± 29.939)
Baseline: Non-Study Eye	()	()	37.50 (± 24.749)	37.67 (± 32.808)
Change at Month 1: Study Eye	()	()	10.00 (± 9.899)	0.33 (± 0.577)
Change at Month 1: Non-Study Eye	()	()	10.00 (± 18.385)	-0.33 (± 7.506)
Change at Month 3: Study Eye	()	()	14.00 (± 11.314)	7.33 (± 6.658)
Change at Month 3: Non-Study Eye	()	()	10.00 (± 16.971)	1.00 (± 1.000)
Change at Month 6: Study Eye	()	()	11.50 (± 7.778)	8.33 (± 7.234)
Change at Month 6: Non-Study Eye	()	()	8.00 (± 15.556)	1.67 (± 2.887)
Change at Month 9: Study Eye	()	()	0.50 (± 4.950)	10.00 (± 6.557)
Change at Month 9: Non-Study Eye	()	()	0.50 (± 4.950)	2.00 (± 4.359)
Change at Month 12: Study Eye	()	()	3.50 (± 0.707)	16.00 (± 13.454)
Change at Month 12: Non-Study Eye	()	()	7.00 (± 9.899)	6.67 (± 8.327)
Change at Month 18: Study Eye	()	()	6.50 (± 7.778)	10.67 (± 8.622)
Change at Month 18: Non-Study Eye	()	()	9.00 (± 21.213)	2.33 (± 2.517)
Change at Month 24: Study Eye	()	()	3.00 (± 8.485)	9.33 (± 14.295)
Change at Month 24: Non-Study Eye	()	()	5.50 (± 24.749)	0.67 (± 4.041)

Notes:

[41] - 'Number of subjects analysed' signifies number of subjects analysed in this endpoint.

[42] - 'Number of subjects analysed' signifies number of subjects analysed in this endpoint.

[43] - 'Number of subjects analysed' signifies number of subjects analysed in this endpoint.

[44] - 'Number of subjects analysed' signifies number of subjects analysed in this endpoint.

End point values	Part 1: BIIB112 Dose 5	Part 1: BIIB112 Dose 6		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	3 ^[45]	3 ^[46]		
Units: letters				
arithmetic mean (standard deviation)				
Baseline: Study Eye	58.00 (± 3.000)	41.67 (± 34.646)		
Baseline: Non-Study Eye	61.00 (± 2.646)	57.33 (± 14.844)		
Change at Month 1: Study Eye	3.00 (± 5.292)	4.67 (± 26.502)		
Change at Month 1: Non-Study Eye	3.00 (± 5.196)	-4.33 (± 7.572)		
Change at Month 3: Study Eye	-14.33 (± 38.214)	-7.67 (± 10.263)		
Change at Month 3: Non-Study Eye	3.00 (± 4.583)	2.00 (± 3.464)		
Change at Month 6: Study Eye	-16.67 (± 35.810)	7.33 (± 9.713)		
Change at Month 6: Non-Study Eye	5.33 (± 1.155)	0.67 (± 3.215)		
Change at Month 9: Study Eye	-14.33 (± 37.820)	4.33 (± 8.083)		
Change at Month 9: Non-Study Eye	2.00 (± 3.464)	3.33 (± 2.309)		
Change at Month 12: Study Eye	-11.33 (± 40.612)	8.33 (± 11.590)		
Change at Month 12: Non-Study Eye	9.00 (± 4.359)	4.00 (± 6.083)		
Change at Month 18: Study Eye	-12.33 (± 40.079)	8.33 (± 5.508)		
Change at Month 18: Non-Study Eye	5.67 (± 4.726)	-4.33 (± 7.234)		
Change at Month 24: Study Eye	-14.67 (± 38.371)	-1.67 (± 6.506)		
Change at Month 24: Non-Study Eye	3.33 (± 3.512)	-12.67 (± 11.547)		

Notes:

[45] - 'Number of subjects analysed' signifies number of subjects analysed in this endpoint.

[46] - 'Number of subjects analysed' signifies number of subjects analysed in this endpoint.

Statistical analyses

No statistical analyses for this end point

Secondary: Part 1: Percentage of Eyes with a ≥15 Letters Increase from Baseline for BCVA

End point title	Part 1: Percentage of Eyes with a ≥15 Letters Increase from Baseline for BCVA ^[47]
-----------------	---

End point description:

BCVA was assessed using the ETDRS VA chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. BCVA was to be reported as number of letters read correctly by the subject. An increase in the number of letters read correctly means that vision has improved. Safety analysis set included all subjects who received study treatment (vitrectomy/AAV8-RPGR).

End point type	Secondary
----------------	-----------

End point timeframe:

Month 1, 3, 6, 9, 12, 18 and 24

Notes:

[47] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was for Part 1, hence data was reported for Part 1 reporting arm groups only.

End point values	Part 1: BIIB112 Dose 1	Part 1: BIIB112 Dose 2	Part 1: BIIB112 Dose 3	Part 1: BIIB112 Dose 4
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	3	3	3
Units: percentage of eyes				
number (confidence interval 95%)				
Month 1: Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)
Month 1: Non-Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)
Month 3: Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)
Month 3: Non-Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)
Month 6: Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)
Month 6: Non-Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)
Month 9: Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)
Month 9: Non-Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)
Month 12: Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)
Month 12: Non-Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)
Month 18: Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)
Month 18: Non-Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)
Month 24: Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)
Month 24: Non-Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)

End point values	Part 1: BIIB112 Dose 5	Part 1: BIIB112 Dose 6		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	3	3		
Units: percentage of eyes				
number (confidence interval 95%)				
Month 1: Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)		
Month 1: Non-Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)		

Month 3: Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)		
Month 3: Non-Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)		
Month 6: Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)		
Month 6: Non-Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)		
Month 9: Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)		
Month 9: Non-Study Eye	33.3 (0.8 to 90.6)	0.0 (0.0 to 70.8)		
Month 12: Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)		
Month 12: Non-Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)		
Month 18: Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)		
Month 18: Non-Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)		
Month 24: Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)		
Month 24: Non-Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)		

Statistical analyses

No statistical analyses for this end point

Secondary: Part 1: Percentage of Eyes with a ≥ 15 Letters Increase from Baseline for LLVA

End point title	Part 1: Percentage of Eyes with a ≥ 15 Letters Increase from Baseline for LLVA ^[48]
-----------------	---

End point description:

LLVA was measured by placing a 2.0-log-unit neutral density filter over the front of each eye and having the subject read the normally illuminated ETDRS chart. Initially, letters were read at a distance of 4 meters from the chart. If < 20 letters were read at 4 meters, testing at 1 meter was performed. LLVA was reported as number of letters read correctly by the subject. Safety analysis set included all subjects who received study treatment (vitrectomy/AAV8-RPGR).

End point type	Secondary
----------------	-----------

End point timeframe:

Month 1, 3, 6, 9, 12, 18 and 24

Notes:

[48] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was for Part 1, hence data was reported for Part 1 reporting arm groups only.

End point values	Part 1: BIIB112 Dose 1	Part 1: BIIB112 Dose 2	Part 1: BIIB112 Dose 3	Part 1: BIIB112 Dose 4
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	0 ^[49]	0 ^[50]	2 ^[51]	3 ^[52]
Units: percentage of eyes				
number (confidence interval 95%)				

Month 1: Study Eye	(to)	(to)	50.0 (1.3 to 98.7)	0.0 (0.0 to 70.8)
Month 1: Non-Study Eye	(to)	(to)	50.0 (1.3 to 98.7)	0.0 (0.0 to 70.8)
Month 3: Study Eye	(to)	(to)	50.0 (1.3 to 98.7)	0.0 (0.0 to 70.8)
Month 3: Non-Study Eye	(to)	(to)	50.0 (1.3 to 98.7)	0.0 (0.0 to 70.8)
Month 6: Study Eye	(to)	(to)	50.0 (1.3 to 98.7)	0.0 (0.0 to 70.8)
Month 6: Non-Study Eye	(to)	(to)	50.0 (1.3 to 98.7)	0.0 (0.0 to 70.8)
Month 9: Study Eye	(to)	(to)	0.0 (0.0 to 84.2)	33.3 (0.8 to 90.6)
Month 9: Non-Study Eye	(to)	(to)	0.0 (0.0 to 84.2)	0.0 (0.0 to 70.8)
Month 12: Study Eye	(to)	(to)	0.0 (0.0 to 84.2)	33.3 (0.8 to 90.6)
Month 12: Non-Study Eye	(to)	(to)	0.0 (0.0 to 84.2)	33.3 (0.8 to 90.6)
Month 18: Study Eye	(to)	(to)	0.0 (0.0 to 84.2)	33.3 (0.8 to 90.6)
Month 18: Non-Study Eye	(to)	(to)	50.0 (1.3 to 98.7)	0.0 (0.0 to 70.8)
Month 24: Study Eye	(to)	(to)	0.0 (0.0 to 84.2)	33.3 (0.8 to 90.6)
Month 24: Non-Study Eye	(to)	(to)	50.0 (1.3 to 98.7)	0.0 (0.0 to 70.8)

Notes:

[49] - 'Number of subjects analysed' signifies number of subjects analysed in this endpoint.

[50] - 'Number of subjects analysed' signifies number of subjects analysed in this endpoint.

[51] - 'Number of subjects analysed' signifies number of subjects analysed in this endpoint.

[52] - 'Number of subjects analysed' signifies number of subjects analysed in this endpoint.

End point values	Part 1: BIIB112 Dose 5	Part 1: BIIB112 Dose 6		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	3 ^[53]	3 ^[54]		
Units: percentage of eyes				
number (confidence interval 95%)				
Month 1: Study Eye	0.0 (0.0 to 70.8)	33.3 (0.8 to 90.6)		
Month 1: Non-Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)		
Month 3: Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)		
Month 3: Non-Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)		
Month 6: Study Eye	0.0 (0.0 to 70.8)	33.3 (0.8 to 90.6)		
Month 6: Non-Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)		
Month 9: Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)		
Month 9: Non-Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)		
Month 12: Study Eye	33.3 (0.8 to 90.6)	33.3 (0.8 to 90.6)		

Month 12: Non-Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)		
Month 18: Study Eye	33.3 (0.8 to 90.6)	0.0 (0.0 to 70.8)		
Month 18: Non-Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)		
Month 24: Study Eye	33.3 (0.8 to 90.6)	0.0 (0.0 to 70.8)		
Month 24: Non-Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)		

Notes:

[53] - 'Number of subjects analysed' signifies number of subjects analysed in this endpoint.

[54] - 'Number of subjects analysed' signifies number of subjects analysed in this endpoint.

Statistical analyses

No statistical analyses for this end point

Secondary: Part 1: Percentage of Eyes with a ≥ 10 Letters Increase from Baseline for BCVA

End point title	Part 1: Percentage of Eyes with a ≥ 10 Letters Increase from Baseline for BCVA ^[55]
-----------------	---

End point description:

BCVA was assessed using the ETDRS VA chart. Initially, letters were read at a distance of 4 meters from the chart. If < 20 letters were read at 4 meters, testing at 1 meter was performed. BCVA was to be reported as number of letters read correctly by the subject. An increase in the number of letters read correctly means that vision has improved. Safety analysis set included all subjects who received study treatment (vitrectomy/AAV8-RPGR).

End point type	Secondary
----------------	-----------

End point timeframe:

Month 1, 3, 6, 9, 12, 18 and 24

Notes:

[55] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was for Part 1, hence data was reported for Part 1 reporting arm groups only.

End point values	Part 1: BIIB112 Dose 1	Part 1: BIIB112 Dose 2	Part 1: BIIB112 Dose 3	Part 1: BIIB112 Dose 4
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	3	3	3
Units: percentage of eyes				
number (confidence interval 95%)				
Month 1: Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)
Month 1: Non-Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)
Month 3: Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)
Month 3: Non-Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)
Month 6: Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	33.3 (0.8 to 90.6)
Month 6: Non-Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)
Month 9: Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	33.3 (0.8 to 90.6)

Month 9: Non-Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)
Month 12: Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	33.3 (0.8 to 90.6)
Month 12: Non-Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)
Month 18: Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)
Month 18: Non-Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)
Month 24: Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	33.3 (0.8 to 90.6)
Month 24: Non-Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)

End point values	Part 1: BIIB112 Dose 5	Part 1: BIIB112 Dose 6		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	3	3		
Units: percentage of eyes				
number (confidence interval 95%)				
Month 1: Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)		
Month 1: Non-Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)		
Month 3: Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)		
Month 3: Non-Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)		
Month 6: Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)		
Month 6: Non-Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)		
Month 9: Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)		
Month 9: Non-Study Eye	33.3 (0.8 to 90.6)	0.0 (0.0 to 70.8)		
Month 12: Study Eye	33.3 (0.8 to 90.6)	0.0 (0.0 to 70.8)		
Month 12: Non-Study Eye	33.3 (0.8 to 90.6)	0.0 (0.0 to 70.8)		
Month 18: Study Eye	33.3 (0.8 to 90.6)	0.0 (0.0 to 70.8)		
Month 18: Non-Study Eye	33.3 (0.8 to 90.6)	0.0 (0.0 to 70.8)		
Month 24: Study Eye	33.3 (0.8 to 90.6)	0.0 (0.0 to 70.8)		
Month 24: Non-Study Eye	33.3 (0.8 to 90.6)	0.0 (0.0 to 70.8)		

Statistical analyses

Secondary: Part 1: Percentage of Eyes with a ≥ 10 Letters Increase from Baseline for LLVA

End point title	Part 1: Percentage of Eyes with a ≥ 10 Letters Increase from Baseline for LLVA ^[56]
-----------------	---

End point description:

LLVA was measured by placing a 2.0-log-unit neutral density filter over the front of each eye and having the subject read the normally illuminated ETDRS chart. Initially, letters were read at a distance of 4 meters from the chart. If < 20 letters were read at 4 meters, testing at 1 meter was performed. LLVA was reported as number of letters read correctly by the subject. Safety analysis set included all subjects who received study treatment (vitrectomy/AAV8-RPGR).

End point type	Secondary
----------------	-----------

End point timeframe:

Month 1, 3, 6, 9, 12, 18 and 24

Notes:

[56] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was for Part 1, hence data was reported for Part 1 reporting arm groups only.

End point values	Part 1: BIIB112 Dose 1	Part 1: BIIB112 Dose 2	Part 1: BIIB112 Dose 3	Part 1: BIIB112 Dose 4
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	0 ^[57]	0 ^[58]	2 ^[59]	3 ^[60]
Units: percentage of eyes				
number (confidence interval 95%)				
Month 1: Study Eye	(to)	(to)	50.0 (1.3 to 98.7)	0.0 (0.0 to 70.8)
Month 1: Non-Study Eye	(to)	(to)	50.0 (1.3 to 98.7)	0.0 (0.0 to 70.8)
Month 3: Study Eye	(to)	(to)	50.0 (1.3 to 98.7)	33.3 (0.8 to 90.6)
Month 3: Non-Study Eye	(to)	(to)	50.0 (1.3 to 98.7)	0.0 (0.0 to 70.8)
Month 6: Study Eye	(to)	(to)	50.0 (1.3 to 98.7)	66.7 (9.4 to 99.2)
Month 6: Non-Study Eye	(to)	(to)	50.0 (1.3 to 98.7)	0.0 (0.0 to 70.8)
Month 9: Study Eye	(to)	(to)	0.0 (0.0 to 84.2)	33.3 (0.8 to 90.6)
Month 9: Non-Study Eye	(to)	(to)	0.0 (0.0 to 84.2)	0.0 (0.0 to 70.8)
Month 12: Study Eye	(to)	(to)	0.0 (0.0 to 84.2)	66.7 (9.4 to 99.2)
Month 12: Non-Study Eye	(to)	(to)	50.0 (1.3 to 98.7)	33.3 (0.8 to 90.6)
Month 18: Study Eye	(to)	(to)	50.0 (1.3 to 98.7)	33.3 (0.8 to 90.6)
Month 18: Non-Study Eye	(to)	(to)	50.0 (1.3 to 98.7)	0.0 (0.0 to 70.8)
Month 24: Study Eye	(to)	(to)	0.0 (0.0 to 84.2)	33.3 (0.8 to 90.6)
Month 24: Non-Study Eye	(to)	(to)	50.0 (1.3 to 98.7)	0.0 (0.0 to 70.8)

Notes:

[57] - 'Number of subjects analysed' signifies number of subjects analysed in this endpoint.

[58] - 'Number of subjects analysed' signifies number of subjects analysed in this endpoint.

[59] - 'Number of subjects analysed' signifies number of subjects analysed in this endpoint.

[60] - 'Number of subjects analysed' signifies number of subjects analysed in this endpoint.

End point values	Part 1: BIIB112 Dose 5	Part 1: BIIB112 Dose 6		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	3 ^[61]	3 ^[62]		
Units: percentage of eyes				
number (confidence interval 95%)				
Month 1: Study Eye	0.0 (0.0 to 70.8)	66.7 (9.4 to 99.2)		
Month 1: Non-Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)		
Month 3: Study Eye	33.3 (0.8 to 90.6)	0.0 (0.0 to 70.8)		
Month 3: Non-Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)		
Month 6: Study Eye	0.0 (0.0 to 70.8)	33.3 (0.8 to 90.6)		
Month 6: Non-Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)		
Month 9: Study Eye	0.0 (0.0 to 70.8)	33.3 (0.8 to 90.6)		
Month 9: Non-Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)		
Month 12: Study Eye	33.3 (0.8 to 90.6)	66.7 (9.4 to 99.2)		
Month 12: Non-Study Eye	33.3 (0.8 to 90.6)	33.3 (0.8 to 90.6)		
Month 18: Study Eye	33.3 (0.8 to 90.6)	33.3 (0.8 to 90.6)		
Month 18: Non-Study Eye	33.3 (0.8 to 90.6)	0.0 (0.0 to 70.8)		
Month 24: Study Eye	33.3 (0.8 to 90.6)	0.0 (0.0 to 70.8)		
Month 24: Non-Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)		

Notes:

[61] - 'Number of subjects analysed' signifies number of subjects analysed in this endpoint.

[62] - 'Number of subjects analysed' signifies number of subjects analysed in this endpoint.

Statistical analyses

No statistical analyses for this end point

Secondary: Part 1: Percentage of Eyes with a ≥ 5 Letters Increase from Baseline for BCVA

End point title	Part 1: Percentage of Eyes with a ≥ 5 Letters Increase from Baseline for BCVA ^[63]
-----------------	--

End point description:

BCVA was assessed using the ETDRS VA chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. BCVA was to be reported as number of letters read correctly by the subject. An increase in the number of letters read correctly means that vision has improved. Safety analysis set included all subjects who received study treatment (vitrectomy/AAV8-RPGR).

End point type	Secondary
----------------	-----------

End point timeframe:

Month 1, 3, 6, 9, 12, 18, and 24

Notes:

[63] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was for Part 1, hence data was reported for Part 1 reporting arm groups only.

End point values	Part 1: BIIB112 Dose 1	Part 1: BIIB112 Dose 2	Part 1: BIIB112 Dose 3	Part 1: BIIB112 Dose 4
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	3	3	3
Units: percentage of eyes				
number (confidence interval 95%)				
Month 1: Study Eye	33.3 (0.8 to 90.6)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	33.3 (0.8 to 90.6)
Month 1: Non-Study Eye	33.3 (0.8 to 90.6)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)
Month 3: Study Eye	100.0 (29.2 to 100.0)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	33.3 (0.8 to 90.6)
Month 3: Non-Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	33.3 (0.8 to 90.6)
Month 6: Study Eye	66.7 (9.4 to 99.2)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	33.3 (0.8 to 90.6)
Month 6: Non-Study Eye	33.3 (0.8 to 90.6)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	33.3 (0.8 to 90.6)
Month 9: Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	33.3 (0.8 to 90.6)	33.3 (0.8 to 90.6)
Month 9: Non-Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	33.3 (0.8 to 90.6)
Month 12: Study Eye	66.7 (9.4 to 99.2)	0.0 (0.0 to 70.8)	33.3 (0.8 to 90.6)	33.3 (0.8 to 90.6)
Month 12: Non-Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	33.3 (0.8 to 90.6)
Month 18: Study Eye	66.7 (9.4 to 99.2)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	66.7 (9.4 to 99.2)
Month 18: Non-Study Eye	0.0 (0.0 to 70.8)	33.3 (0.8 to 90.6)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)
Month 24: Study Eye	66.7 (9.4 to 99.2)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	66.7 (9.4 to 99.2)
Month 24: Non-Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	33.3 (0.8 to 90.6)

End point values	Part 1: BIIB112 Dose 5	Part 1: BIIB112 Dose 6		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	3	3		
Units: percentage of eyes				
number (confidence interval 95%)				
Month 1: Study Eye	0.0 (0.0 to 70.8)	66.7 (9.4 to 99.2)		
Month 1: Non-Study Eye	33.3 (0.8 to 90.6)	0.0 (0.0 to 70.8)		

Month 3: Study Eye	33.3 (0.8 to 90.6)	33.3 (0.8 to 90.6)		
Month 3: Non-Study Eye	66.7 (9.4 to 99.2)	0.0 (0.0 to 70.8)		
Month 6: Study Eye	33.3 (0.8 to 90.6)	0.0 (0.0 to 70.8)		
Month 6: Non-Study Eye	33.3 (0.8 to 90.6)	0.0 (0.0 to 70.8)		
Month 9: Study Eye	33.3 (0.8 to 90.6)	33.3 (0.8 to 90.6)		
Month 9: Non-Study Eye	33.3 (0.8 to 90.6)	33.3 (0.8 to 90.6)		
Month 12: Study Eye	33.3 (0.8 to 90.6)	33.3 (0.8 to 90.6)		
Month 12: Non-Study Eye	33.3 (0.8 to 90.6)	0.0 (0.0 to 70.8)		
Month 18: Study Eye	33.3 (0.8 to 90.6)	0.0 (0.0 to 70.8)		
Month 18: Non-Study Eye	33.3 (0.8 to 90.6)	33.3 (0.8 to 90.6)		
Month 24: Study Eye	33.3 (0.8 to 90.6)	0.0 (0.0 to 70.8)		
Month 24: Non-Study Eye	33.3 (0.8 to 90.6)	0.0 (0.0 to 70.8)		

Statistical analyses

No statistical analyses for this end point

Secondary: Part 1: Percentage of Eyes with a ≥ 5 Letters Increase from Baseline for LLVA

End point title	Part 1: Percentage of Eyes with a ≥ 5 Letters Increase from Baseline for LLVA ^[64]
-----------------	--

End point description:

LLVA was measured by placing a 2.0-log-unit neutral density filter over the front of each eye and having the subject read the normally illuminated ETDRS chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. LLVA was reported as number of letters read correctly by the subject. Safety analysis set included all subjects who received study treatment (vitrectomy/AAV8-RPGR).

End point type	Secondary
----------------	-----------

End point timeframe:

Month 1, 3, 6, 9, 12, 18 and 24

Notes:

[64] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was for Part 1, hence data was reported for Part 1 reporting arm groups only.

End point values	Part 1: BIIB112 Dose 1	Part 1: BIIB112 Dose 2	Part 1: BIIB112 Dose 3	Part 1: BIIB112 Dose 4
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	0 ^[65]	0 ^[66]	2 ^[67]	3 ^[68]
Units: percentage of eyes				
number (confidence interval 95%)				

Month 1: Study Eye	(to)	(to)	50.0 (1.3 to 98.7)	0.0 (0.0 to 70.8)
Month 1: Non-Study Eye	(to)	(to)	50.0 (1.3 to 98.7)	33.3 (0.8 to 90.6)
Month 3: Study Eye	(to)	(to)	100.0 (15.8 to 100.0)	66.7 (9.4 to 99.2)
Month 3: Non-Study Eye	(to)	(to)	50.0 (1.3 to 98.7)	0.0 (0.0 to 70.8)
Month 6: Study Eye	(to)	(to)	100.0 (15.8 to 100.0)	66.7 (9.4 to 99.2)
Month 6: Non-Study Eye	(to)	(to)	50.0 (1.3 to 98.7)	33.3 (0.8 to 90.6)
Month 9: Study Eye	(to)	(to)	0.0 (0.0 to 84.2)	66.7 (9.4 to 99.2)
Month 9: Non-Study Eye	(to)	(to)	0.0 (0.0 to 84.2)	33.3 (0.8 to 90.6)
Month 12: Study Eye	(to)	(to)	0.0 (0.0 to 84.2)	100.0 (29.2 to 100.0)
Month 12: Non-Study Eye	(to)	(to)	50.0 (1.3 to 98.7)	33.3 (0.8 to 90.6)
Month 18: Study Eye	(to)	(to)	50.0 (1.3 to 98.7)	66.7 (9.4 to 99.2)
Month 18: Non-Study Eye	(to)	(to)	50.0 (1.3 to 98.7)	33.3 (0.8 to 90.6)
Month 24: Study Eye	(to)	(to)	50.0 (1.3 to 98.7)	66.7 (9.4 to 99.2)
Month 24: Non-Study Eye	(to)	(to)	50.0 (1.3 to 98.7)	33.3 (0.8 to 90.6)

Notes:

[65] - 'Number of subjects analysed' signifies number of subjects analysed in this endpoint.

[66] - 'Number of subjects analysed' signifies number of subjects analysed in this endpoint.

[67] - 'Number of subjects analysed' signifies number of subjects analysed in this endpoint.

[68] - 'Number of subjects analysed' signifies number of subjects analysed in this endpoint.

End point values	Part 1: BIIB112 Dose 5	Part 1: BIIB112 Dose 6		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	3 ^[69]	3 ^[70]		
Units: percentage of eyes				
number (confidence interval 95%)				
Month 1: Study Eye	66.7 (9.4 to 99.2)	66.7 (9.4 to 99.2)		
Month 1: Non-Study Eye	33.3 (0.8 to 90.6)	0.0 (0.0 to 70.8)		
Month 3: Study Eye	33.3 (0.8 to 90.6)	0.0 (0.0 to 70.8)		
Month 3: Non-Study Eye	33.3 (0.8 to 90.6)	0.0 (0.0 to 70.8)		
Month 6: Study Eye	33.3 (0.8 to 90.6)	66.7 (9.4 to 99.2)		
Month 6: Non-Study Eye	66.7 (9.4 to 99.2)	0.0 (0.0 to 70.8)		
Month 9: Study Eye	66.7 (9.4 to 99.2)	33.3 (0.8 to 90.6)		
Month 9: Non-Study Eye	0.0 (0.0 to 70.8)	33.3 (0.8 to 90.6)		
Month 12: Study Eye	66.7 (9.4 to 99.2)	66.7 (9.4 to 99.2)		

Month 12: Non-Study Eye	100.0 (29.2 to 100.0)	33.3 (0.8 to 90.6)		
Month 18: Study Eye	33.3 (0.8 to 90.6)	66.7 (9.4 to 99.2)		
Month 18: Non-Study Eye	33.3 (0.8 to 90.6)	0.0 (0.0 to 70.8)		
Month 24: Study Eye	33.3 (0.8 to 90.6)	33.3 (0.8 to 90.6)		
Month 24: Non-Study Eye	33.3 (0.8 to 90.6)	0.0 (0.0 to 70.8)		

Notes:

[69] - 'Number of subjects analysed' signifies number of subjects analysed in this endpoint.

[70] - 'Number of subjects analysed' signifies number of subjects analysed in this endpoint.

Statistical analyses

No statistical analyses for this end point

Secondary: Part 1: Percentage of Eyes with a ≥ 15 Letters Loss from Baseline for BCVA

End point title	Part 1: Percentage of Eyes with a ≥ 15 Letters Loss from Baseline for BCVA ^[71]
-----------------	---

End point description:

BCVA was assessed using the ETDRS VA chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. BCVA was to be reported as number of letters read correctly by the subject. An increase in the number of letters read correctly means that vision has improved. Safety analysis set included all subjects who received study treatment (vitrectomy/AAV8-RPGR).

End point type	Secondary
----------------	-----------

End point timeframe:

Month 1, 3, 6, 9, 12, 18 and 24

Notes:

[71] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was for Part 1, hence data was reported for Part 1 reporting arm groups only.

End point values	Part 1: BIIB112 Dose 1	Part 1: BIIB112 Dose 2	Part 1: BIIB112 Dose 3	Part 1: BIIB112 Dose 4
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	3	3	3
Units: percentage of eyes				
number (confidence interval 95%)				
Month 1: Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)
Month 1: Non-Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)
Month 3: Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)
Month 3: Non-Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)
Month 6: Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)
Month 6: Non-Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)
Month 9: Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)

Month 9: Non-Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)
Month 12: Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)
Month 12: Non-Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)
Month 18: Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)
Month 18: Non-Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)
Month 24: Study Eye	33.3 (0.8 to 90.6)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)
Month 24: Non-Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)

End point values	Part 1: BIIB112 Dose 5	Part 1: BIIB112 Dose 6		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	3	3		
Units: percentage of eyes				
number (confidence interval 95%)				
Month 1: Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)		
Month 1: Non-Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)		
Month 3: Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)		
Month 3: Non-Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)		
Month 6: Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)		
Month 6: Non-Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)		
Month 9: Study Eye	33.3 (0.8 to 90.6)	0.0 (0.0 to 70.8)		
Month 9: Non-Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)		
Month 12: Study Eye	33.3 (0.8 to 90.6)	0.0 (0.0 to 70.8)		
Month 12: Non-Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)		
Month 18: Study Eye	33.3 (0.8 to 90.6)	0.0 (0.0 to 70.8)		
Month 18: Non-Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)		
Month 24: Study Eye	33.3 (0.8 to 90.6)	0.0 (0.0 to 70.8)		
Month 24: Non-Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)		

Statistical analyses

Secondary: Part 1: Percentage of Eyes with a ≥ 15 Letters Loss from Baseline for LLVA

End point title	Part 1: Percentage of Eyes with a ≥ 15 Letters Loss from Baseline for LLVA ^[72]
-----------------	---

End point description:

LLVA was measured by placing a 2.0-log-unit neutral density filter over the front of each eye and having the subject read the normally illuminated ETDRS chart. Initially, letters were read at a distance of 4 meters from the chart. If < 20 letters were read at 4 meters, testing at 1 meter was performed. LLVA was reported as number of letters read correctly by the subject. Safety analysis set included all subjects who received study treatment (vitrectomy/AAV8-RPGR).

End point type	Secondary
----------------	-----------

End point timeframe:

Month 1, 3, 6, 9, 12, 18 and 24

Notes:

[72] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was for Part 1, hence data was reported for Part 1 reporting arm groups only.

End point values	Part 1: BIIB112 Dose 1	Part 1: BIIB112 Dose 2	Part 1: BIIB112 Dose 3	Part 1: BIIB112 Dose 4
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	0 ^[73]	0 ^[74]	2 ^[75]	3 ^[76]
Units: percentage of eyes				
number (confidence interval 95%)				
Month 1: Study Eye	(to)	(to)	0.0 (0.0 to 84.2)	0.0 (0.0 to 70.8)
Month 1: Non-Study Eye	(to)	(to)	0.0 (0.0 to 84.2)	0.0 (0.0 to 70.8)
Month 3: Study Eye	(to)	(to)	0.0 (0.0 to 84.2)	0.0 (0.0 to 70.8)
Month 3: Non-Study Eye	(to)	(to)	0.0 (0.0 to 84.2)	0.0 (0.0 to 70.8)
Month 6: Study Eye	(to)	(to)	0.0 (0.0 to 84.2)	0.0 (0.0 to 70.8)
Month 6: Non-Study Eye	(to)	(to)	0.0 (0.0 to 84.2)	0.0 (0.0 to 70.8)
Month 9: Study Eye	(to)	(to)	0.0 (0.0 to 84.2)	0.0 (0.0 to 70.8)
Month 9: Non-Study Eye	(to)	(to)	0.0 (0.0 to 84.2)	0.0 (0.0 to 70.8)
Month 12: Study Eye	(to)	(to)	0.0 (0.0 to 84.2)	0.0 (0.0 to 70.8)
Month 12: Non-Study Eye	(to)	(to)	0.0 (0.0 to 84.2)	0.0 (0.0 to 70.8)
Month 18: Study Eye	(to)	(to)	0.0 (0.0 to 84.2)	0.0 (0.0 to 70.8)
Month 18: Non-Study Eye	(to)	(to)	0.0 (0.0 to 84.2)	0.0 (0.0 to 70.8)
Month 24: Study Eye	(to)	(to)	0.0 (0.0 to 84.2)	0.0 (0.0 to 70.8)
Month 24: Non-Study Eye	(to)	(to)	0.0 (0.0 to 84.2)	0.0 (0.0 to 70.8)

Notes:

[73] - 'Number of subjects analysed' signifies number of subjects analysed in this endpoint.

[74] - 'Number of subjects analysed' signifies number of subjects analysed in this endpoint.

[75] - 'Number of subjects analysed' signifies number of subjects analysed in this endpoint.

[76] - 'Number of subjects analysed' signifies number of subjects analysed in this endpoint.

End point values	Part 1: BIIB112 Dose 5	Part 1: BIIB112 Dose 6		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	3 ^[77]	3 ^[78]		
Units: percentage of eyes				
number (confidence interval 95%)				
Month 1: Study Eye	0.0 (0.0 to 70.8)	33.3 (0.8 to 90.6)		
Month 1: Non-Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)		
Month 3: Study Eye	33.3 (0.8 to 90.6)	33.3 (0.8 to 90.6)		
Month 3: Non-Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)		
Month 6: Study Eye	33.3 (0.8 to 90.6)	0.0 (0.0 to 70.8)		
Month 6: Non-Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)		
Month 9: Study Eye	33.3 (0.8 to 90.6)	0.0 (0.0 to 70.8)		
Month 9: Non-Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)		
Month 12: Study Eye	33.3 (0.8 to 90.6)	0.0 (0.0 to 70.8)		
Month 12: Non-Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)		
Month 18: Study Eye	33.3 (0.8 to 90.6)	0.0 (0.0 to 70.8)		
Month 18: Non-Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)		
Month 24: Study Eye	33.3 (0.8 to 90.6)	0.0 (0.0 to 70.8)		
Month 24: Non-Study Eye	0.0 (0.0 to 70.8)	33.3 (0.8 to 90.6)		

Notes:

[77] - 'Number of subjects analysed' signifies number of subjects analysed in this endpoint.

[78] - 'Number of subjects analysed' signifies number of subjects analysed in this endpoint.

Statistical analyses

No statistical analyses for this end point

Secondary: Part 1: Percentage of Eyes with a ≥ 10 Letters Loss from Baseline for BCVA

End point title	Part 1: Percentage of Eyes with a ≥ 10 Letters Loss from Baseline for BCVA ^[79]
-----------------	---

End point description:

BCVA was assessed using the ETDRS VA chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. BCVA was to be reported as number of letters read correctly by the subject. An increase in the number of letters read correctly means that vision has improved. Safety analysis set included all subjects who received study treatment (vitrectomy/AAV8-RPGR).

End point type	Secondary
----------------	-----------

End point timeframe:

Month 1, 3, 6, 9, 12, 18 and 24

Notes:

[79] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was for Part 1, hence data was reported for Part 1 reporting arm groups only.

End point values	Part 1: BIIB112 Dose 1	Part 1: BIIB112 Dose 2	Part 1: BIIB112 Dose 3	Part 1: BIIB112 Dose 4
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	3	3	3
Units: percentage of eyes				
number (confidence interval 95%)				
Month 1: Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)
Month 1: Non-Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)
Month 3: Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)
Month 3: Non-Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)
Month 6: Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)
Month 6: Non-Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)
Month 9: Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)
Month 9: Non-Study Eye	33.3 (0.8 to 90.6)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)
Month 12: Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)
Month 12: Non-Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)
Month 18: Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)
Month 18: Non-Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)
Month 24: Study Eye	33.3 (0.8 to 90.6)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)
Month 24: Non-Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)

End point values	Part 1: BIIB112 Dose 5	Part 1: BIIB112 Dose 6		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	3	3		
Units: percentage of eyes				
number (confidence interval 95%)				
Month 1: Study Eye	0.0 (0.0 to 70.8)	33.3 (0.8 to 90.6)		
Month 1: Non-Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)		

Month 3: Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)		
Month 3: Non-Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)		
Month 6: Study Eye	33.3 (0.8 to 90.6)	0.0 (0.0 to 70.8)		
Month 6: Non-Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)		
Month 9: Study Eye	33.3 (0.8 to 90.6)	33.3 (0.8 to 90.6)		
Month 9: Non-Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)		
Month 12: Study Eye	33.3 (0.8 to 90.6)	0.0 (0.0 to 70.8)		
Month 12: Non-Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)		
Month 18: Study Eye	33.3 (0.8 to 90.6)	33.3 (0.8 to 90.6)		
Month 18: Non-Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)		
Month 24: Study Eye	33.3 (0.8 to 90.6)	33.3 (0.8 to 90.6)		
Month 24: Non-Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)		

Statistical analyses

No statistical analyses for this end point

Secondary: Part 1: Percentage of Eyes with a ≥ 10 Letters Loss from Baseline for LLVA

End point title	Part 1: Percentage of Eyes with a ≥ 10 Letters Loss from Baseline for LLVA ^[80]
-----------------	---

End point description:

LLVA was measured by placing a 2.0-log-unit neutral density filter over the front of each eye and having the subject read the normally illuminated ETDRS chart. Initially, letters were read at a distance of 4 meters from the chart. If < 20 letters were read at 4 meters, testing at 1 meter was performed. LLVA was reported as number of letters read correctly by the subject. Safety analysis set included all subjects who received study treatment (vitrectomy/AAV8-RPGR).

End point type	Secondary
----------------	-----------

End point timeframe:

Month 1, 3, 6, 9, 12, 18 and 24

Notes:

[80] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was for Part 1, hence data was reported for Part 1 reporting arm groups only.

End point values	Part 1: BIIB112 Dose 1	Part 1: BIIB112 Dose 2	Part 1: BIIB112 Dose 3	Part 1: BIIB112 Dose 4
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	0 ^[81]	0 ^[82]	2 ^[83]	3 ^[84]
Units: percentage of eyes				
number (confidence interval 95%)				

Month 1: Study Eye	(to)	(to)	0.0 (0.0 to 84.2)	0.0 (0.0 to 70.8)
Month 1: Non-Study Eye	(to)	(to)	0.0 (0.0 to 84.2)	0.0 (0.0 to 70.8)
Month 3: Study Eye	(to)	(to)	0.0 (0.0 to 84.2)	0.0 (0.0 to 70.8)
Month 3: Non-Study Eye	(to)	(to)	0.0 (0.0 to 84.2)	0.0 (0.0 to 70.8)
Month 6: Study Eye	(to)	(to)	0.0 (0.0 to 84.2)	0.0 (0.0 to 70.8)
Month 6: Non-Study Eye	(to)	(to)	0.0 (0.0 to 84.2)	0.0 (0.0 to 70.8)
Month 9: Study Eye	(to)	(to)	0.0 (0.0 to 84.2)	0.0 (0.0 to 70.8)
Month 9: Non-Study Eye	(to)	(to)	0.0 (0.0 to 84.2)	0.0 (0.0 to 70.8)
Month 12: Study Eye	(to)	(to)	0.0 (0.0 to 84.2)	0.0 (0.0 to 70.8)
Month 12: Non-Study Eye	(to)	(to)	0.0 (0.0 to 84.2)	0.0 (0.0 to 70.8)
Month 18: Study Eye	(to)	(to)	0.0 (0.0 to 84.2)	0.0 (0.0 to 70.8)
Month 18: Non-Study Eye	(to)	(to)	0.0 (0.0 to 84.2)	0.0 (0.0 to 70.8)
Month 24: Study Eye	(to)	(to)	0.0 (0.0 to 84.2)	0.0 (0.0 to 70.8)
Month 24: Non-Study Eye	(to)	(to)	50.0 (1.3 to 98.7)	0.0 (0.0 to 70.8)

Notes:

[81] - 'Number of subjects analysed' signifies number of subjects analysed in this endpoint.

[82] - 'Number of subjects analysed' signifies number of subjects analysed in this endpoint.

[83] - 'Number of subjects analysed' signifies number of subjects analysed in this endpoint.

[84] - 'Number of subjects analysed' signifies number of subjects analysed in this endpoint.

End point values	Part 1: BIIB112 Dose 5	Part 1: BIIB112 Dose 6		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	3 ^[85]	3 ^[86]		
Units: percentage of eyes				
number (confidence interval 95%)				
Month 1: Study Eye	0.0 (0.0 to 70.8)	33.3 (0.8 to 90.6)		
Month 1: Non-Study Eye	0.0 (0.0 to 70.8)	33.3 (0.8 to 90.6)		
Month 3: Study Eye	33.3 (0.8 to 90.6)	33.3 (0.8 to 90.6)		
Month 3: Non-Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)		
Month 6: Study Eye	33.3 (0.8 to 90.6)	0.0 (0.0 to 70.8)		
Month 6: Non-Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)		
Month 9: Study Eye	33.3 (0.8 to 90.6)	0.0 (0.0 to 70.8)		
Month 9: Non-Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)		
Month 12: Study Eye	33.3 (0.8 to 90.6)	0.0 (0.0 to 70.8)		

Month 12: Non-Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)		
Month 18: Study Eye	33.3 (0.8 to 90.6)	0.0 (0.0 to 70.8)		
Month 18: Non-Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)		
Month 24: Study Eye	33.3 (0.8 to 90.6)	0.0 (0.0 to 70.8)		
Month 24: Non-Study Eye	0.0 (0.0 to 70.8)	33.3 (0.8 to 90.6)		

Notes:

[85] - 'Number of subjects analysed' signifies number of subjects analysed in this endpoint.

[86] - 'Number of subjects analysed' signifies number of subjects analysed in this endpoint.

Statistical analyses

No statistical analyses for this end point

Secondary: Part 1: Percentage of Eyes with a ≥ 5 Letters Loss from Baseline for BCVA

End point title	Part 1: Percentage of Eyes with a ≥ 5 Letters Loss from Baseline for BCVA ^[87]
-----------------	--

End point description:

BCVA was assessed using the ETDRS VA chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. BCVA was to be reported as number of letters read correctly by the subject. An increase in the number of letters read correctly means that vision has improved. Safety analysis set included all subjects who received study treatment (vitrectomy/AAV8-RPGR).

End point type	Secondary
----------------	-----------

End point timeframe:

Month 1, 3, 6, 9, 12, 18 and 24

Notes:

[87] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was for Part 1, hence data was reported for Part 1 reporting arm groups only.

End point values	Part 1: BIIB112 Dose 1	Part 1: BIIB112 Dose 2	Part 1: BIIB112 Dose 3	Part 1: BIIB112 Dose 4
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	3	3	3
Units: percentage of eyes				
number (confidence interval 95%)				
Month 1: Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	33.3 (0.8 to 90.6)
Month 1: Non-Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)
Month 3: Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)
Month 3: Non-Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)
Month 6: Study Eye	0.0 (0.0 to 70.8)	33.3 (0.8 to 90.6)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)
Month 6: Non-Study Eye	33.3 (0.8 to 90.6)	33.3 (0.8 to 90.6)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)
Month 9: Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)

Month 9: Non-Study Eye	33.3 (0.8 to 90.6)	33.3 (0.8 to 90.6)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)
Month 12: Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	33.3 (0.8 to 90.6)	0.0 (0.0 to 70.8)
Month 12: Non-Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)
Month 18: Study Eye	33.3 (0.8 to 90.6)	33.3 (0.8 to 90.6)	33.3 (0.8 to 90.6)	0.0 (0.0 to 70.8)
Month 18: Non-Study Eye	66.7 (9.4 to 99.2)	33.3 (0.8 to 90.6)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)
Month 24: Study Eye	33.3 (0.8 to 90.6)	33.3 (0.8 to 90.6)	33.3 (0.8 to 90.6)	0.0 (0.0 to 70.8)
Month 24: Non-Study Eye	33.3 (0.8 to 90.6)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)

End point values	Part 1: BIIB112 Dose 5	Part 1: BIIB112 Dose 6		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	3	3		
Units: percentage of eyes				
number (confidence interval 95%)				
Month 1: Study Eye	33.3 (0.8 to 90.6)	33.3 (0.8 to 90.6)		
Month 1: Non-Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)		
Month 3: Study Eye	33.3 (0.8 to 90.6)	33.3 (0.8 to 90.6)		
Month 3: Non-Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)		
Month 6: Study Eye	66.7 (9.4 to 99.2)	33.3 (0.8 to 90.6)		
Month 6: Non-Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)		
Month 9: Study Eye	33.3 (0.8 to 90.6)	33.3 (0.8 to 90.6)		
Month 9: Non-Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)		
Month 12: Study Eye	33.3 (0.8 to 90.6)	66.7 (9.4 to 99.2)		
Month 12: Non-Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)		
Month 18: Study Eye	33.3 (0.8 to 90.6)	66.7 (9.4 to 99.2)		
Month 18: Non-Study Eye	0.0 (0.0 to 70.8)	33.3 (0.8 to 90.6)		
Month 24: Study Eye	33.3 (0.8 to 90.6)	66.7 (9.4 to 99.2)		
Month 24: Non-Study Eye	0.0 (0.0 to 70.8)	33.3 (0.8 to 90.6)		

Statistical analyses

Secondary: Part 1: Percentage of Eyes with a ≥ 5 Letters Loss from Baseline for LLVA

End point title	Part 1: Percentage of Eyes with a ≥ 5 Letters Loss from Baseline for LLVA ^[88]
-----------------	--

End point description:

LLVA was measured by placing a 2.0-log-unit neutral density filter over the front of each eye and having the subject read the normally illuminated ETDRS chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. LLVA was reported as number of letters read correctly by the subject. Safety analysis set included all subjects who received study treatment (vitrectomy/AAV8-RPGR).

End point type	Secondary
----------------	-----------

End point timeframe:

Month 1, 3, 6, 9, 12, 18 and 24

Notes:

[88] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was for Part 1, hence data was reported for Part 1 reporting arm groups only.

End point values	Part 1: BIIB112 Dose 1	Part 1: BIIB112 Dose 2	Part 1: BIIB112 Dose 3	Part 1: BIIB112 Dose 4
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	0 ^[89]	0 ^[90]	2 ^[91]	3 ^[92]
Units: percentage of eyes				
number (confidence interval 95%)				
Month 1: Study Eye	(to)	(to)	0.0 (0.0 to 84.2)	0.0 (0.0 to 70.8)
Month 1: Non-Study Eye	(to)	(to)	0.0 (0.0 to 84.2)	33.3 (0.8 to 90.6)
Month 3: Study Eye	(to)	(to)	0.0 (0.0 to 84.2)	0.0 (0.0 to 70.8)
Month 3: Non-Study Eye	(to)	(to)	0.0 (0.0 to 84.2)	0.0 (0.0 to 70.8)
Month 6: Study Eye	(to)	(to)	0.0 (0.0 to 84.2)	0.0 (0.0 to 70.8)
Month 6: Non-Study Eye	(to)	(to)	0.0 (0.0 to 84.2)	0.0 (0.0 to 70.8)
Month 9: Study Eye	(to)	(to)	0.0 (0.0 to 84.2)	0.0 (0.0 to 70.8)
Month 9: Non-Study Eye	(to)	(to)	0.0 (0.0 to 84.2)	0.0 (0.0 to 70.8)
Month 12: Study Eye	(to)	(to)	0.0 (0.0 to 84.2)	0.0 (0.0 to 70.8)
Month 12: Non-Study Eye	(to)	(to)	0.0 (0.0 to 84.2)	0.0 (0.0 to 70.8)
Month 18: Study Eye	(to)	(to)	0.0 (0.0 to 84.2)	0.0 (0.0 to 70.8)
Month 18: Non-Study Eye	(to)	(to)	50.0 (1.3 to 98.7)	0.0 (0.0 to 70.8)
Month 24: Study Eye	(to)	(to)	0.0 (0.0 to 84.2)	0.0 (0.0 to 70.8)
Month 24: Non-Study Eye	(to)	(to)	50.0 (1.3 to 98.7)	0.0 (0.0 to 70.8)

Notes:

[89] - 'Number of subjects analysed' signifies number of subjects analysed in this endpoint.

[90] - 'Number of subjects analysed' signifies number of subjects analysed in this endpoint.

[91] - 'Number of subjects analysed' signifies number of subjects analysed in this endpoint.

[92] - 'Number of subjects analysed' signifies number of subjects analysed in this endpoint.

End point values	Part 1: BIIB112 Dose 5	Part 1: BIIB112 Dose 6		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	3 ^[93]	3 ^[94]		
Units: percentage of eyes				
number (confidence interval 95%)				
Month 1: Study Eye	0.0 (0.0 to 70.8)	33.3 (0.8 to 90.6)		
Month 1: Non-Study Eye	0.0 (0.0 to 70.8)	33.3 (0.8 to 90.6)		
Month 3: Study Eye	33.3 (0.8 to 90.6)	66.7 (9.4 to 99.2)		
Month 3: Non-Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)		
Month 6: Study Eye	33.3 (0.8 to 90.6)	0.0 (0.0 to 70.8)		
Month 6: Non-Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)		
Month 9: Study Eye	33.3 (0.8 to 90.6)	0.0 (0.0 to 70.8)		
Month 9: Non-Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)		
Month 12: Study Eye	33.3 (0.8 to 90.6)	33.3 (0.8 to 90.6)		
Month 12: Non-Study Eye	0.0 (0.0 to 70.8)	0.0 (0.0 to 70.8)		
Month 18: Study Eye	33.3 (0.8 to 90.6)	0.0 (0.0 to 70.8)		
Month 18: Non-Study Eye	0.0 (0.0 to 70.8)	66.7 (9.4 to 99.2)		
Month 24: Study Eye	33.3 (0.8 to 90.6)	33.3 (0.8 to 90.6)		
Month 24: Non-Study Eye	0.0 (0.0 to 70.8)	100.0 (29.2 to 100.0)		

Notes:

[93] - 'Number of subjects analysed' signifies number of subjects analysed in this endpoint.

[94] - 'Number of subjects analysed' signifies number of subjects analysed in this endpoint.

Statistical analyses

No statistical analyses for this end point

Secondary: Part 1: Percentage of Eyes with Change from Baseline > -5 Letters for BCVA

End point title	Part 1: Percentage of Eyes with Change from Baseline > -5 Letters for BCVA ^[95]
-----------------	--

End point description:

BCVA was assessed using the ETDRS VA chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. BCVA was to be reported as number of letters read correctly by the subject. An increase in the number of letters read correctly means that vision has improved. Safety analysis set included all subjects who received study treatment (vitrectomy/AAV8-RPGR).

End point type	Secondary
----------------	-----------

End point timeframe:

Month 1, 3, 6, 9, 12, 18 and 24

Notes:

[95] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was for Part 1, hence data was reported for Part 1 reporting arm groups only.

End point values	Part 1: BIIB112 Dose 1	Part 1: BIIB112 Dose 2	Part 1: BIIB112 Dose 3	Part 1: BIIB112 Dose 4
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	3	3	3
Units: percentage of eyes				
number (confidence interval 95%)				
Month 1: Study Eye	100.0 (29.2 to 100.0)	100.0 (29.2 to 100.0)	100.0 (29.2 to 100.0)	66.7 (9.4 to 99.2)
Month 1: Non-Study Eye	100.0 (29.2 to 100.0)	100.0 (29.2 to 100.0)	100.0 (29.2 to 100.0)	100.0 (29.2 to 100.0)
Month 3: Study Eye	100.0 (29.2 to 100.0)	100.0 (29.2 to 100.0)	100.0 (29.2 to 100.0)	100.0 (29.2 to 100.0)
Month 3: Non-Study Eye	100.0 (29.2 to 100.0)	100.0 (29.2 to 100.0)	100.0 (29.2 to 100.0)	100.0 (29.2 to 100.0)
Month 6: Study Eye	100.0 (29.2 to 100.0)	66.7 (9.4 to 99.2)	100.0 (29.2 to 100.0)	100.0 (29.2 to 100.0)
Month 6: Non-Study Eye	66.7 (9.4 to 99.2)	66.7 (9.4 to 99.2)	100.0 (29.2 to 100.0)	100.0 (29.2 to 100.0)
Month 9: Study Eye	100.0 (29.2 to 100.0)	100.0 (29.2 to 100.0)	100.0 (29.2 to 100.0)	100.0 (29.2 to 100.0)
Month 9: Non-Study Eye	66.7 (9.4 to 99.2)	66.7 (9.4 to 99.2)	100.0 (29.2 to 100.0)	100.0 (29.2 to 100.0)
Month 12: Study Eye	100.0 (29.2 to 100.0)	100.0 (29.2 to 100.0)	66.7 (9.4 to 99.2)	100.0 (29.2 to 100.0)
Month 12: Non-Study Eye	100.0 (29.2 to 100.0)	100.0 (29.2 to 100.0)	100.0 (29.2 to 100.0)	100.0 (29.2 to 100.0)
Month 18: Study Eye	66.7 (9.4 to 99.2)	66.7 (9.4 to 99.2)	66.7 (9.4 to 99.2)	100.0 (29.2 to 100.0)
Month 18: Non-Study Eye	33.3 (0.8 to 90.6)	66.7 (9.4 to 99.2)	100.0 (29.2 to 100.0)	100.0 (29.2 to 100.0)
Month 24: Study Eye	66.7 (9.4 to 99.2)	66.7 (9.4 to 99.2)	66.7 (9.4 to 99.2)	100.0 (29.2 to 100.0)
Month 24: Non-Study Eye	66.7 (9.4 to 99.2)	100.0 (29.2 to 100.0)	100.0 (29.2 to 100.0)	100.0 (29.2 to 100.0)

End point values	Part 1: BIIB112 Dose 5	Part 1: BIIB112 Dose 6		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	3	3		
Units: percentage of eyes				
number (confidence interval 95%)				
Month 1: Study Eye	66.7 (9.4 to 99.2)	66.7 (9.4 to 99.2)		
Month 1: Non-Study Eye	100.0 (29.2 to 100.0)	100.0 (29.2 to 100.0)		

Month 3: Study Eye	66.7 (9.4 to 99.2)	66.7 (9.4 to 99.2)		
Month 3: Non-Study Eye	100.0 (29.2 to 100.0)	100.0 (29.2 to 100.0)		
Month 6: Study Eye	33.3 (0.8 to 90.6)	66.7 (9.4 to 99.2)		
Month 6: Non-Study Eye	100.0 (29.2 to 100.0)	100.0 (29.2 to 100.0)		
Month 9: Study Eye	66.7 (9.4 to 99.2)	66.7 (9.4 to 99.2)		
Month 9: Non-Study Eye	100.0 (29.2 to 100.0)	100.0 (29.2 to 100.0)		
Month 12: Study Eye	66.7 (9.4 to 99.2)	33.3 (0.8 to 90.6)		
Month 12: Non-Study Eye	100.0 (29.2 to 100.0)	100.0 (29.2 to 100.0)		
Month 18: Study Eye	66.7 (9.4 to 99.2)	33.3 (0.8 to 90.6)		
Month 18: Non-Study Eye	100.0 (29.2 to 100.0)	66.7 (9.4 to 99.2)		
Month 24: Study Eye	66.7 (9.4 to 99.2)	33.3 (0.8 to 90.6)		
Month 24: Non-Study Eye	100.0 (29.2 to 100.0)	66.7 (9.4 to 99.2)		

Statistical analyses

No statistical analyses for this end point

Secondary: Part 1: Percentage of Eyes with Change from Baseline > -5 Letters for LLVA

End point title	Part 1: Percentage of Eyes with Change from Baseline > -5 Letters for LLVA ^[96]
-----------------	--

End point description:

LLVA was measured by placing a 2.0-log-unit neutral density filter over the front of each eye and having the subject read the normally illuminated ETDRS chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. LLVA was reported as number of letters read correctly by the subject. Safety analysis set included all subjects who received study treatment (vitrectomy/AAV8-RPGR).

End point type	Secondary
----------------	-----------

End point timeframe:

Month 1, 3, 6, 9, 12, 18 and 24

Notes:

[96] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was for Part 1, hence data was reported for Part 1 reporting arm groups only.

End point values	Part 1: BIIB112 Dose 1	Part 1: BIIB112 Dose 2	Part 1: BIIB112 Dose 3	Part 1: BIIB112 Dose 4
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	0 ^[97]	0 ^[98]	2 ^[99]	3 ^[100]
Units: percentage of eyes				
number (confidence interval 95%)				

Change at Month 1: Study Eye	(to)	(to)	100.0 (15.8 to 100.0)	100.0 (29.2 to 100.0)
Change at Month 1: Non-Study Eye	(to)	(to)	100.0 (15.8 to 100.0)	66.7 (9.4 to 99.2)
Change at Month 3: Study Eye	(to)	(to)	100.0 (15.8 to 100.0)	100.0 (29.2 to 100.0)
Change at Month 3: Non-Study Eye	(to)	(to)	100.0 (15.8 to 100.0)	100.0 (29.2 to 100.0)
Change at Month 6: Study Eye	(to)	(to)	100.0 (15.8 to 100.0)	100.0 (29.2 to 100.0)
Change at Month 6: Non-Study Eye	(to)	(to)	100.0 (15.8 to 100.0)	100.0 (29.2 to 100.0)
Change at Month 9: Study Eye	(to)	(to)	100.0 (15.8 to 100.0)	100.0 (29.2 to 100.0)
Change at Month 9: Non-Study Eye	(to)	(to)	100.0 (15.8 to 100.0)	100.0 (29.2 to 100.0)
Change at Month 12: Study Eye	(to)	(to)	100.0 (15.8 to 100.0)	100.0 (29.2 to 100.0)
Change at Month 12: Non-Study Eye	(to)	(to)	100.0 (15.8 to 100.0)	100.0 (29.2 to 100.0)
Change at Month 18: Study Eye	(to)	(to)	100.0 (15.8 to 100.0)	100.0 (29.2 to 100.0)
Change at Month 18: Non-Study Eye	(to)	(to)	50.0 (1.3 to 98.7)	100.0 (29.2 to 100.0)
Change at Month 24: Study Eye	(to)	(to)	100.0 (15.8 to 100.0)	100.0 (29.2 to 100.0)
Change at Month 24: Non-Study Eye	(to)	(to)	50.0 (1.3 to 98.7)	100.0 (29.2 to 100.0)

Notes:

[97] - 'Number of subjects analysed' signifies number of subjects analysed in this endpoint.

[98] - 'Number of subjects analysed' signifies number of subjects analysed in this endpoint.

[99] - 'Number of subjects analysed' signifies number of subjects analysed in this endpoint.

[100] - 'Number of subjects analysed' signifies number of subjects analysed in this endpoint.

End point values	Part 1: BIIB112 Dose 5	Part 1: BIIB112 Dose 6		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	3 ^[101]	3 ^[102]		
Units: percentage of eyes				
number (confidence interval 95%)				
Change at Month 1: Study Eye	100.0 (29.2 to 100.0)	66.7 (9.4 to 99.2)		
Change at Month 1: Non-Study Eye	100.0 (29.2 to 100.0)	66.7 (9.4 to 99.2)		
Change at Month 3: Study Eye	66.7 (9.4 to 99.2)	33.3 (0.8 to 90.6)		
Change at Month 3: Non-Study Eye	100.0 (29.2 to 100.0)	100.0 (29.2 to 100.0)		
Change at Month 6: Study Eye	66.7 (9.4 to 99.2)	100.0 (29.2 to 100.0)		
Change at Month 6: Non-Study Eye	100.0 (29.2 to 100.0)	100.0 (29.2 to 100.0)		
Change at Month 9: Study Eye	66.7 (9.4 to 99.2)	100.0 (29.2 to 100.0)		
Change at Month 9: Non-Study Eye	100.0 (29.2 to 100.0)	100.0 (29.2 to 100.0)		
Change at Month 12: Study Eye	66.7 (9.4 to 99.2)	66.7 (9.4 to 99.2)		

Change at Month 12: Non-Study Eye	100.0 (29.2 to 100.0)	100.0 (29.2 to 100.0)		
Change at Month 18: Study Eye	66.7 (9.4 to 99.2)	100.0 (29.2 to 100.0)		
Change at Month 18: Non-Study Eye	100.0 (29.2 to 100.0)	33.3 (0.8 to 90.6)		
Change at Month 24: Study Eye	66.7 (9.4 to 99.2)	66.7 (9.4 to 99.2)		
Change at Month 24: Non-Study Eye	100.0 (29.2 to 100.0)	0.0 (0.0 to 70.8)		

Notes:

[101] - 'Number of subjects analysed' signifies number of subjects analysed in this endpoint.

[102] - 'Number of subjects analysed' signifies number of subjects analysed in this endpoint.

Statistical analyses

No statistical analyses for this end point

Secondary: Part 1: Change from Baseline in Central Ellipsoid Area

End point title	Part 1: Change from Baseline in Central Ellipsoid Area ^[103]
-----------------	---

End point description:

Spectral Domain Optical Coherence Tomography (SD-OCT) was used to assess change in central ellipsoid area. Here negative values indicate decline in central ellipsoid area. Safety analysis included all subjects who received study treatment (vitrectomy/AAV8-RPGR). n=number of subjects analysed at specific timepoint.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Month 1, 3, 6, 9, 12, 18 and 24

Notes:

[103] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was for Part 1, hence data was reported for Part 1 reporting arm groups only.

End point values	Part 1: BIIB112 Dose 1	Part 1: BIIB112 Dose 2	Part 1: BIIB112 Dose 3	Part 1: BIIB112 Dose 4
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	3	3	3
Units: millimeter square (mm ²)				
arithmetic mean (standard deviation)				
Baseline: Study Eye (n=3,3,3,3,3)	0.140 (± 0.1637)	2.750 (± 4.7631)	0.137 (± 0.1582)	0.193 (± 0.1686)
Baseline: Non-Study Eye (n=3,3,3,2,3)	0.130 (± 0.0985)	2.313 (± 3.7500)	0.093 (± 0.0814)	0.465 (± 0.1061)
Change at Month 1: Study Eye (n=3,3,3,3,3)	-0.077 (± 0.1159)	-0.493 (± 0.8545)	-0.103 (± 0.1050)	-0.050 (± 0.0458)
Change at Month 1: Non-Study Eye (n=3,3,3,2,3)	-0.060 (± 0.0265)	-0.383 (± 0.4508)	-0.020 (± 0.0693)	-0.080 (± 0.0566)
Change at Month 3: Study Eye (n=3,3,3,3,2,3)	-0.100 (± 0.1249)	-0.560 (± 0.9699)	-0.110 (± 0.1153)	-0.060 (± 0.0529)
Change at Month 3: Non-Study Eye (n=3,3,3,2,3,2)	-0.093 (± 0.0404)	-0.407 (± 0.4895)	-0.043 (± 0.0379)	-0.095 (± 0.0495)
Change at Month 6: Study Eye (n=3,3,3,3,3,2)	-0.120 (± 0.1375)	-0.527 (± 0.9122)	-0.113 (± 0.1206)	-0.070 (± 0.0624)
Change at Month 6: Non-Study Eye (n=3,3,3,2,3,2)	-0.093 (± 0.0404)	-0.410 (± 0.4951)	-0.060 (± 0.0529)	-0.120 (± 0.0424)

Change at Month 9: Study Eye (n=3,3,3,3,3)	-0.127 (± 0.1419)	-0.540 (± 0.9353)	-0.117 (± 0.1258)	-0.063 (± 0.0551)
Change at Month 9: Non-Study Eye (n=3,3,3,2,3,2)	-0.097 (± 0.0451)	-0.437 (± 0.5326)	-0.063 (± 0.0569)	-0.120 (± 0.0141)
Change at Month 12: Study Eye (n=3,3,3,3,3,3)	-0.130 (± 0.1473)	-0.560 (± 0.9699)	-0.117 (± 0.1258)	-0.053 (± 0.0551)
Change at Month 12: Non-Study Eye (n=3,3,3,2,3,3)	-0.097 (± 0.0451)	-0.447 (± 0.5353)	-0.033 (± 0.1266)	-0.120 (± 0.0424)
Change at Month 18: Study Eye (n=3,3,3,3,3,3)	-0.133 (± 0.1528)	-0.567 (± 0.9815)	-0.137 (± 0.1582)	0.027 (± 0.1617)
Change at Month 18: Non-Study Eye (n=3,3,3,2,3,3)	-0.113 (± 0.0709)	-0.450 (± 0.5408)	-0.027 (± 0.1201)	-0.115 (± 0.0919)
Change at Month 24: Study Eye (n=3,3,3,3,3,3)	-0.133 (± 0.1528)	-0.573 (± 0.9930)	-0.137 (± 0.1582)	0.010 (± 0.1552)
Change at Month 24: Non-Study Eye (n=3,3,3,2,3,3)	-0.117 (± 0.0764)	-0.443 (± 0.5297)	-0.060 (± 0.0794)	-0.150 (± 0.0283)

End point values	Part 1: BIIB112 Dose 5	Part 1: BIIB112 Dose 6		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	3	3		
Units: millimeter square (mm ²)				
arithmetic mean (standard deviation)				
Baseline: Study Eye (n=3,3,3,3,3,3)	8.327 (± 13.8600)	3.107 (± 5.2001)		
Baseline: Non-Study Eye (n=3,3,3,2,3,3)	14.307 (± 24.1914)	5.257 (± 8.8720)		
Change at Month 1: Study Eye (n=3,3,3,3,3,3)	-1.360 (± 2.2863)	-1.310 (± 2.2258)		
Change at Month 1: Non-Study Eye (n=3,3,3,2,3,3)	-0.410 (± 0.7645)	0.873 (± 1.5824)		
Change at Month 3: Study Eye (n=3,3,3,3,2,3)	-2.255 (± 3.0335)	-2.960 (± 5.0319)		
Change at Month 3: Non-Study Eye (n=3,3,3,2,3,2)	-0.407 (± 0.7778)	-0.040 (± 0.0566)		
Change at Month 6: Study Eye (n=3,3,3,3,3,2)	-4.847 (± 8.1176)	-0.055 (± 0.0778)		
Change at Month 6: Non-Study Eye (n=3,3,3,2,3,2)	-0.983 (± 1.7747)	-0.050 (± 0.0707)		
Change at Month 9: Study Eye (n=3,3,3,3,3,3)	-5.640 (± 9.4830)	-2.960 (± 5.0664)		
Change at Month 9: Non-Study Eye (n=3,3,3,2,3,2)	-1.100 (± 1.9504)	-0.050 (± 0.0707)		
Change at Month 12: Study Eye (n=3,3,3,3,3,3)	-5.623 (± 9.4975)	-3.007 (± 5.1386)		
Change at Month 12: Non-Study Eye (n=3,3,3,2,3,3)	-1.010 (± 2.0313)	0.997 (± 1.8312)		
Change at Month 18: Study Eye (n=3,3,3,3,3,3)	-5.633 (± 9.4975)	-2.993 (± 5.1155)		
Change at Month 18: Non-Study Eye (n=3,3,3,2,3,3)	-1.107 (± 2.0124)	0.590 (± 1.1364)		
Change at Month 24: Study Eye (n=3,3,3,3,3,3)	-5.657 (± 9.5292)	-3.010 (± 5.1357)		
Change at Month 24: Non-Study Eye (n=3,3,3,2,3,3)	-1.163 (± 2.0063)	0.367 (± 0.7505)		

Statistical analyses

No statistical analyses for this end point

Secondary: Part 1: Change from Baseline in Central Horizontal Ellipsoid Width

End point title	Part 1: Change from Baseline in Central Horizontal Ellipsoid Width ^[104]
End point description:	
SD-OCT was used to assess change in central horizontal ellipsoid width. Here negative values indicate decline in central horizontal ellipsoid width. Safety analysis set included all subjects who received study treatment (vitrectomy/AAV8-RPGR). n=number of subjects analysed at specific timepoint.	
End point type	Secondary
End point timeframe:	
Baseline, Month 1, 3, 6, 9, 12, 18 and 24	

Notes:

[104] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was for Part 1, hence data was reported for Part 1 reporting arm groups only.

End point values	Part 1: BIIB112 Dose 1	Part 1: BIIB112 Dose 2	Part 1: BIIB112 Dose 3	Part 1: BIIB112 Dose 4
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	3	3	3
Units: Micron (um)				
arithmetic mean (standard deviation)				
Baseline: Study Eye (n=3,3,3,3,3)	162.67 (± 175.104)	1375.33 (± 2382.147)	248.00 (± 275.158)	462.33 (± 400.775)
Baseline: Non-Study Eye (n=3,3,3,2,3,3)	355.67 (± 280.878)	1383.67 (± 2396.581)	250.00 (± 223.139)	792.00 (± 100.409)
Change at Month 1: Study Eye (n=3,3,3,3,3,3)	-56.33 (± 73.894)	-311.00 (± 538.668)	-174.00 (± 162.567)	-26.33 (± 24.007)
Change at Month 1: Non-Study Eye (n=3,3,3,2,3,3)	-62.33 (± 40.216)	-321.67 (± 557.143)	47.33 (± 226.509)	-56.00 (± 63.640)
Change at Month 3: Study Eye (n=3,3,3,3,3,3)	-73.00 (± 70.193)	-318.00 (± 550.792)	-174.33 (± 163.022)	-89.33 (± 125.644)
Change at Month 3: Non-Study Eye (n=3,3,3,2,3,3)	-149.00 (± 80.988)	-333.33 (± 577.350)	-60.67 (± 78.258)	-151.00 (± 15.556)
Change at Month 6: Study Eye (n=3,3,3,3,3,3)	-115.67 (± 105.624)	-318.67 (± 551.947)	-175.67 (± 164.852)	-146.67 (± 129.454)
Change at Month 6: Non-Study Eye (n=3,3,3,2,3,2)	-158.67 (± 65.033)	-347.00 (± 601.022)	-76.33 (± 79.135)	-195.50 (± 6.364)
Change at Month 9: Study Eye (n=3,3,3,3,3,3)	-127.00 (± 121.025)	-321.33 (± 556.566)	-178.33 (± 168.548)	-149.00 (± 131.936)
Change at Month 9: Non-Study Eye (n=3,3,3,2,3,2)	-175.00 (± 39.585)	-348.00 (± 602.754)	-77.33 (± 79.053)	-202.50 (± 4.950)
Change at Month 12: Study Eye (n=3,3,3,3,3,3)	-130.00 (± 125.300)	-238.33 (± 412.805)	-217.00 (± 225.980)	-106.33 (± 132.666)
Change at Month 12: Non-Study Eye (n=3,3,3,2,3,3)	-181.67 (± 30.665)	-349.33 (± 605.063)	-35.67 (± 255.895)	-113.50 (± 47.376)

Change at Month 18: Study Eye (n=3,3,3,3,3)	-131.00 (± 126.740)	-239.33 (± 414.537)	-248.00 (± 275.158)	21.67 (± 332.031)
Change at Month 18: Non-Study Eye (n=3,3,3,2,3,3)	-316.67 (± 213.601)	-354.67 (± 614.301)	-168.67 (± 161.122)	-188.00 (± 65.054)
Change at Month 24: Study Eye (n=3,3,3,3,3,3)	-131.33 (± 127.222)	-242.33 (± 419.734)	-248.00 (± 275.158)	-43.33 (± 243.904)
Change at Month 24: Non-Study Eye (n=3,3,3,2,3,3)	-329.33 (± 235.434)	-358.00 (± 620.074)	-145.67 (± 162.543)	-254.50 (± 7.778)

End point values	Part 1: BIIB112 Dose 5	Part 1: BIIB112 Dose 6		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	3	3		
Units: Micron (um)				
arithmetic mean (standard deviation)				
Baseline: Study Eye (n=3,3,3,3,3,3)	2411.33 (± 3048.253)	745.67 (± 774.448)		
Baseline: Non-Study Eye (n=3,3,3,2,3,3)	3341.00 (± 4556.473)	937.67 (± 1088.262)		
Change at Month 1: Study Eye (n=3,3,3,3,3,3)	-203.33 (± 248.605)	88.67 (± 422.044)		
Change at Month 1: Non-Study Eye (n=3,3,3,2,3,3)	-14.00 (± 113.331)	977.33 (± 1814.500)		
Change at Month 3: Study Eye (n=3,3,3,3,3,3)	-369.00 (± 271.070)	-453.33 (± 554.795)		
Change at Month 3: Non-Study Eye (n=3,3,3,2,3,3)	-19.00 (± 123.503)	1008.33 (± 1869.924)		
Change at Month 6: Study Eye (n=3,3,3,3,3,3)	-1070.67 (± 1365.685)	-461.33 (± 553.453)		
Change at Month 6: Non-Study Eye (n=3,3,3,2,3,2)	-20.00 (± 144.503)	-108.50 (± 153.442)		
Change at Month 9: Study Eye (n=3,3,3,3,3,3)	-1096.33 (± 1343.289)	-441.00 (± 505.720)		
Change at Month 9: Non-Study Eye (n=3,3,3,2,3,2)	-81.67 (± 217.721)	-124.00 (± 175.362)		
Change at Month 12: Study Eye (n=3,3,3,3,3,3)	-1055.33 (± 1394.128)	-463.00 (± 537.199)		
Change at Month 12: Non-Study Eye (n=3,3,3,2,3,3)	-143.00 (± 221.007)	1108.00 (± 2145.532)		
Change at Month 18: Study Eye (n=3,3,3,3,3,3)	-1059.67 (± 1438.362)	-461.67 (± 530.381)		
Change at Month 18: Non-Study Eye (n=3,3,3,2,3,3)	-113.00 (± 242.736)	1078.67 (± 2094.819)		
Change at Month 24: Study Eye (n=3,3,3,3,3,3)	-1162.00 (± 1352.050)	-465.67 (± 587.699)		
Change at Month 24: Non-Study Eye (n=3,3,3,2,3,3)	-159.67 (± 265.038)	1065.67 (± 2074.136)		

Statistical analyses

No statistical analyses for this end point

Secondary: Part 1: Change from Baseline in Fundus Autofluorescence- Total Area of

Preserved Autofluorescence

End point title	Part 1: Change from Baseline in Fundus Autofluorescence-Total Area of Preserved Autofluorescence ^[105]
-----------------	---

End point description:

Fundus Autofluorescence was used to assess change in total area of preserved autofluorescence. Here negative values indicate decline in total area of preserved autofluorescence. Safety analysis set included all subjects who received study treatment (vitrectomy/AAV8-RPGR). 99999 indicates that standard deviation was not evaluable as there was only 1 subject. 999999 indicates that data was not evaluable at given time point. n=number of subjects analysed at specific timepoint.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Month 1, 3, 6, 12, 18 and 24

Notes:

[105] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was for Part 1, hence data was reported for Part 1 reporting arm groups only.

End point values	Part 1: BIIB112 Dose 1	Part 1: BIIB112 Dose 2	Part 1: BIIB112 Dose 3	Part 1: BIIB112 Dose 4
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	3	3	3
Units: mm ²				
arithmetic mean (standard deviation)				
Baseline: Study Eye (n=1,0,0,0,0,0)	27.050 (± 99999)	999999 (± 999999)	999999 (± 999999)	999999 (± 999999)
Baseline: Non-Study Eye (n=1,0,1,0,0,0)	22.910 (± 99999)	999999 (± 999999)	50.640 (± 99999)	999999 (± 999999)
Change at Month 1: Study Eye (n=1,0,0,0,0,0)	-1.820 (± 99999)	999999 (± 999999)	999999 (± 999999)	999999 (± 999999)
Change at Month 1: Non-Study Eye (n=1,0,1,0,0,0)	-2.420 (± 99999)	999999 (± 999999)	-8.620 (± 99999)	999999 (± 999999)
Change at Month 3: Study Eye (n=1,0,0,0,0,0)	-2.940 (± 99999)	999999 (± 999999)	999999 (± 999999)	999999 (± 999999)
Change at Month 3: Non-Study Eye (n=1,0,1,0,0,0)	-2.650 (± 99999)	999999 (± 999999)	-5.150 (± 99999)	999999 (± 999999)
Change at Month 6: Study Eye (n=1,0,0,0,0,0)	-3.460 (± 99999)	999999 (± 999999)	999999 (± 999999)	999999 (± 999999)
Change at Month 6: Non-Study Eye (n=1,0,1,0,0,0)	-3.050 (± 99999)	999999 (± 999999)	-6.530 (± 99999)	999999 (± 999999)
Change at Month 9: Study Eye (n=1,0,0,0,0,0)	-3.470 (± 99999)	999999 (± 999999)	999999 (± 999999)	999999 (± 999999)
Change at Month 9: Non-Study Eye (n=1,0,1,0,0,0)	-3.100 (± 99999)	999999 (± 999999)	-9.130 (± 99999)	999999 (± 999999)
Change at Month 12: Study Eye (n=1,0,0,0,0,0)	-3.640 (± 99999)	999999 (± 999999)	999999 (± 999999)	999999 (± 999999)
Change at Month 12: Non-Study Eye (n=1,0,1,0,0,0)	-3.760 (± 99999)	999999 (± 999999)	-9.220 (± 99999)	999999 (± 999999)
Change at Month 18: Study Eye (n=1,0,0,0,0,0)	-3.670 (± 99999)	999999 (± 999999)	999999 (± 999999)	999999 (± 999999)
Change at Month 18: Non-Study Eye (n=1,0,1,0,0,0)	-3.830 (± 99999)	999999 (± 99999)	-11.700 (± 99999)	999999 (± 999999)
Change at Month 24: Study Eye (n=1,0,0,0,0,0)	-3.740 (± 99999)	999999 (± 999999)	999999 (± 999999)	999999 (± 999999)
Change at Month 24: Non-Study Eye (n=1,0,0,0,0,0)	-4.120 (± 99999)	999999 (± 999999)	999999 (± 999999)	999999 (± 999999)

End point values	Part 1: BIIB112 Dose 5	Part 1: BIIB112 Dose 6		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	3	3		
Units: mm ²				
arithmetic mean (standard deviation)				
Baseline: Study Eye (n=1,0,0,0,0,0)	999999 (± 999999)	999999 (± 999999)		
Baseline: Non-Study Eye (n=1,0,1,0,0,0)	999999 (± 999999)	999999 (± 999999)		
Change at Month 1: Study Eye (n=1,0,0,0,0,0)	999999 (± 999999)	999999 (± 999999)		
Change at Month 1: Non-Study Eye (n=1,0,1,0,0,0)	999999 (± 999999)	999999 (± 999999)		
Change at Month 3: Study Eye (n=1,0,0,0,0,0)	999999 (± 999999)	999999 (± 999999)		
Change at Month 3: Non-Study Eye (n=1,0,1,0,0,0)	999999 (± 999999)	999999 (± 999999)		
Change at Month 6: Study Eye (n=1,0,0,0,0,0)	999999 (± 999999)	999999 (± 999999)		
Change at Month 6: Non-Study Eye (n=1,0,1,0,0,0)	999999 (± 999999)	999999 (± 999999)		
Change at Month 9: Study Eye (n=1,0,0,0,0,0)	999999 (± 999999)	999999 (± 999999)		
Change at Month 9: Non-Study Eye (n=1,0,1,0,0,0)	999999 (± 999999)	999999 (± 999999)		
Change at Month 12: Study Eye (n=1,0,0,0,0,0)	999999 (± 999999)	999999 (± 999999)		
Change at Month 12: Non-Study Eye (n=1,0,1,0,0,0)	999999 (± 999999)	999999 (± 999999)		
Change at Month 18: Study Eye (n=1,0,0,0,0,0)	999999 (± 999999)	999999 (± 999999)		
Change at Month 18: Non-Study Eye (n=1,0,1,0,0,0)	999999 (± 999999)	999999 (± 999999)		
Change at Month 24: Study Eye (n=1,0,0,0,0,0)	999999 (± 999999)	999999 (± 999999)		
Change at Month 24: Non-Study Eye (n=1,0,0,0,0,0)	999999 (± 999999)	999999 (± 999999)		

Statistical analyses

No statistical analyses for this end point

Secondary: Part 1: Change from Baseline in Fundus Autofluorescence- Distance from Foveal Center (FC) to Nearest Border of Preserved Autofluorescence

End point title	Part 1: Change from Baseline in Fundus Autofluorescence- Distance from Foveal Center (FC) to Nearest Border of Preserved Autofluorescence ^[106]
-----------------	--

End point description:

Fundus Autofluorescence was used to assess change in distance from foveal center (FC) to nearest border of preserved autofluorescence. Here negative values indicate decline in total area of preserved autofluorescence. Safety analysis set included all subjects who received study treatment

(vitrectomy/AAV8-RPGR). 99999 indicates that standard deviation was not evaluable as there was only 1 subject. 999999 indicates that data was not evaluable at given time point. n=number of subjects analysed at specific timepoint.

End point type	Secondary
End point timeframe:	
Baseline, Month 1, 3, 6, 9, 12, 18 and 24	

Notes:

[106] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was for Part 1, hence data was reported for Part 1 reporting arm groups only.

End point values	Part 1: BIIB112 Dose 1	Part 1: BIIB112 Dose 2	Part 1: BIIB112 Dose 3	Part 1: BIIB112 Dose 4
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	3	3	3
Units: mm ²				
arithmetic mean (standard deviation)				
Baseline: Study Eye (n=2,1,1,1,0)	2394.50 (± 665.387)	-39.00 (± 99999)	3018.00 (± 99999)	361.00 (± 99999)
Baseline: Non-Study Eye (n=2,1,1,1,1)	2609.00 (± 386.080)	-24.00 (± 99999)	3052.00 (± 99999)	369.00 (± 99999)
Change at Month 1: Study Eye (n=2,1,1,1,0)	-33.00 (± 5.657)	-14.00 (± 99999)	-52.00 (± 99999)	-14.00 (± 99999)
Change at Month 1: Non-Study Eye (n=2,1,1,1,1)	-255.50 (± 297.692)	-19.00 (± 99999)	-281.00 (± 99999)	-18.00 (± 99999)
Change at Month 3: Study Eye (n=2,1,1,1,0)	-87.00 (± 24.042)	-16.00 (± 99999)	-138.00 (± 99999)	-89.00 (± 99999)
Change at Month 3: Non-Study Eye (n=2,1,1,1,1)	-276.50 (± 324.562)	-30.00 (± 99999)	-375.00 (± 99999)	-22.00 (± 99999)
Change at Month 6: Study Eye (n=2,1,1,1,0)	-128.50 (± 54.447)	-24.00 (± 99999)	-179.00 (± 99999)	-93.00 (± 99999)
Change at Month 6: Non-Study Eye (n=2,1,1,1,1)	-297.00 (± 349.311)	-41.00 (± 99999)	-462.00 (± 99999)	-36.00 (± 99999)
Change at Month 9: Study Eye (n=2,1,1,1,0)	-140.00 (± 41.012)	-35.00 (± 99999)	-281.00 (± 99999)	-94.00 (± 99999)
Change at Month 9: Non-Study Eye (n=2,1,1,1,1)	-310.50 (± 333.047)	-58.00 (± 99999)	-413.00 (± 99999)	-38.00 (± 99999)
Change at Month 12: Study Eye (n=2,0,1,1,1,0)	-1489.50 (± 1829.285)	999999 (± 999999)	-282.00 (± 99999)	-101.00 (± 99999)
Change at Month 12: Non-Study Eye (n=2,0,1,1,1,1)	-353.50 (± 318.905)	999999 (± 999999)	-422.00 (± 99999)	-39.00 (± 99999)
Change at Month 18: Study Eye (n=2,1,1,1,1,0)	-1493.00 (± 1829.992)	-55.00 (± 99999)	-310.00 (± 99999)	-123.00 (± 99999)
Change at Month 18: Non-Study Eye (n=2,1,1,1,1,0)	-358.00 (± 318.198)	-86.00 (± 99999)	-425.00 (± 99999)	-11.00 (± 99999)
Change at Month 24: Study Eye (n=2,1,1,1,1,0)	-1501.00 (± 1820.093)	-69.00 (± 99999)	-226.00 (± 99999)	-125.00 (± 99999)
Change at Month 24: Non-Study Eye (n=2,1,1,1,1,0)	-391.00 (± 301.227)	-91.00 (± 99999)	-2646.00 (± 99999)	-13.00 (± 99999)

End point values	Part 1: BIIB112 Dose 5	Part 1: BIIB112 Dose 6		
------------------	------------------------------	------------------------------	--	--

Subject group type	Reporting group	Reporting group		
Number of subjects analysed	3	3		
Units: mm ²				
arithmetic mean (standard deviation)				
Baseline: Study Eye (n=2,1,1,1,1,0)	2853.00 (± 99999)	999999 (± 999999)		
Baseline: Non-Study Eye (n=2,1,1,1,1,1)	2816.00 (± 99999)	4047.00 (± 99999)		
Change at Month 1: Study Eye (n=2,1,1,1,1,0)	-5.00 (± 99999)	999999 (± 999999)		
Change at Month 1: Non-Study Eye (n=2,1,1,1,1,1)	-12.00 (± 99999)	-3.00 (± 99999)		
Change at Month 3: Study Eye (n=2,1,1,1,1,0)	-104.00 (± 99999)	999999 (± 999999)		
Change at Month 3: Non-Study Eye (n=2,1,1,1,1,1)	-93.00 (± 99999)	-21.00 (± 99999)		
Change at Month 6: Study Eye (n=2,1,1,1,1,0)	-122.00 (± 99999)	999999 (± 999999)		
Change at Month 6: Non-Study Eye (n=2,1,1,1,1,1)	-102.00 (± 99999)	999999 (± 999999)		
Change at Month 9: Study Eye (n=2,1,1,1,1,0)	-140.00 (± 99999)	999999 (± 999999)		
Change at Month 9: Non-Study Eye (n=2,1,1,1,1,1)	92.00 (± 99999)	999999 (± 999999)		
Change at Month 12: Study Eye (n=2,0,1,1,1,0)	-708.00 (± 99999)	999999 (± 999999)		
Change at Month 12: Non-Study Eye (n=2,0,1,1,1,1)	89.00 (± 99999)	999999 (± 999999)		
Change at Month 18: Study Eye (n=2,1,1,1,1,0)	-1278.00 (± 99999)	999999 (± 999999)		
Change at Month 18: Non-Study Eye (n=2,1,1,1,1,0)	65.00 (± 99999)	999999 (± 999999)		
Change at Month 24: Study Eye (n=2,1,1,1,1,0)	-1293.00 (± 99999)	999999 (± 999999)		
Change at Month 24: Non-Study Eye (n=2,1,1,1,1,0)	62.00 (± 99999)	999999 (± 999999)		

Statistical analyses

No statistical analyses for this end point

Secondary: Part 1: Change from Baseline in Volume of 30-Degree Hill of Vision

End point title	Part 1: Change from Baseline in Volume of 30-Degree Hill of Vision ^[107]
-----------------	---

End point description:

Visual field testing was performed to assess change in volume of 30-degree hill vision. Reliability Factor (RF)=number of false positive responses + number of false negative responses/number of false positive presentations + number of false negative presentations*100. If there are 0 responses, then RF value=0. RFpositive=number of false positive responses/number of false positive presentations*100. If RF ≤ 20% measurement is considered reliable. If 20% < RF ≤ 25% and RFpositive ≤ 10% measurement is also considered reliable. Otherwise if 20% < RF ≤ 25% and RFpositive > 10%, or RF > 25%, measurement is not reliable. Only reliable measurements were included for analysis of this endpoint. Here negative values indicate decline in volume of 30-degree hill vision. Safety analysis set. 99999= standard deviation was not evaluable as there was only 1 subject. 999999=data was not evaluable at given time point. n=number of subjects analysed at specific timepoint.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Month 6, 12 and 24

Notes:

[107] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was for Part 1, hence data was reported for Part 1 reporting arm groups only.

End point values	Part 1: BIIB112 Dose 1	Part 1: BIIB112 Dose 2	Part 1: BIIB112 Dose 3	Part 1: BIIB112 Dose 4
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	3	3	3
Units: decibel				
arithmetic mean (standard deviation)				
Baseline: Study Eye (n=0,0,0,0,1,1)	999999 (± 999999)	999999 (± 999999)	999999 (± 999999)	999999 (± 999999)
Baseline: Non-Study Eye (n=0,0,0,0,0,1)	999999 (± 999999)	999999 (± 999999)	999999 (± 999999)	999999 (± 999999)
Change at Month 6: Study Eye (n=0,0,0,0,0,1)	999999 (± 999999)	999999 (± 999999)	999999 (± 999999)	999999 (± 999999)
Change at Month 6: Non-Study Eye (n=0,0,0,0,0,1)	999999 (± 999999)	999999 (± 999999)	999999 (± 999999)	999999 (± 999999)
Change at Month 12: Study Eye (n=0,0,0,0,1,1),	999999 (± 999999)	999999 (± 999999)	9999999 (± 999999)	999999 (± 999999)
Change at Month 12: Non-Study Eye (n=0,0,0,0,0,1)	999999 (± 999999)	999999 (± 999999)	999999 (± 999999)	999999 (± 999999)
Change at Month 24: Study Eye (n=0,0,0,0,1,1)	999999 (± 999999)	999999 (± 999999)	999999 (± 999999)	999999 (± 999999)
Change at Month 24: Non-Study Eye (n=0,0,0,0,0,1)	999999 (± 999999)	999999 (± 999999)	999999 (± 999999)	999999 (± 999999)

End point values	Part 1: BIIB112 Dose 5	Part 1: BIIB112 Dose 6		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	3	3		
Units: decibel				
arithmetic mean (standard deviation)				
Baseline: Study Eye (n=0,0,0,0,1,1)	2.73 (± 999999)	5.07 (± 999999)		
Baseline: Non-Study Eye (n=0,0,0,0,0,1)	999999 (± 999999)	5.17 (± 999999)		
Change at Month 6: Study Eye (n=0,0,0,0,0,1)	999999 (± 999999)	-2.14 (± 99999)		
Change at Month 6: Non-Study Eye (n=0,0,0,0,0,1)	999999 (± 999999)	-1.10 (± 99999)		
Change at Month 12: Study Eye (n=0,0,0,0,1,1),	0.33 (± 999999)	-2.80 (± 99999)		
Change at Month 12: Non-Study Eye (n=0,0,0,0,0,1)	999999 (± 999999)	-1.02 (± 99999)		
Change at Month 24: Study Eye (n=0,0,0,0,1,1)	-1.89 (± 99999)	-3.08 (± 99999)		
Change at Month 24: Non-Study Eye (n=0,0,0,0,0,1)	999999 (± 999999)	-2.11 (± 99999)		

Statistical analyses

No statistical analyses for this end point

Secondary: Part 1: Change from Baseline in Volume of Full Field Hill of Vision

End point title	Part 1: Change from Baseline in Volume of Full Field Hill of Vision ^[108]
-----------------	--

End point description:

Visual field testing was performed to assess change in volume of full field of hill vision. Reliability Factor (RF)=number of false positive responses + number of false negative responses/number of false positive presentations + number of false negative presentations*100. If there are 0 responses, then RF value=0. RFpositive=number of false positive responses/number of false positive presentations*100. If RF ≤ 20% measurement is considered reliable. If 20% < RF ≤ 25% and RFpositive ≤ 10% measurement is also considered reliable. Otherwise if 20% < RF ≤ 25% and RFpositive > 10%, or RF > 25%, measurement is not reliable. Only reliable measurements were included for analysis of this endpoint. Here negative values indicate decline in volume of 30-degree hill vision. Safety analysis set. 99999= standard deviation was not evaluable as there was only 1 subject. 999999= data was not evaluable at given time point. n=number of subjects analysed at specific timepoint.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Month 6, 12, and 24

Notes:

[108] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was for Part 1, hence data was reported for Part 1 reporting arm groups only.

End point values	Part 1: BIIB112 Dose 1	Part 1: BIIB112 Dose 2	Part 1: BIIB112 Dose 3	Part 1: BIIB112 Dose 4
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	3	3	3
Units: decibel				
arithmetic mean (standard deviation)				
Baseline: Study Eye (n=0,0,0,0,1,1)	999999 (± 999999)	999999 (± 999999)	999999 (± 999999)	999999 (± 999999)
Baseline: Non-Study Eye (n=0,0,0,0,0,1)	999999 (± 999999)	999999 (± 999999)	999999 (± 999999)	999999 (± 999999)
Change at Month 6: Study Eye (n=0,0,0,0,0,1)	999999 (± 999999)	999999 (± 999999)	999999 (± 999999)	999999 (± 999999)
Change at Month 6: Non-Study Eye (n=0,0,0,0,0,1)	999999 (± 999999)	999999 (± 999999)	999999 (± 999999)	999999 (± 999999)
Change at Month 12: Study Eye (n=0,0,0,0,1,1)	999999 (± 999999)	999999 (± 999999)	999999 (± 999999)	999999 (± 999999)
Change at Month 12: Non-Study Eye (n=0,0,0,0,0,1)	999999 (± 999999)	999999 (± 999999)	999999 (± 999999)	999999 (± 999999)
Change at Month 24: Study Eye (n=0,0,0,0,1,1)	999999 (± 999999)	999999 (± 999999)	999999 (± 999999)	999999 (± 999999)
Change at Month 24: Non-Study Eye (n=0,0,0,0,0,1)	999999 (± 999999)	999999 (± 999999)	999999 (± 999999)	999999 (± 999999)

End point values	Part 1: BIIB112 Dose 5	Part 1: BIIB112 Dose 6		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	3	3		
Units: decibel				
arithmetic mean (standard deviation)				
Baseline: Study Eye (n=0,0,0,0,1,1)	15.77 (± 99999)	18.31 (± 99999)		
Baseline: Non-Study Eye (n=0,0,0,0,0,1)	99999 (± 999999)	23.41 (± 99999)		
Change at Month 6: Study Eye (n=0,0,0,0,0,1)	999999 (± 999999)	-0.86 (± 99999)		
Change at Month 6: Non-Study Eye (n=0,0,0,0,0,1)	999999 (± 999999)	-4.91 (± 99999)		
Change at Month 12: Study Eye (n=0,0,0,0,1,1)	1.29 (± 99999)	-2.98 (± 99999)		
Change at Month 12: Non-Study Eye (n=0,0,0,0,0,1)	999999 (± 999999)	-3.70 (± 99999)		
Change at Month 24: Study Eye (n=0,0,0,0,1,1)	-6.28 (± 99999)	-5.36 (± 99999)		
Change at Month 24: Non-Study Eye (n=0,0,0,0,0,1)	999999 (± 999999)	-7.87 (± 99999)		

Statistical analyses

No statistical analyses for this end point

Secondary: Part 1: Change from Baseline in Contrast Sensitivity

End point title	Part 1: Change from Baseline in Contrast Sensitivity ^[109]
-----------------	---

End point description:

Change in contrast sensitivity (CS) was assessed by Pelli-Robson chart which uses a single large letter size (20/60 optotype), with contrast varying across groups of letters. Chart uses letters (6 per line), arranged in groups whose contrast varies from high to low. Subjects read the letters, starting with the highest contrast, until they are unable to read two or three letters in a single group. Each group has three letters of the same contrast level, so there are three trials per contrast level. Subject is assigned a score based on the contrast of the last group in which two or three letters were correctly read. Score is a measure of the subject's log contrast sensitivity ranging from 0-2.25, with 0 being no letters read, and 2.25 being all letters read. Total CS score = [(total # letters correct - 3) x 0.05]. Safety analysis set consist of all subjects who received study treatment (vitrectomy/AAV8-RPGR). n=number of subjects analysed at specific timepoint.

End point type	Secondary
----------------	-----------

End point timeframe:

Part 1: Month 3, 6, 12 and 24

Notes:

[109] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was for Part 1, hence data was reported for Part 1 reporting arm groups only.

End point values	Part 1: BIIB112 Dose 1	Part 1: BIIB112 Dose 2	Part 1: BIIB112 Dose 3	Part 1: BIIB112 Dose 4
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	3	3	3
Units: Score on scale				
arithmetic mean (standard deviation)				
Baseline: Study Eye (n=3,3,3,3,3,3)	0.300 (± 0.1732)	0.533 (± 0.2309)	0.900 (± 0.1732)	0.883 (± 0.3884)
Baseline: Non-Study (n=3,3,3,3,3,3)	0.433 (± 0.2082)	0.583 (± 0.2255)	1.050 (± 0.2598)	0.933 (± 0.4646)
Change at Month 3: Study Eye (n=3,3,3,3,3,3)	0.167 (± 0.1528)	0.183 (± 0.2566)	0.150 (± 0.0866)	0.133 (± 0.1155)
Change at Month 3: Non-Study Eye (n=3,3,3,3,3,3)	0.000 (± 0.0000)	0.017 (± 0.4010)	0.050 (± 0.0500)	0.050 (± 0.0500)
Change at Month 6: Study Eye (n=3,3,3,3,3,3)	0.133 (± 0.2082)	0.067 (± 0.2363)	0.100 (± 0.1323)	0.133 (± 0.0577)
Change at Month 6: Non-Study Eye (n=3,3,3,3,3,3)	0.000 (± 0.1732)	0.033 (± 0.2255)	0.083 (± 0.0764)	0.050 (± 0.1000)
Change at Month 12: Study Eye (n=2,3,3,3,3,3)	0.100 (± 0.1414)	0.133 (± 0.3512)	-0.017 (± 0.1041)	0.183 (± 0.0577)
Change at Month 12: Non-Study Eye (n=2,3,3,3,3,3)	-0.100 (± 0.2828)	0.067 (± 0.3512)	0.000 (± 0.0000)	0.000 (± 0.0500)
Change at Month 24: Study Eye (n=3,3,3,3,3,3)	0.000 (± 0.2291)	0.017 (± 0.5965)	-0.100 (± 0.0000)	0.217 (± 0.1893)
Change at Month 24: Non-Study Eye (n=3,3,3,3,3,3)	-0.183 (± 0.1258)	0.117 (± 0.3884)	-0.100 (± 0.1732)	0.017 (± 0.2021)

End point values	Part 1: BIIB112 Dose 5	Part 1: BIIB112 Dose 6		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	3	3		
Units: Score on scale				
arithmetic mean (standard deviation)				
Baseline: Study Eye (n=3,3,3,3,3,3)	1.267 (± 0.0289)	1.067 (± 0.6110)		
Baseline: Non-Study (n=3,3,3,3,3,3)	1.350 (± 0.1803)	1.100 (± 0.3279)		
Change at Month 3: Study Eye (n=3,3,3,3,3,3)	-0.033 (± 0.4163)	-0.167 (± 0.3014)		
Change at Month 3: Non-Study Eye (n=3,3,3,3,3,3)	0.100 (± 0.0000)	0.000 (± 0.1000)		
Change at Month 6: Study Eye (n=3,3,3,3,3,3)	-0.183 (± 0.4072)	0.117 (± 0.2021)		
Change at Month 6: Non-Study Eye (n=3,3,3,3,3,3)	-0.100 (± 0.0500)	0.000 (± 0.0500)		
Change at Month 12: Study Eye (n=2,3,3,3,3,3)	-0.167 (± 0.6788)	-0.017 (± 0.3329)		
Change at Month 12: Non-Study Eye (n=2,3,3,3,3,3)	-0.100 (± 0.1323)	-0.050 (± 0.1323)		
Change at Month 24: Study Eye (n=3,3,3,3,3,3)	-0.217 (± 0.5346)	-0.117 (± 0.2466)		
Change at Month 24: Non-Study Eye (n=3,3,3,3,3,3)	-0.050 (± 0.1323)	-0.050 (± 0.0500)		

Statistical analyses

No statistical analyses for this end point

Secondary: Part 2: Percentage of Study Eyes with ≥ 7 dB Improvement from Baseline at ≥ 5 out of the 16 Central Loci in Microperimetry

End point title	Part 2: Percentage of Study Eyes with ≥ 7 dB Improvement from Baseline at ≥ 5 out of the 16 Central Loci in Microperimetry ^[110]
-----------------	---

End point description:

MAIA microperimetry assessment was measured in decibel (dB) using a 10-2 grid of 68 points. Each point was labelled as '< 0', '0' or a positive integer. The point labelled as '< 0' is assigned a value of '-1' by MAIA in the calculation. Improvement in Retinal Sensitivity in center grid was defined as an increase from baseline of 7 or more decibels in any 5 or more points out of the 16 central points. ITT analysis set included all subjects who were randomized, under the 3-arm randomization schedules. n=number of subjects analysed at specific timepoint.

End point type	Secondary
----------------	-----------

End point timeframe:

Month 1, 2, 3, 6 and 9

Notes:

[110] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was for Part 2, hence data was reported for Part 2 reporting arm groups only.

End point values	Part 2: Untreated Group	Part 2: BIIB112 Low Dose	Part 2: BIIB112 High Dose	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	9	10	10	
Units: percentage of study eyes				
number (confidence interval 80%)				
Month 1 (n=9,10,10)	22.2 (6.1 to 49.0)	30.0 (11.6 to 55.2)	40.0 (18.8 to 64.6)	
Month 2 (n=9,10,10)	22.2 (6.1 to 49.0)	30.0 (11.6 to 55.2)	50.0 (26.7 to 73.3)	
Month 3 (n=8,10,10)	12.5 (1.3 to 40.6)	30.0 (11.6 to 55.2)	60.0 (35.4 to 81.2)	
Month 6 (n=9,9,8)	22.2 (6.1 to 49.0)	33.3 (12.9 to 59.9)	62.5 (34.5 to 85.3)	
Month 9 (n=9,7,7)	22.2 (6.1 to 49.0)	28.6 (7.9 to 59.6)	42.9 (17.0 to 72.1)	

Statistical analyses

No statistical analyses for this end point

Secondary: Part 2: Percentage of Study Eyes with ≥ 7 dB Improvement from Baseline at ≥ 5 Out of the 68 Loci in Microperimetry

End point title	Part 2: Percentage of Study Eyes with ≥ 7 dB Improvement from Baseline at ≥ 5 Out of the 68 Loci in Microperimetry ^[111]
-----------------	---

End point description:

MAIA microperimetry assessment was measured in decibel (dB) using a 10-2 grid of 68 points. Each point was labelled as '< 0', '0' or a positive integer. The point labelled as '< 0' was assigned a value of '-1' by MAIA in the calculation. Improvement in Retinal Sensitivity in whole grid was defined as an increase from baseline of 7 or more decibels in any 5 or more points of the grid as a whole (68 points). ITT analysis set included all subjects who were randomized, under the 3-arm randomization schedules. n=number of subjects analysed at specific timepoint.

End point type	Secondary
----------------	-----------

End point timeframe:

Month 1, 2, 3, 6, 9 and 12

Notes:

[111] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was for Part 2, hence data was reported for Part 2 reporting arm groups only.

End point values	Part 2: Untreated Group	Part 2: BIIB112 Low Dose	Part 2: BIIB112 High Dose	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	9	10	10	
Units: percentage of study eyes				
number (confidence interval 80%)				
Month 1 (n=9,10,10)	33.3 (12.9 to 59.9)	60.0 (35.4 to 81.2)	40.0 (18.8 to 64.6)	
Month 2 (n=9,10,10)	22.2 (6.1 to 49.0)	80.0 (55.0 to 94.5)	80.0 (55.0 to 94.5)	
Month 3 (n=8,10,10)	25.0 (6.9 to 53.8)	80.0 (55.0 to 94.5)	70.0 (44.8 to 88.4)	
Month 6 (n=9,9,8)	33.3 (12.9 to 59.9)	77.8 (51.0 to 93.9)	100.0 (75.0 to 100.0)	
Month 9 (n=9,7,7)	33.3 (12.9 to 59.9)	85.7 (54.7 to 98.5)	71.4 (40.4 to 92.1)	
Month 12 (n=9,8,8)	33.3 (12.9 to 59.9)	62.5 (34.5 to 85.3)	62.5 (34.5 to 85.3)	

Statistical analyses

No statistical analyses for this end point

Secondary: Part 2: Change from Baseline in Mean Sensitivity of the 16 Central Loci

End point title	Part 2: Change from Baseline in Mean Sensitivity of the 16 Central Loci ^[112]
-----------------	--

End point description:

MAIA microperimetry assessment was measured in dB using a 10-2 grid of 68 points. Each point was labelled as '< 0', '0' or a positive integer. The point labelled as '< 0' was assigned a value of '-1' by MAIA in the calculation. Mean Sensitivity in center grid was defined as the mean in dB of the 16 points located in the center of the grid. Here negative values indicate a decline in retinal sensitivity. ITT analysis set included all subjects who were randomized, under the 3-arm randomization schedules. n=number of subjects analysed at specific timepoint.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Month 1, 2, 3, 6, 9 and 12

Notes:

[112] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was for Part 2, hence data was reported for Part 2 reporting arm groups only.

End point values	Part 2: Untreated Group	Part 2: BIIB112 Low Dose	Part 2: BIIB112 High Dose	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	9	10	10	
Units: decibel				
arithmetic mean (standard deviation)				
Baseline: Study Eye (n=9,10,10)	6.78 (± 3.488)	7.39 (± 5.207)	7.38 (± 3.095)	
Baseline: Non-Study Eye (n=9,10,10)	9.56 (± 3.321)	9.09 (± 5.003)	8.98 (± 3.583)	
Change at Month 1: Study Eye (n=9,10,10)	1.53 (± 3.086)	2.70 (± 3.731)	0.10 (± 5.723)	
Change at Month 1: Non-Study Eye (n=9,10,10)	-0.26 (± 1.692)	-0.76 (± 1.793)	-0.08 (± 0.834)	
Change at Month 2: Study Eye (n=9,10,10)	1.62 (± 2.846)	2.73 (± 4.360)	1.55 (± 5.886)	
Change at Month 2: Non-Study Eye (n=9,10,10)	-0.34 (± 2.027)	-0.44 (± 1.723)	0.26 (± 1.118)	
Change at Month 3: Study Eye (n=8,10,10)	1.17 (± 2.760)	2.77 (± 4.598)	1.00 (± 6.862)	
Change at Month 3: Non-Study Eye (n=8,10,10)	-1.24 (± 1.253)	0.07 (± 1.393)	-0.24 (± 0.500)	
Change at Month 6: Study Eye (n=9,9,8)	0.72 (± 3.208)	3.38 (± 4.770)	3.74 (± 3.931)	
Change at Month 6: Non-Study Eye (n=9,9,8)	-0.69 (± 2.199)	-0.35 (± 1.125)	-0.66 (± 0.702)	
Change at Month 9: Study Eye (n=9,7,7)	0.65 (± 3.272)	2.52 (± 4.619)	2.54 (± 6.317)	
Change at Month 9: Non-Study Eye (n=9,8,7)	-1.01 (± 1.943)	0.30 (± 1.654)	-0.54 (± 0.636)	
Change at Month 12: Study Eye (n=9,8,8)	-0.11 (± 4.446)	2.79 (± 4.663)	1.16 (± 5.660)	
Change at Month 12: Non-Study Eye (n=9,9,8)	-2.23 (± 4.018)	-0.44 (± 1.078)	-1.04 (± 1.292)	

Statistical analyses

No statistical analyses for this end point

Secondary: Part 2: Change from Baseline in Mean Sensitivity of the 68 Central Loci

End point title	Part 2: Change from Baseline in Mean Sensitivity of the 68 Central Loci ^[113]
-----------------	--

End point description:

MAIA microperimetry assessment was measured in decibel (dB) using a 10-2 grid of 68 points. Each point was labelled as '< 0', '0' or a positive integer. The point labelled as '< 0' was assigned a value of '-1' by MAIA in the calculation. Improvement in Retinal Sensitivity in whole grid was defined as an increase from baseline of 7 or more decibels in any 5 or more points of the grid as a whole (68 points). Here negative values indicate a decline in retinal sensitivity. ITT analysis set included all subjects who were randomized, under the 3-arm randomization schedules. n=number of subjects analysed at specific

timepoint.

End point type	Secondary
End point timeframe:	
Baseline, Month 1, 2, 3, 6, 9, and 12	

Notes:

[113] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was for Part 2, hence data was reported for Part 2 reporting arm groups only.

End point values	Part 2: Untreated Group	Part 2: BIIB112 Low Dose	Part 2: BIIB112 High Dose	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	9	10	10	
Units: decibel				
arithmetic mean (standard deviation)				
Baseline: Study Eye (n=9,10,10)	2.15 (± 2.182)	2.46 (± 1.911)	3.84 (± 2.138)	
Baseline: Non-Study Eye (n=9,10,10)	3.32 (± 2.539)	3.34 (± 2.092)	4.47 (± 2.331)	
Change at Month 1: Study Eye (n=9,10,10)	0.91 (± 1.389)	1.60 (± 2.225)	-0.07 (± 3.898)	
Change at Month 1: Non-Study Eye (n=9,10,10)	0.12 (± 1.214)	-0.46 (± 1.044)	-0.03 (± 0.850)	
Change at Month 2: Study Eye (n=9,10,10)	0.90 (± 0.972)	2.34 (± 2.353)	1.18 (± 3.367)	
Change at Month 2: Non-Study Eye (n=9,10,10)	0.30 (± 1.111)	-0.23 (± 0.859)	0.13 (± 0.668)	
Change at Month 3: Study Eye (n=8,10,10)	0.46 (± 1.064)	2.64 (± 2.962)	0.24 (± 3.962)	
Change at Month 3: Non-Study Eye (n=8,10,10)	-0.16 (± 0.743)	-0.03 (± 0.516)	-0.11 (± 0.619)	
Change at Month 6: Study Eye (n=9,9,8)	0.32 (± 1.301)	3.15 (± 3.283)	2.05 (± 3.007)	
Change at Month 6: Non-Study Eye (n=9,9,8)	-0.13 (± 1.283)	-0.27 (± 0.527)	-0.50 (± 0.632)	
Change at Month 9: Study Eye (n=9,7,7)	0.40 (± 1.456)	2.80 (± 3.116)	1.71 (± 3.605)	
Change at Month 9: Non-Study Eye (n=9,8,7)	-0.41 (± 1.150)	-0.05 (± 0.790)	0.09 (± 0.544)	
Change at Month 12: Study Eye (n=9,8,8)	0.11 (± 1.592)	2.79 (± 3.045)	0.89 (± 3.132)	
Change at Month 12: Non-Study Eye (n=9,9,8)	-0.84 (± 1.749)	-0.28 (± 0.476)	-0.35 (± 1.004)	

Statistical analyses

No statistical analyses for this end point

Secondary: Part 2: Change From Baseline in BCVA

End point title	Part 2: Change From Baseline in BCVA ^[114]
-----------------	---

End point description:

BCVA was assessed using the ETDRS VA chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. BCVA was to be reported as number of letters read correctly by the subject. An increase in the number of letters read correctly means that vision has improved. Here negative values indicate a decline in BCVA. ITT analysis

set consist of all subjects that were randomised under the 3-arm randomisation schedules. n=number of subjects analysed at specific timepoint.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Month 1, 2, 3, 6, 9, and 12

Notes:

[114] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was for Part 2, hence data was reported for Part 2 reporting arm groups only.

End point values	Part 2: Untreated Group	Part 2: BIIB112 Low Dose	Part 2: BIIB112 High Dose	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	9	10	10	
Units: letters				
arithmetic mean (standard deviation)				
Baseline: Study Eye (n=9,10,10)	68.78 (± 5.954)	65.90 (± 10.104)	68.20 (± 8.991)	
Baseline: Non-Study Eye (n=9,10,10)	72.89 (± 6.846)	68.50 (± 9.675)	68.80 (± 6.989)	
Change at Month 1: Study Eye (n=9,10,10)	0.44 (± 2.833)	1.60 (± 6.450)	0.60 (± 7.545)	
Change at Month 1: Non-Study Eye (n=9,10,10)	-0.89 (± 2.028)	0.00 (± 4.110)	3.80 (± 3.360)	
Change at Month 2: Study Eye (n=9,10,10)	0.22 (± 2.108)	-1.00 (± 12.392)	0.00 (± 8.957)	
Change at Month 2: Non-Study Eye (n=9,10,10)	-0.11 (± 1.269)	0.60 (± 2.836)	3.10 (± 2.644)	
Change at Month 3: Study Eye (n=8,10,10)	1.38 (± 2.615)	0.10 (± 6.540)	-0.30 (± 11.036)	
Change at Month 3: Non-Study Eye (n=8,10,10)	0.13 (± 2.642)	1.10 (± 2.470)	3.20 (± 2.860)	
Change at Month 6: Study Eye (n=9,9,8)	1.00 (± 2.000)	2.44 (± 5.003)	-0.38 (± 5.630)	
Change at Month 6: Non-Study Eye (n=9,9,8)	-1.56 (± 2.833)	0.67 (± 1.581)	1.00 (± 4.629)	
Change at Month 9: Study Eye (n=9,8,7)	0.44 (± 1.944)	-2.50 (± 14.263)	-0.57 (± 1.397)	
Change at Month 9: Non-Study Eye (n=9,8,7)	-1.78 (± 2.949)	1.00 (± 2.000)	1.71 (± 3.147)	
Change at Month 12: Study Eye (n=9,9,8)	0.22 (± 2.949)	-4.00 (± 17.436)	-0.75 (± 3.370)	
Change at Month 12: Non-Study Eye (n=9,9,7)	-4.11 (± 3.983)	0.89 (± 3.100)	2.14 (± 3.976)	

Statistical analyses

No statistical analyses for this end point

Secondary: Part 2: Change From Baseline in LLVA

End point title	Part 2: Change From Baseline in LLVA ^[115]
-----------------	---

End point description:

LLVA was measured by placing a 2.0-log-unit neutral density filter over the front of each eye and having

the subject read the normally illuminated ETDRS chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. LLVA was reported as number of letters read correctly by the subject. Here negative values indicate decline in LLVA. ITT analysis set included all subjects that were randomised under the 3-arm randomisation schedules. n=number of subjects analysed at specific timepoint.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Month 1, 3, 6, 9, and 12

Notes:

[115] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was for Part 2, hence data was reported for Part 2 reporting arm groups only.

End point values	Part 2: Untreated Group	Part 2: BIIB112 Low Dose	Part 2: BIIB112 High Dose	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	9 ^[116]	10 ^[117]	10 ^[118]	
Units: letters				
arithmetic mean (standard deviation)				
Baseline: Study Eye (n=9,10,10)	50.22 (± 13.349)	39.30 (± 22.246)	47.90 (± 14.970)	
Baseline: Non-Study Eye (n=9,10,10)	54.78 (± 11.872)	49.50 (± 19.127)	51.60 (± 9.524)	
Change at Month 1: Study Eye (n=9,10,10)	0.56 (± 7.618)	11.30 (± 16.918)	-1.30 (± 18.397)	
Change at Month 1: Non-Study Eye (n=9,10,10)	0.22 (± 5.215)	-3.00 (± 9.165)	3.50 (± 4.882)	
Change at Month 3: Study Eye (n=8,10,10)	3.63 (± 7.230)	8.10 (± 16.251)	-3.50 (± 22.609)	
Change at Month 3: Non-Study Eye (n=8,10,10)	-0.63 (± 8.158)	0.50 (± 3.749)	1.20 (± 3.553)	
Change at Month 6: Study Eye (n=9,9,8)	1.22 (± 7.032)	8.00 (± 18.581)	3.25 (± 14.636)	
Change at Month 6: Non-Study Eye (n=9,9,8)	0.11 (± 6.274)	-3.56 (± 8.472)	2.13 (± 2.850)	
Change at Month 9: Study Eye (n=9,8,7)	-1.78 (± 7.225)	8.38 (± 16.088)	6.00 (± 12.356)	
Change at Month 9: Non-Study Eye (n=9,8,7)	-3.11 (± 7.491)	-1.13 (± 6.749)	4.00 (± 4.082)	
Change at Month 12: Study Eye (n=9,9,8)	-2.22 (± 7.412)	5.11 (± 14.426)	-0.63 (± 11.575)	
Change at Month 12: Non-Study Eye (n=9,9,8)	-4.44 (± 7.002)	-3.56 (± 11.652)	-1.50 (± 4.309)	

Notes:

[116] - 'Number of Subjects Analyzed' signifies number of subjects analyzed in this endpoint.

[117] - 'Number of Subjects Analyzed' signifies number of subjects analyzed in this endpoint.

[118] - 'Number of Subjects Analyzed' signifies number of subjects analyzed in this endpoint.

Statistical analyses

No statistical analyses for this end point

Secondary: Part 2: Percentage of Eyes with a ≥15 Letter Increase From Baseline for BCVA

End point title	Part 2: Percentage of Eyes with a ≥15 Letter Increase From Baseline for BCVA ^[119]
-----------------	---

End point description:

BCVA was assessed using the ETDRS VA chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. BCVA was to be reported as number of letters read correctly by the subject. An increase in the number of letters read correctly means that vision has improved. ITT analysis set included all subjects that were randomised under the 3-arm randomisation schedules. n=number of subjects analysed at specific timepoint.

End point type	Secondary
----------------	-----------

End point timeframe:

Month 1, 2, 3, 6, 9, and 12

Notes:

[119] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was for Part 2, hence data was reported for Part 2 reporting arm groups only.

End point values	Part 2: Untreated Group	Part 2: BIIB112 Low Dose	Part 2: BIIB112 High Dose	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	9	10	10	
Units: percentage of eyes				
number (confidence interval 80%)				
Month 1: Study Eye (n=9,10,10)	0.0 (0.0 to 22.6)	0.0 (0.0 to 20.6)	10.0 (1.0 to 33.7)	
Month 1: Non-Study Eye (n=9,10,10)	0.0 (0.0 to 22.6)	0.0 (0.0 to 20.6)	0.0 (0.0 to 20.6)	
Month 2: Study Eye (n=9,10,10)	0.0 (0.0 to 22.6)	0.0 (0.0 to 20.6)	10.0 (1.0 to 33.7)	
Month 2: Non-Study Eye (n=9,10,10)	0.0 (0.0 to 22.6)	0.0 (0.0 to 20.6)	0.0 (0.0 to 20.6)	
Month 3: Study Eye (n=8,10,10)	0.0 (0.0 to 25.0)	0.0 (0.0 to 20.6)	10.0 (1.0 to 33.7)	
Month 3: Non-Study Eye (n=8,10,10)	0.0 (0.0 to 25.0)	0.0 (0.0 to 20.6)	0.0 (0.0 to 20.6)	
Month 6: Study Eye (n=9,9,8)	0.0 (0.0 to 22.6)	0.0 (0.0 to 22.6)	0.0 (0.0 to 25.0)	
Month 6: Non-Study Eye (n=9,9,8)	0.0 (0.0 to 22.6)	0.0 (0.0 to 22.6)	0.0 (0.0 to 25.0)	
Month 9: Study Eye (n=9,8,7)	0.0 (0.0 to 22.6)	0.0 (0.0 to 25.0)	0.0 (0.0 to 28.0)	
Month 9: Non-Study Eye (n=9,8,7)	0.0 (0.0 to 22.6)	0.0 (0.0 to 25.0)	0.0 (0.0 to 28.0)	
Month 12: Study Eye (n=9,9,8)	0.0 (0.0 to 22.6)	0.0 (0.0 to 22.6)	0.0 (0.0 to 25.0)	
Month 12: Non-Study Eye (n=9,9,7)	0.0 (0.0 to 22.6)	0.0 (0.0 to 22.6)	0.0 (0.0 to 28.0)	

Statistical analyses

No statistical analyses for this end point

Secondary: Part 2: Percentage of Eyes with a ≥ 15 Letter Increase From Baseline for LLVA

End point title	Part 2: Percentage of Eyes with a ≥ 15 Letter Increase From Baseline for LLVA ^[120]
-----------------	---

End point description:

LLVA was measured by placing a 2.0-log-unit neutral density filter over the front of each eye and having the subject read the normally illuminated ETDRS chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. LLVA was reported as number of letters read correctly by the subject. ITT analysis set included all subjects that were randomised under the 3-arm randomisation schedules. n=number of subjects analysed at specific timepoint.

End point type	Secondary
----------------	-----------

End point timeframe:

Month 1, 3, 6, 9, and 12

Notes:

[120] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was for Part 2, hence data was reported for Part 2 reporting arm groups only.

End point values	Part 2: Untreated Group	Part 2: BIIB112 Low Dose	Part 2: BIIB112 High Dose	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	9	10	10	
Units: percentage of eyes				
number (confidence interval 80%)				
Month 1: Study Eye (n=9,10,10)	0.0 (0.0 to 22.6)	40.0 (18.8 to 64.6)	20.0 (5.5 to 45.0)	
Month 1: Non-Study Eye (n=9,10,10)	0.0 (0.0 to 22.6)	0.0 (0.0 to 20.6)	10.0 (1.0 to 33.7)	
Month 3: Study Eye (n=8,10,10)	0.0 (0.0 to 25.0)	40.0 (18.8 to 64.6)	30.0 (11.6 to 55.2)	
Month 3: Non-Study Eye (n=8,10,10)	0.0 (0.0 to 25.0)	0.0 (0.0 to 20.6)	0.0 (0.0 to 20.6)	
Month 6: Study Eye (n=9,9,8)	0.0 (0.0 to 22.6)	33.3 (12.9 to 59.9)	12.5 (1.3 to 40.6)	
Month 6: Non-Study Eye (n=9,9,8)	0.0 (0.0 to 22.6)	0.0 (0.0 to 22.6)	0.0 (0.0 to 25.0)	
Month 9: Study Eye (n=9,8,7)	0.0 (0.0 to 22.6)	25.0 (6.9 to 53.8)	28.6 (7.9 to 59.6)	
Month 9: Non-Study Eye (n=9,8,7)	0.0 (0.0 to 22.6)	0.0 (0.0 to 25.0)	0.0 (0.0 to 28.0)	
Month 12: Study Eye (n=9,9,8)	0.0 (0.0 to 22.6)	33.3 (12.9 to 59.9)	12.5 (1.3 to 40.6)	
Month 12: Non-Study Eye (n=9,9,8)	0.0 (0.0 to 22.6)	0.0 (0.0 to 22.6)	0.0 (0.0 to 25.0)	

Statistical analyses

No statistical analyses for this end point

Secondary: Part 2: Percentage of Eyes with a ≥ 10 Letter Increase From Baseline for BCVA

End point title	Part 2: Percentage of Eyes with a ≥ 10 Letter Increase From Baseline for BCVA ^[121]
-----------------	---

End point description:

BCVA was assessed using the ETDRS VA chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. BCVA was to be reported as number of letters read correctly by the subject. An increase in the number of letters read

correctly means that vision has improved. ITT analysis set included all subjects that were randomised under the 3-arm randomisation schedules. n=number of subjects analysed at specific timepoint.

End point type	Secondary
----------------	-----------

End point timeframe:

Month 1, 2, 3, 6, 9, and 12

Notes:

[121] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was for Part 2, hence data was reported for Part 2 reporting arm groups only.

End point values	Part 2: Untreated Group	Part 2: BIIB112 Low Dose	Part 2: BIIB112 High Dose	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	9	10	10	
Units: percentage of eyes				
number (confidence interval 80%)				
Month 1: Study Eye (n=9,10,10)	0.0 (0.0 to 22.6)	0.0 (0.0 to 20.6)	10.0 (1.0 to 33.7)	
Month 1: Non-Study Eye (n=9,10,10)	0.0 (0.0 to 22.6)	0.0 (0.0 to 20.6)	10.0 (1.0 to 33.7)	
Month 2: Study Eye (n=9,10,10)	0.0 (0.0 to 22.6)	0.0 (0.0 to 20.6)	20.0 (5.5 to 45.0)	
Month 2: Non-Study Eye (n=9,10,10)	0.0 (0.0 to 22.6)	0.0 (0.0 to 20.6)	0.0 (0.0 to 20.6)	
Month 3: Study Eye (n=8,10,10)	0.0 (0.0 to 25.0)	0.0 (0.0 to 20.6)	10.0 (1.0 to 33.7)	
Month 3: Non-Study Eye (n=8,10,10)	0.0 (0.0 to 25.0)	0.0 (0.0 to 20.6)	0.0 (0.0 to 20.6)	
Month 6: Study Eye (n=9,9,8)	0.0 (0.0 to 22.6)	0.0 (0.0 to 22.6)	12.5 (1.3 to 40.6)	
Month 6: Non-Study Eye (n=9,9,8)	0.0 (0.0 to 22.6)	0.0 (0.0 to 22.6)	0.0 (0.0 to 25.0)	
Month 9: Study Eye (n=9,8,7)	0.0 (0.0 to 22.6)	0.0 (0.0 to 25.0)	0.0 (0.0 to 28.0)	
Month 9: Non-Study Eye (n=9,8,7)	0.0 (0.0 to 22.6)	0.0 (0.0 to 25.0)	0.0 (0.0 to 28.0)	
Month 12: Study Eye (n=9,9,8)	0.0 (0.0 to 22.6)	11.1 (1.2 to 36.8)	0.0 (0.0 to 25.0)	
Month 12: Non-Study Eye (n=9,9,7)	0.0 (0.0 to 22.6)	0.0 (0.0 to 22.6)	0.0 (0.0 to 28.0)	

Statistical analyses

No statistical analyses for this end point

Secondary: Part 2: Percentage of Eyes with a ≥ 10 Letter Increase From Baseline for LLVA

End point title	Part 2: Percentage of Eyes with a ≥ 10 Letter Increase From Baseline for LLVA ^[122]
-----------------	---

End point description:

LLVA was measured by placing a 2.0-log-unit neutral density filter over the front of each eye and having the subject read the normally illuminated ETDRS chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. LLVA

was reported as number of letters read correctly by the subject. ITT analysis set included all subjects that were randomised under the 3-arm randomisation schedules. n=number of subjects analysed at specific timepoint.

End point type	Secondary
End point timeframe:	
Month 1, 3, 6, 9, and 12	

Notes:

[122] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was for Part 2, hence data was reported for Part 2 reporting arm groups only.

End point values	Part 2: Untreated Group	Part 2: BIIB112 Low Dose	Part 2: BIIB112 High Dose	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	9	10	10	
Units: percentage of eyes				
number (confidence interval 80%)				
Month 1: Study Eye (n=9,10,10)	11.1 (1.2 to 36.8)	40.0 (18.8 to 64.6)	30.0 (11.6 to 55.2)	
Month 1: Non-Study Eye (n=9,10,10)	0.0 (0.0 to 22.6)	0.0 (0.0 to 20.6)	0.0 (0.0 to 20.6)	
Month 3: Study Eye (n=8,10,10)	25.0 (6.9 to 53.8)	40.0 (18.8 to 64.6)	30.0 (11.6 to 55.2)	
Month 3: Non-Study Eye (n=8,10,10)	12.5 (1.3 to 40.6)	0.0 (0.0 to 20.6)	0.0 (0.0 to 20.6)	
Month 6: Study Eye (n=9,9,8)	11.1 (1.2 to 36.8)	44.4 (21.0 to 69.9)	37.5 (14.7 to 65.5)	
Month 6: Non-Study Eye (n=9,9,8)	11.1 (1.2 to 36.8)	11.1 (1.2 to 36.8)	0.0 (0.0 to 25.0)	
Month 9: Study Eye (n=9,8,7)	11.1 (1.2 to 36.8)	37.5 (14.7 to 65.5)	28.6 (7.9 to 59.6)	
Month 9: Non-Study Eye (n=9,8,7)	11.1 (1.2 to 36.8)	12.5 (1.3 to 40.6)	14.3 (1.5 to 45.3)	
Month 12: Study Eye (n=9,9,8)	11.1 (1.2 to 36.8)	33.3 (12.9 to 59.9)	12.5 (1.3 to 40.6)	
Month 12: Non-Study Eye (n=9,9,8)	0.0 (0.0 to 22.6)	11.1 (1.2 to 36.8)	0.0 (0.0 to 25.0)	

Statistical analyses

No statistical analyses for this end point

Secondary: Part 2: Percentage of Eyes with a ≥ 5 Letter Increase From Baseline for BCVA

End point title	Part 2: Percentage of Eyes with a ≥ 5 Letter Increase From Baseline for BCVA ^[123]
-----------------	--

End point description:

BCVA was assessed using the ETDRS VA chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. BCVA was to be reported as number of letters read correctly by the subject. An increase in the number of letters read correctly means that vision has improved. ITT analysis set included all subjects that were randomised under the 3-arm randomisation schedules. n=number of subjects analysed at specific timepoint.

End point type	Secondary
----------------	-----------

End point timeframe:

Month 1, 2, 3, 6, 9, and 12

Notes:

[123] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was for Part 2, hence data was reported for Part 2 reporting arm groups only.

End point values	Part 2: Untreated Group	Part 2: BIIB112 Low Dose	Part 2: BIIB112 High Dose	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	9	10	10	
Units: percentage of eyes				
number (confidence interval 80%)				
Month 1: Study Eye (n=9,10,10)	0.0 (0.0 to 22.6)	60.0 (35.4 to 81.2)	20.0 (5.5 to 45.0)	
Month 1: Non-Study Eye (n=9,10,10)	0.0 (0.0 to 22.6)	10.0 (1.0 to 33.7)	40.0 (18.8 to 64.6)	
Month 2: Study Eye (n=9,10,10)	0.0 (0.0 to 22.6)	60.0 (35.4 to 81.2)	30.0 (11.6 to 55.2)	
Month 2: Non-Study Eye (n=9,10,10)	0.0 (0.0 to 22.6)	0.0 (0.0 to 22.6)	30.0 (11.6 to 55.2)	
Month 3: Study Eye (n=8,10,10)	12.5 (1.3 to 40.6)	20.0 (5.5 to 45.0)	30.0 (11.6 to 55.2)	
Month 3: Non-Study Eye (n=8,10,10)	0.0 (0.0 to 25.0)	0.0 (0.0 to 20.6)	20.0 (5.5 to 45.0)	
Month 6: Study Eye (n=9,9,8)	11.1 (1.2 to 36.8)	44.4 (21.0 to 69.9)	12.5 (1.3 to 40.6)	
Month 6: Non-Study Eye (n=9,9,8)	0.0 (0.0 to 22.6)	0.0 (0.0 to 22.6)	25.0 (6.9 to 53.8)	
Month 9: Study Eye (n=9,8,7)	0.0 (0.0 to 22.6)	37.5 (14.7 to 65.5)	0.0 (0.0 to 28.0)	
Month 9: Non-Study Eye (n=9,8,7)	0.0 (0.0 to 22.6)	0.0 (0.0 to 25.0)	42.9 (17.0 to 72.1)	
Month 12: Study Eye (n=9,9,8)	0.0 (0.0 to 22.6)	22.2 (6.1 to 49.0)	0.0 (0.0 to 25.0)	
Month 12: Non-Study Eye (n=9,9,7)	0.0 (0.0 to 22.6)	11.1 (1.2 to 36.8)	28.6 (7.9 to 59.6)	

Statistical analyses

No statistical analyses for this end point

Secondary: Part 2: Percentage of Eyes with a ≥ 5 Letter Increase From Baseline for LLVA

End point title	Part 2: Percentage of Eyes with a ≥ 5 Letter Increase From Baseline for LLVA ^[124]
-----------------	--

End point description:

LLVA was measured by placing a 2.0-log-unit neutral density filter over the front of each eye and having the subject read the normally illuminated ETDRS chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. LLVA was reported as number of letters read correctly by the subject. ITT analysis set included all subjects that were randomised under the 3-arm randomisation schedules. n=number of subjects analysed at specific timepoint.

End point type	Secondary
----------------	-----------

End point timeframe:

Month 1, 3, 6, 9, and 12

Notes:

[124] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was for Part 2, hence data was reported for Part 2 reporting arm groups only.

End point values	Part 2: Untreated Group	Part 2: BIIB112 Low Dose	Part 2: BIIB112 High Dose	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	9 ^[125]	10 ^[126]	10 ^[127]	
Units: percentage of eyes				
number (confidence interval 80%)				
Month 1: Study Eye (n=9,10,10)	22.2 (6.1 to 49.0)	60.0 (35.4 to 81.2)	40.0 (18.8 to 64.6)	
Month 1: Non-Study Eye (n=9,10,10)	22.2 (6.1 to 49.0)	30.0 (11.6 to 55.2)	30.0 (11.6 to 55.2)	
Month 3: Study Eye (n=8,10,10)	37.5 (14.7 to 65.5)	50.0 (26.7 to 73.3)	30.0 (11.6 to 55.2)	
Month 3: Non-Study Eye (n=8,10,10)	25.0 (6.9 to 53.8)	20.0 (5.5 to 45.0)	10.0 (1.0 to 33.7)	
Month 6: Study Eye (n=9,9,8)	44.4 (21.0 to 69.9)	66.7 (40.1 to 87.1)	50.0 (24.0 to 76.0)	
Month 6: Non-Study Eye (n=9,9,8)	22.2 (6.1 to 49.0)	11.1 (1.2 to 36.8)	25.0 (6.9 to 53.8)	
Month 9: Study Eye (n=9,8,7)	22.2 (6.1 to 49.0)	62.5 (34.5 to 85.3)	57.1 (27.9 to 83.0)	
Month 9: Non-Study Eye (n=9,8,7)	11.1 (1.2 to 36.8)	12.5 (1.3 to 40.6)	42.9 (17.0 to 72.1)	
Month 12: Study Eye (n=9,9,8)	22.2 (6.1 to 49.0)	44.4 (21.0 to 69.9)	12.5 (1.3 to 40.6)	
Month 12: Non-Study Eye (n=9,9,8)	11.1 (1.2 to 36.8)	22.2 (6.1 to 49.0)	0.0 (0.0 to 25.0)	

Notes:

[125] - 'Number of Subjects Analyzed' signifies number of subjects analyzed in this endpoint.

[126] - 'Number of Subjects Analyzed' signifies number of subjects analyzed in this endpoint.

[127] - 'Number of Subjects Analyzed' signifies number of subjects analyzed in this endpoint.

Statistical analyses

No statistical analyses for this end point

Secondary: Part 2: Percentage of Eyes with a ≥ 15 Letters Loss From Baseline for BCVA

End point title	Part 2: Percentage of Eyes with a ≥ 15 Letters Loss From Baseline for BCVA ^[128]
-----------------	--

End point description:

BCVA was assessed using the ETDRS VA chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. BCVA was to be reported as number of letters read correctly by the subject. An increase in the number of letters read correctly means that vision has improved. Safety analysis set consist of all subjects who received study treatment (vitrectomy/AAV8-RPGR). n=number of subjects analysed at specific timepoint.

End point type	Secondary
----------------	-----------

End point timeframe:

Month 1, 2, 3, 6, 9, and 12

Notes:

[128] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was for Part 2, hence data was reported for Part 2 reporting arm groups only.

End point values	Part 2: Untreated Group	Part 2: BIIB112 Low Dose	Part 2: BIIB112 High Dose	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	9	11	12	
Units: percentage of eyes				
number (confidence interval 80%)				
Month 1: Study Eye (n=9,11,12)	0.0 (0.0 to 22.6)	0.0 (0.0 to 18.9)	8.3 (0.9 to 28.7)	
Month 1: Non-Study Eye (n=9,11,12)	0.0 (0.0 to 22.6)	0.0 (0.0 to 18.9)	0.0 (0.0 to 17.5)	
Month 2: Study Eye (n=9,10,10)	0.0 (0.0 to 22.6)	10.0 (1.0 to 33.7)	0.0 (0.0 to 20.6)	
Month 2: Non-Study Eye (n=9,10,10)	0.0 (0.0 to 22.6)	0.0 (0.0 to 20.6)	0.0 (0.0 to 20.6)	
Month 3: Study Eye (n=8,11,12)	0.0 (0.0 to 25.0)	0.0 (0.0 to 18.9)	8.3 (0.9 to 28.7)	
Month 3: Non-Study Eye (n=8,11,12)	0.0 (0.0 to 25.0)	0.0 (0.0 to 18.9)	0.0 (0.0 to 17.5)	
Month 6: Study Eye (n=9,10,10)	0.0 (0.0 to 22.6)	0.0 (0.0 to 20.6)	0.0 (0.0 to 20.6)	
Month 6: Non-Study Eye (n=9,10,10)	0.0 (0.0 to 22.6)	0.0 (0.0 to 20.6)	0.0 (0.0 to 20.6)	
Month 9: Study Eye (n=9,9,9)	0.0 (0.0 to 22.6)	11.1 (1.2 to 36.8)	11.1 (1.2 to 36.8)	
Month 9: Non-Study Eye (n=9,9,9)	0.0 (0.0 to 22.6)	0.0 (0.0 to 22.6)	0.0 (0.0 to 22.6)	
Month 12: Study Eye (n=9,10,10)	0.0 (0.0 to 22.6)	10.0 (1.0 to 33.7)	0.0 (0.0 to 20.6)	
Month 12: Non-Study Eye (n=9,10,9)	0.0 (0.0 to 22.6)	0.0 (0.0 to 20.6)	0.0 (0.0 to 22.6)	

Statistical analyses

No statistical analyses for this end point

Secondary: Part 2: Percentage of Eyes with a ≥ 15 Letters Loss From Baseline for LLVA

End point title	Part 2: Percentage of Eyes with a ≥ 15 Letters Loss From Baseline for LLVA ^[129]
-----------------	--

End point description:

LLVA was measured by placing a 2.0-log-unit neutral density filter over the front of each eye and having the subject read the normally illuminated ETDRS chart. Initially, letters were read at a distance of 4 meters from the chart. If < 20 letters were read at 4 meters, testing at 1 meter was performed. LLVA was reported as number of letters read correctly by the subject. Safety analysis set included all subjects who received study treatment (vitrectomy/AAV8-RPGR). n=number of subjects analysed at specific timepoint.

End point type	Secondary
----------------	-----------

End point timeframe:

Month 1, 3, 6, 9, and 12

Notes:

[129] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was for Part 2, hence data was reported for Part 2 reporting arm groups only.

End point values	Part 2: Untreated Group	Part 2: BIIB112 Low Dose	Part 2: BIIB112 High Dose	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	9	11	12	
Units: percentage of eyes				
number (confidence interval 80%)				
Month 1: Study Eye (n=9,11,12)	0.0 (0.0 to 22.6)	0.0 (0.0 to 18.9)	33.3 (15.4 to 55.9)	
Month 1: Non-Study Eye (n=9,11,12)	0.0 (0.0 to 22.6)	18.2 (4.9 to 41.5)	0.0 (0.0 to 17.5)	
Month 3: Study Eye (n=8,11,12)	0.0 (0.0 to 25.0)	9.1 (1.0 to 31.0)	33.3 (15.4 to 55.9)	
Month 3: Non-Study Eye (n=8,11,12)	0.0 (0.0 to 25.0)	0.0 (0.0 to 18.9)	0.0 (0.0 to 17.5)	
Month 6: Study Eye (n=9,10,10)	0.0 (0.0 to 22.6)	20.0 (5.5 to 45.0)	20.0 (5.5 to 45.0)	
Month 6: Non-Study Eye(n=9,10,10)	0.0 (0.0 to 22.6)	10.0 (1.0 to 33.7)	0.0 (0.0 to 20.6)	
Month 9: Study Eye (n=9,9,9)	0.0 (0.0 to 22.6)	11.1 (1.2 to 36.8)	11.1 (1.2 to 36.8)	
Month 9: Non-Study Eye (n=9,9,9)	11.1 (1.2 to 36.8)	0.0 (0.0 to 22.6)	0.0 (0.0 to 22.6)	
Month 12: Study Eye (n=9,10,10)	0.0 (0.0 to 22.6)	10.0 (1.0 to 33.7)	20.0 (5.5 to 45.0)	
Month 12: Non-Study Eye (n=9,10,10)	0.0 (0.0 to 22.6)	10.0 (1.0 to 33.7)	0.0 (0.0 to 20.6)	

Statistical analyses

No statistical analyses for this end point

Secondary: Part 2: Percentage of Eyes with a ≥ 10 Letters Loss From Baseline for BCVA

End point title	Part 2: Percentage of Eyes with a ≥ 10 Letters Loss From Baseline for BCVA ^[130]
-----------------	--

End point description:

BCVA was assessed using the ETDRS VA chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. BCVA was to be reported as number of letters read correctly by the subject. An increase in the number of letters read correctly means that vision has improved. Safety analysis set consist of all subjects who received study treatment (vitrectomy/AAV8-RPGR). n=number of subjects analysed at specific timepoint.

End point type	Secondary
----------------	-----------

End point timeframe:

Month 1, 2, 3, 6, 9, and 12

Notes:

[130] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was for Part 2, hence data was reported for Part 2 reporting arm groups

only.

End point values	Part 2: Untreated Group	Part 2: BIIB112 Low Dose	Part 2: BIIB112 High Dose	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	9	11	12	
Units: percentage of eyes				
arithmetic mean (confidence interval 80%)				
Month 1: Study Eye (n=9,11,12)	0.0 (0.0 to 22.6)	9.1 (1.0 to 31.0)	8.3 (0.9 to 28.7)	
Month 1: Non-Study Eye (n=9,11,12)	0.0 (0.0 to 22.6)	0.0 (0.0 to 18.9)	0.0 (0.0 to 17.5)	
Month 2: Study Eye (n=9,10,10)	0.0 (0.0 to 22.6)	20.0 (5.5 to 45.0)	10.0 (1.0 to 33.7)	
Month 2: Non-Study Eye (n=9,10,10)	0.0 (0.0 to 22.6)	0.0 (0.0 to 20.6)	0.0 (0.0 to 20.6)	
Month 3: Study Eye (n=8,11,12)	0.0 (0.0 to 25.0)	9.1 (1.0 to 31.0)	8.3 (0.9 to 28.7)	
Month 3: Non-Study Eye (n=8,11,12)	0.0 (0.0 to 25.0)	0.0 (0.0 to 18.9)	0.0 (0.0 to 17.5)	
Month 6: Study Eye (n=9,10,10)	0.0 (0.0 to 22.6)	0.0 (0.0 to 20.6)	10.0 (1.0 to 33.7)	
Month 6: Non-Study Eye (n=9,10,10)	0.0 (0.0 to 22.6)	0.0 (0.0 to 20.6)	0.0 (0.0 to 20.6)	
Month 9: Study Eye (n=9,9,9)	0.0 (0.0 to 22.6)	11.1 (1.2 to 36.8)	11.1 (1.2 to 36.8)	
Month 9: Non-Study Eye (n=9,9,9)	0.0 (0.0 to 22.6)	0.0 (0.0 to 22.6)	0.0 (0.0 to 22.6)	
Month 12: Study Eye (n=9,10,10)	0.0 (0.0 to 22.6)	20.0 (5.5 to 45.0)	10.0 (1.0 to 33.7)	
Month 12: Non-Study Eye (n=9,10,9)	11.1 (1.2 to 36.8)	0.0 (0.0 to 20.6)	0.0 (0.0 to 22.6)	

Statistical analyses

No statistical analyses for this end point

Secondary: Part 2: Percentage of Eyes with a ≥ 10 Letters Loss From Baseline for LLVA

End point title	Part 2: Percentage of Eyes with a ≥ 10 Letters Loss From Baseline for LLVA ^[131]
-----------------	--

End point description:

LLVA was measured by placing a 2.0-log-unit neutral density filter over the front of each eye and having the subject read the normally illuminated ETDRS chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. LLVA was reported as number of letters read correctly by the subject. Safety analysis set included all subjects who received study treatment (vitrectomy/AAV8-RPGR). n=number of subjects analysed at specific timepoint.

End point type	Secondary
----------------	-----------

End point timeframe:

Month 1, 3, 6, 9, and 12

Notes:

[131] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was for Part 2, hence data was reported for Part 2 reporting arm groups only.

End point values	Part 2: Untreated Group	Part 2: BIIB112 Low Dose	Part 2: BIIB112 High Dose	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	9	11	12	
Units: percentage of eyes				
number (confidence interval 80%)				
Month 1: Study Eye (n=9,11,12)	11.1 (1.2 to 36.8)	0.0 (0.0 to 18.9)	33.3 (15.4 to 55.9)	
Month 1: Non-Study Eye (n=9,11,12)	0.0 (0.0 to 22.6)	18.2 (4.9 to 41.5)	0.0 (0.0 to 17.5)	
Month 3: Study Eye (n=8,11,12)	0.0 (0.0 to 25.0)	18.2 (4.9 to 41.5)	33.3 (15.4 to 55.9)	
Month 3: Non-Study Eye (n=8,11,12)	12.5 (1.3 to 40.6)	0.0 (0.0 to 18.9)	0.0 (0.0 to 17.5)	
Month 6: Study Eye (n=9,10,10)	0.0 (0.0 to 22.6)	20.0 (5.5 to 45.0)	20.0 (5.5 to 45.0)	
Month 6: Non-Study Eye (n=9,10,10)	0.0 (0.0 to 22.6)	20.0 (5.5 to 45.0)	0.0 (0.0 to 20.6)	
Month 9: Study Eye (n=9,9,9)	11.1 (1.2 to 36.8)	11.1 (1.2 to 36.8)	11.1 (1.2 to 36.8)	
Month 9: Non-Study Eye (n=9,9,9)	11.1 (1.2 to 36.8)	0.0 (0.0 to 22.6)	0.0 (0.0 to 22.6)	
Month 12: Study Eye (n=9,10,10)	0.0 (0.0 to 22.6)	10.0 (1.0 to 33.7)	30.0 (11.6 to 55.2)	
Month 12: Non-Study Eye (n=9,10,10)	33.3 (12.9 to 59.9)	10.0 (1.0 to 33.7)	0.0 (0.0 to 20.6)	

Statistical analyses

No statistical analyses for this end point

Secondary: Part 2: Percentage of Eyes with a ≥ 5 Letters Loss From Baseline for BCVA

End point title	Part 2: Percentage of Eyes with a ≥ 5 Letters Loss From Baseline for BCVA ^[132]
-----------------	---

End point description:

BCVA was assessed using the ETDRS VA chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. BCVA was to be reported as number of letters read correctly by the subject. An increase in the number of letters read correctly means that vision has improved. Safety analysis set consist of all subjects who received study treatment (vitrectomy/AAV8-RPGR). n=number of subjects analysed at specific timepoint.

End point type	Secondary
----------------	-----------

End point timeframe:

Month 1, 2, 3, 6, 9, and 12

Notes:

[132] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was for Part 2, hence data was reported for Part 2 reporting arm groups

only.

End point values	Part 2: Untreated Group	Part 2: BIIB112 Low Dose	Part 2: BIIB112 High Dose	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	9	11	12	
Units: percentage of eyes				
number (confidence interval 80%)				
Month 1: Study Eye (n=9,11,12)	11.1 (1.2 to 36.8)	9.1 (1.0 to 31.0)	33.3 (15.4 to 55.9)	
Month 1: Non-Study Eye (n=9,11,12)	11.1 (1.2 to 36.8)	9.1 (1.0 to 31.0)	0.0 (0.0 to 17.5)	
Month 2: Study Eye (n=9,10,10)	0.0 (0.0 to 22.6)	20.0 (5.5 to 45.0)	40.0 (18.8 to 64.6)	
Month 2: Non-Study Eye (n=9,10,10)	0.0 (0.0 to 22.6)	10.0 (1.0 to 33.7)	0.0 (0.0 to 20.6)	
Month 3: Study Eye (n=8,11,12)	0.0 (0.0 to 25.0)	18.2 (4.9 to 41.5)	33.3 (15.4 to 55.9)	
Month 3: Non-Study Eye (n=8,11,12)	0.0 (0.0 to 25.0)	18.2 (4.9 to 41.5)	0.0 (0.0 to 17.5)	
Month 6: Study Eye (n=9,10,10)	0.0 (0.0 to 22.6)	10.0 (1.0 to 33.7)	30.0 (11.6 to 55.2)	
Month 6: Non-Study Eye (n=9,10,10)	22.2 (6.1 to 49.0)	0.0 (0.0 to 20.6)	10.0 (1.0 to 33.7)	
Month 9: Study Eye (n=9,9,9)	22.2 (6.1 to 49.0)	0.0 (0.0 to 22.6)	0.0 (0.0 to 22.6)	
Month 9: Non-Study Eye (n=9,9,9)	22.2 (6.1 to 49.0)	0.0 (0.0 to 22.6)	0.0 (0.0 to 22.6)	
Month 12: Study Eye (n=9,10,10)	11.1 (1.2 to 36.8)	20.0 (5.5 to 45.0)	20.0 (5.5 to 45.0)	
Month 12: Non-Study Eye (n=9,10,9)	33.3 (12.9 to 59.9)	10.0 (1.0 to 33.7)	0.0 (0.0 to 22.6)	

Statistical analyses

No statistical analyses for this end point

Secondary: Part 2: Percentage of Eyes with a ≥ 5 Letters Loss From Baseline for LLVA

End point title	Part 2: Percentage of Eyes with a ≥ 5 Letters Loss From Baseline for LLVA ^[133]
-----------------	---

End point description:

LLVA was measured by placing a 2.0-log-unit neutral density filter over the front of each eye and having the subject read the normally illuminated ETDRS chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. LLVA was reported as number of letters read correctly by the subject. Safety analysis set included all subjects who received study treatment (vitrectomy/AAV8-RPGR). n=number of subjects analysed at specific timepoint.

End point type	Secondary
----------------	-----------

End point timeframe:

Month 1, 3, 6, 9, and 12

Notes:

[133] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was for Part 2, hence data was reported for Part 2 reporting arm groups only.

End point values	Part 2: Untreated Group	Part 2: BIIB112 Low Dose	Part 2: BIIB112 High Dose	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	9	11	12	
Units: percentage of eyes				
number (confidence interval 80%)				
Month 1: Study Eye (n=9,11,12)	33.3 (12.9 to 59.9)	18.2 (4.9 to 41.5)	41.7 (21.9 to 63.8)	
Month 1: Non-Study Eye (n=9,11,12)	33.3 (12.9 to 59.9)	36.4 (16.9 to 59.9)	0.0 (0.0 to 17.5)	
Month 3: Study Eye (n=8,11,12)	12.5 (1.3 to 40.6)	18.2 (4.9 to 41.5)	41.7 (21.9 to 63.8)	
Month 3: Non-Study Eye (n=8,11,12)	37.5 (14.7 to 65.5)	9.1 (1.0 to 31.0)	0.0 (0.0 to 17.5)	
Month 6: Study Eye (n=9,10,10)	22.2 (6.1 to 49.0)	20.0 (5.5 to 45.0)	30.0 (11.6 to 55.2)	
Month 6: Non-Study Eye (n=9,10,10)	33.3 (12.9 to 59.9)	50.0 (26.7 to 73.3)	0.0 (0.0 to 20.6)	
Month 9: Study Eye (n=9,9,9)	33.3 (12.9 to 59.9)	22.2 (6.1 to 49.0)	33.3 (12.9 to 59.9)	
Month 9: Non-Study Eye (n=9,9,9)	55.6 (30.1 to 79.0)	33.3 (12.9 to 59.9)	0.0 (0.0 to 22.6)	
Month 12: Study Eye (n=9,10,10)	55.6 (30.1 to 79.0)	30.0 (11.6 to 55.2)	40.0 (18.8 to 64.6)	
Month 12: Non-Study Eye (n=9,10,10)	44.4 (21.0 to 69.9)	40.0 (18.8 to 64.6)	30.0 (11.6 to 55.2)	

Statistical analyses

No statistical analyses for this end point

Secondary: Part 2: Percentage of Eyes with Change From Baseline >-5 Letters for BCVA

End point title	Part 2: Percentage of Eyes with Change From Baseline >-5 Letters for BCVA ^[134]
-----------------	--

End point description:

BCVA was assessed using the ETDRS VA chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. BCVA was to be reported as number of letters read correctly by the subject. An increase in the number of letters read correctly means that vision has improved. ITT analysis set included all subjects that were randomised under the 3-arm randomisation schedules. n=number of subjects analysed at specific timepoint.

End point type	Secondary
----------------	-----------

End point timeframe:

Month 1, 2, 3, 6, 9, and 12

Notes:

[134] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was for Part 2, hence data was reported for Part 2 reporting arm groups

only.

End point values	Part 2: Untreated Group	Part 2: BIIB112 Low Dose	Part 2: BIIB112 High Dose	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	9	10	10	
Units: percentage of eyes				
number (confidence interval 80%)				
Month 1: Study Eye (n=9,10,10)	88.9 (63.2 to 98.8)	90.0 (66.3 to 99.0)	70.0 (44.8 to 88.4)	
Month 1: Non-Study Eye (n=9,10,10)	88.9 (63.2 to 98.8)	90.0 (66.3 to 99.0)	100.0 (79.4 to 100.0)	
Month 2: Study Eye (n=9,10,10)	100.0 (77.4 to 100.0)	80.0 (55.0 to 94.5)	60.0 (35.4 to 81.2)	
Month 2: Non-Study Eye (n=9,10,10)	100.0 (77.4 to 100.0)	90.0 (66.3 to 99.0)	100.0 (79.4 to 100.0)	
Month 3: Study Eye (n=8,10,10)	100.0 (75.0 to 100.0)	80.0 (55.0 to 94.5)	70.0 (44.8 to 88.4)	
Month 3: Non-Study Eye (n=8,10,10)	100.0 (75.0 to 100.0)	90.0 (66.3 to 99.0)	100.0 (79.4 to 100.0)	
Month 6: Study Eye (n=9,9,8)	100.0 (77.4 to 100.0)	88.9 (63.2 to 98.8)	75.0 (46.2 to 93.1)	
Month 6: Non-Study Eye (n=9,9,8)	77.8 (51.0 to 93.9)	100.0 (77.4 to 100.0)	87.5 (59.4 to 98.7)	
Month 9: Study Eye (n=9,8,7)	100.0 (77.4 to 100.0)	75.0 (46.2 to 93.1)	100.0 (72.0 to 100.0)	
Month 9: Non-Study Eye (n=9,8,7)	77.8 (51.0 to 93.9)	100.0 (75.0 to 100.0)	100.0 (72.0 to 100.0)	
Month 12: Study Eye (n=9,9,8)	88.9 (63.2 to 98.8)	77.8 (51.0 to 93.9)	87.5 (59.4 to 98.7)	
Month 12: Non-Study Eye (n=9,9,7)	66.7 (40.1 to 87.1)	88.9 (63.2 to 98.8)	100.0 (72.0 to 100.0)	

Statistical analyses

No statistical analyses for this end point

Secondary: Part 2: Percentage of Eyes with Change From Baseline >-5 Letters for LLVA

End point title	Part 2: Percentage of Eyes with Change From Baseline >-5 Letters for LLVA ^[135]
End point description:	
LLVA was measured by placing a 2.0-log-unit neutral density filter over the front of each eye and having the subject read the normally illuminated ETDRS chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. LLVA was reported as number of letters read correctly by the subject. ITT analysis set included all subjects that were randomised under the 3-arm randomisation schedules. n=number of subjects analysed at specific timepoint.	
End point type	Secondary
End point timeframe:	
Month 1, 3, 6, 9, and 12	

Notes:

[135] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was for Part 2, hence data was reported for Part 2 reporting arm groups only.

End point values	Part 2: Untreated Group	Part 2: BIIB112 Low Dose	Part 2: BIIB112 High Dose	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	9 ^[136]	10 ^[137]	10 ^[138]	
Units: percentage of eyes				
number (confidence interval 80%)				
Month 1: Study Eye (n=9,10,10)	66.7 (40.1 to 87.1)	80.0 (55.0 to 94.5)	70.0 (44.8 to 88.4)	
Month 1: Non-Study Eye (n=9,10,10)	66.7 (40.1 to 87.1)	60.0 (35.4 to 81.2)	100.0 (79.4 to 100.0)	
Month 3: Study Eye (n=8,10,10)	87.5 (59.4 to 98.7)	80.0 (55.0 to 94.5)	60.0 (35.4 to 81.2)	
Month 3: Non-Study Eye (n=8,10,10)	62.5 (34.5 to 85.3)	100.0 (79.4 to 100.0)	100.0 (79.4 to 100.0)	
Month 6: Study Eye (n=9,9,8)	77.8 (51.0 to 93.9)	77.8 (51.0 to 93.9)	75.0 (46.2 to 93.1)	
Month 6: Non-Study Eye (n=9,9,8)	66.7 (40.1 to 87.1)	44.4 (21.0 to 69.9)	100.0 (75.0 to 100.0)	
Month 9: Study Eye (n=9,8,7)	66.7 (40.1 to 87.1)	75.0 (46.2 to 93.1)	71.4 (40.4 to 92.1)	
Month 9: Non-Study Eye (n=9,8,7)	44.4 (21.0 to 69.9)	62.5 (34.5 to 85.3)	100.0 (72.0 to 100.0)	
Month 12: Study Eye (n=9,9,8)	44.4 (21.0 to 69.9)	66.7 (40.1 to 87.1)	75.0 (46.2 to 93.1)	
Month 12: Non-Study Eye (n=9,9,8)	55.6 (30.1 to 79.0)	55.6 (30.1 to 79.0)	62.5 (34.5 to 85.3)	

Notes:

[136] - 'Number of Subjects Analyzed' signifies number of subjects analyzed in this endpoint.

[137] - 'Number of Subjects Analyzed' signifies number of subjects analyzed in this endpoint.

[138] - 'Number of Subjects Analyzed' signifies number of subjects analyzed in this endpoint.

Statistical analyses

No statistical analyses for this end point

Secondary: Part 2: Change from Baseline in Volume of 30-Degree Hill of Vision Assessed by Octopus 900

End point title	Part 2: Change from Baseline in Volume of 30-Degree Hill of Vision Assessed by Octopus 900 ^[139]
-----------------	---

End point description:

Visual field testing was performed to assess change in volume of 30-degree hill vision. Reliability Factor (RF)=number of false positive responses + number of false negative responses/number of false positive presentations + number of false negative presentations*100. If there are 0 responses, then RF value=0. RFpositive=number of false positive responses/number of false positive presentations*100. If RF ≤ 20% measurement is considered reliable. If 20% < RF ≤ 25% and RFpositive ≤ 10% measurement is also considered reliable. Otherwise if 20% < RF ≤ 25% and RFpositive > 10%, or RF > 25%, measurement is not reliable. Only reliable measurements were included for analysis of this endpoint. Here negative values indicate decline in the volume of 30-degree hill vision. ITT analysis set included all subjects that were randomised under the 3-arm randomisation schedules. n=number of subjects analysed at specific timepoint.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Month 3, 6 and 12

Notes:

[139] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was for Part 2, hence data was reported for Part 2 reporting arm groups only.

End point values	Part 2: Untreated Group	Part 2: BIIB112 Low Dose	Part 2: BIIB112 High Dose	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	9	10	10	
Units: decibel				
arithmetic mean (standard deviation)				
Baseline: Study Eye (n=8,10,10)	3.61 (± 3.436)	3.58 (± 2.549)	5.70 (± 3.161)	
Baseline: Non-Study Eye (n=8,10,10)	3.05 (± 3.223)	3.71 (± 2.668)	6.23 (± 2.956)	
Change at Month 3: Study Eye (n=7,10,8)	0.80 (± 1.236)	0.63 (± 1.162)	-0.01 (± 5.288)	
Change at Month 3: Non-Study Eye (n=7,10,10)	0.52 (± 1.315)	0.45 (± 0.759)	-0.02 (± 1.110)	
Change at Month 6: Study Eye (n=8,8,7)	0.13 (± 0.499)	0.57 (± 1.354)	-1.22 (± 1.566)	
Change at Month 6: Non-Study Eye (n=7,9,8)	0.20 (± 0.516)	0.30 (± 0.665)	0.19 (± 0.576)	
Change at Month 12: Study Eye (n=7,8,8)	-0.36 (± 0.615)	0.26 (± 1.164)	-1.91 (± 1.498)	
Change at Month 12: Non-Study Eye (n=7,8,8)	0.29 (± 0.487)	-0.10 (± 0.781)	-0.56 (± 0.337)	

Statistical analyses

No statistical analyses for this end point

Secondary: Part 2: Change from Baseline in Volume of Full Field Hill of Vision Assessed by Octopus 900

End point title	Part 2: Change from Baseline in Volume of Full Field Hill of Vision Assessed by Octopus 900 ^[140]
-----------------	--

End point description:

Visual field testing was performed to assess change in volume of full field of hill vision. Reliability Factor (RF)=number of false positive responses + number of false negative responses/number of false positive presentations + number of false negative presentations*100. If there are 0 responses, then RF value=0. RFpositive=number of false positive responses/number of false positive presentations*100. If RF ≤ 20% measurement is considered reliable. If 20% < RF ≤ 25% and RFpositive ≤ 10% measurement is also considered reliable. Otherwise if 20% < RF ≤ 25% and RFpositive > 10%, or RF > 25%, measurement is not reliable. Only reliable measurements were included for analysis of this endpoint. Here negative values indicate decline in volume of full field hill vision. ITT analysis set included all subjects that were randomised under the 3-arm randomisation schedules. n=number of subjects analysed at specific timepoint.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Month 3, 6 and 12

Notes:

[140] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was for Part 2, hence data was reported for Part 2 reporting arm groups only.

End point values	Part 2: Untreated Group	Part 2: BIIB112 Low Dose	Part 2: BIIB112 High Dose	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	9	10	10	
Units: decibel				
arithmetic mean (standard deviation)				
Baseline: Study Eye (n=8,10,10)	7.26 (± 8.624)	17.51 (± 17.302)	19.48 (± 16.248)	
Baseline: Non-Study Eye (n=8,10,10)	7.05 (± 8.821)	16.33 (± 16.803)	21.08 (± 17.560)	
Change at Month 3: Study Eye (n=7,10,8)	1.84 (± 3.168)	1.26 (± 3.327)	-0.10 (± 4.059)	
Change at Month 3: Non-Study Eye (n=7,10,10)	1.36 (± 2.460)	2.01 (± 2.832)	0.55 (± 3.097)	
Change at Month 6: Study Eye (n=8,8,7)	-0.35 (± 1.461)	0.98 (± 2.197)	1.52 (± 3.897)	
Change at Month 6: Non-Study Eye (n=7,9,8)	0.46 (± 1.124)	0.99 (± 2.324)	1.38 (± 2.526)	
Change at Month 12: Study Eye (n=7,8,8)	-1.18 (± 1.302)	0.81 (± 3.709)	-0.95 (± 3.992)	
Change at Month 12: Non-Study Eye (n=7,8,8)	0.66 (± 1.193)	0.28 (± 2.736)	-0.91 (± 2.001)	

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Up to Day 1344 (end of study)

Adverse event reporting additional description:

Safety analysis set consists of all subjects who received study treatment (vitrectomy/AAV8-RPGR).

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	23.1
--------------------	------

Reporting groups

Reporting group title	Part 1: BIIB112 Dose 1
-----------------------	------------------------

Reporting group description:

Followed by vitrectomy and retinal detachment in the study eye, subjects received a single Dose 1 (5×10^9 vector genomes {vg}) of BIIB112 by sub-retinal injection on Day 0 (surgery day).

Reporting group title	Part 1: BIIB112 Dose 2
-----------------------	------------------------

Reporting group description:

Followed by vitrectomy and retinal detachment in the study eye, subjects received a single Dose 2 (1×10^{10} vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).

Reporting group title	Part 1: BIIB112 Dose 3
-----------------------	------------------------

Reporting group description:

Followed by vitrectomy and retinal detachment in the study eye, subjects received a single Dose 3 (5×10^{10} vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).

Reporting group title	Part 1: BIIB112 Dose 4
-----------------------	------------------------

Reporting group description:

Followed by vitrectomy and retinal detachment in the study eye, subjects received a single Dose 4 (1×10^{11} vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).

Reporting group title	Part 1: BIIB112 Dose 5
-----------------------	------------------------

Reporting group description:

Followed by vitrectomy and retinal detachment in the study eye, subjects received a single Dose 5 (2.5×10^{11} vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).

Reporting group title	Part 1: BIIB112 Dose 6
-----------------------	------------------------

Reporting group description:

Followed by vitrectomy and retinal detachment in the study eye, subjects received a single Dose 6 (5×10^{11} vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).

Reporting group title	Part 2: Untreated
-----------------------	-------------------

Reporting group description:

Subjects received no intervention to allow for a controlled comparison.

Reporting group title	Part 2: BIIB112 Low Dose
-----------------------	--------------------------

Reporting group description:

Followed by vitrectomy and retinal detachment in the study eye, subjects received a single low dose (5×10^{10} vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).

Reporting group title	Part 2: BIIB112 High Dose
-----------------------	---------------------------

Reporting group description:

Followed by vitrectomy and retinal detachment in the study eye, subjects received a single high dose (2.5×10^{11} vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).

Serious adverse events	Part 1: BIIB112 Dose 1	Part 1: BIIB112 Dose 2	Part 1: BIIB112 Dose 3
Total subjects affected by serious adverse events			
subjects affected / exposed	1 / 3 (33.33%)	1 / 3 (33.33%)	0 / 3 (0.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Immune system disorders			
Anaphylactic reaction			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye disorders			
Noninfective retinitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Retinal detachment			
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subretinal fluid			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Visual acuity reduced			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Visual impairment			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Food poisoning			

subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Nephrolithiasis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Appendicitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Part 1: BIIB112 Dose 4	Part 1: BIIB112 Dose 5	Part 1: BIIB112 Dose 6
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	2 / 3 (66.67%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Immune system disorders			
Anaphylactic reaction			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye disorders			
Noninfective retinitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Retinal detachment			

subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subretinal fluid			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Visual acuity reduced			
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	1 / 3 (33.33%)
occurrences causally related to treatment / all	0 / 0	1 / 1	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Visual impairment			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Food poisoning			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Nephrolithiasis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Appendicitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Part 2: Untreated	Part 2: BIIB112 Low Dose	Part 2: BIIB112 High Dose
Total subjects affected by serious adverse events			
subjects affected / exposed	1 / 9 (11.11%)	3 / 11 (27.27%)	5 / 12 (41.67%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Immune system disorders			
Anaphylactic reaction			
subjects affected / exposed	0 / 9 (0.00%)	1 / 11 (9.09%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye disorders			
Noninfective retinitis			
subjects affected / exposed	0 / 9 (0.00%)	0 / 11 (0.00%)	1 / 12 (8.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Retinal detachment			
subjects affected / exposed	0 / 9 (0.00%)	1 / 11 (9.09%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subretinal fluid			
subjects affected / exposed	0 / 9 (0.00%)	0 / 11 (0.00%)	3 / 12 (25.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	3 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Visual acuity reduced			
subjects affected / exposed	0 / 9 (0.00%)	1 / 11 (9.09%)	2 / 12 (16.67%)
occurrences causally related to treatment / all	0 / 0	2 / 2	3 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Visual impairment			
subjects affected / exposed	0 / 9 (0.00%)	0 / 11 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Food poisoning			

subjects affected / exposed	0 / 9 (0.00%)	0 / 11 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Nephrolithiasis			
subjects affected / exposed	0 / 9 (0.00%)	0 / 11 (0.00%)	1 / 12 (8.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Appendicitis			
subjects affected / exposed	1 / 9 (11.11%)	0 / 11 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			
subjects affected / exposed	0 / 9 (0.00%)	1 / 11 (9.09%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Part 1: BIIB112 Dose 1	Part 1: BIIB112 Dose 2	Part 1: BIIB112 Dose 3
Total subjects affected by non-serious adverse events			
subjects affected / exposed	3 / 3 (100.00%)	3 / 3 (100.00%)	3 / 3 (100.00%)
Vascular disorders			
Hot flush			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hypertension			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Surgical and medical procedures			
Tooth extraction			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Immune system disorders			

Multiple allergies subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Seasonal allergy subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Respiratory, thoracic and mediastinal disorders			
Bronchiectasis subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Cough subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Dyspnoea subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Epistaxis subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Psychiatric disorders			
Depression subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Investigations			
Blood bilirubin increased subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Blood creatinine increased subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Blood glucose increased subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Blood triglycerides increased subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0

Intraocular pressure decreased subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	1 / 3 (33.33%) 1	0 / 3 (0.00%) 0
Intraocular pressure increased subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	1 / 3 (33.33%) 1	1 / 3 (33.33%) 1
Lymphocyte count decreased subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Neutrophil count increased subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Visual field tests abnormal subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Vitamin d decreased subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
White blood cell count increased subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Injury, poisoning and procedural complications			
Corneal abrasion subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	1 / 3 (33.33%) 1
Dysphotopsia subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Eye contusion subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	1 / 3 (33.33%) 1
Muscle rupture subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Ocular procedural complication			

subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Post procedural discomfort			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Post procedural inflammation			
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Post-traumatic neck syndrome			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Post-traumatic pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Procedural pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Skin laceration			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Suture related complication			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Cardiac disorders			
Atrial fibrillation			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Palpitations			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Nervous system disorders			
Dizziness			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Headache			

subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Paraesthesia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Tunnel vision			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Visual field defect			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Ear and labyrinth disorders			
Eustachian tube dysfunction			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Eye disorders			
Aniseikonia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Anterior chamber cell			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Anterior chamber flare			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Anterior chamber inflammation			
subjects affected / exposed	0 / 3 (0.00%)	2 / 3 (66.67%)	0 / 3 (0.00%)
occurrences (all)	0	2	0
Asthenopia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Blepharitis			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Blindness transient			

subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Cataract			
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Cataract subcapsular			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Choroidal detachment			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Chromatopsia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Conjunctival haemorrhage			
subjects affected / exposed	3 / 3 (100.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	3	0	0
Conjunctival hyperaemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Conjunctival irritation			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Conjunctival oedema			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Corneal deposits			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Cystoid macular oedema			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Delayed light adaptation			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Detachment of macular retinal			

pigment epithelium			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Diplopia			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Dry eye			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	1	0	1
Dyschromatopsia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Eye inflammation			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Eye pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Eye pruritus			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Eyelid oedema			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Eyelid ptosis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Foreign body sensation in eyes			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hypotony of eye			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Iridocyclitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1

Iritis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Lacrimation increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Lenticular pigmentation			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Macular fibrosis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Maculopathy			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Metamorphopsia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Noninfective retinitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Ocular discomfort			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Ocular hypertension			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Photophobia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Posterior capsule opacification			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Retinal artery embolism			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0

Retinal cyst			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Retinal degeneration			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Retinal deposits			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Retinal fovea disorder			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Retinal haemorrhage			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Retinal infiltrates			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Retinal oedema			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Retinal tear			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Retinal thickening			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Retinoschisis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Scleritis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Subretinal fluid			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1

Vision blurred subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Visual acuity reduced subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Visual impairment subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Vitreous cells subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Vitreous detachment subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Vitritis subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Gastrointestinal disorders			
Dyspepsia subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Nausea subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Stomatitis subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Vomiting subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Skin and subcutaneous tissue disorders			
Acne subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Erythema			

subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Night sweats			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Rash			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Urticaria			
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Musculoskeletal and connective tissue disorders			
Chondrocalcinosis pyrophosphate			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Muscle spasms			
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Pain in extremity			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Infections and infestations			
Bursitis infective			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Conjunctivitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Ear infection			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Gastroenteritis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hypopyon			

subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Infected dermal cyst			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Influenza			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Lower respiratory tract infection			
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Nasopharyngitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Upper respiratory tract infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Urinary tract infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Metabolism and nutrition disorders			
Hyperglycaemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0

Non-serious adverse events	Part 1: BIIB112 Dose 4	Part 1: BIIB112 Dose 5	Part 1: BIIB112 Dose 6
Total subjects affected by non-serious adverse events			
subjects affected / exposed	3 / 3 (100.00%)	3 / 3 (100.00%)	3 / 3 (100.00%)
Vascular disorders			
Hot flush			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hypertension			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Surgical and medical procedures			

Tooth extraction subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Immune system disorders Multiple allergies subjects affected / exposed occurrences (all) Seasonal allergy subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0 1 / 3 (33.33%) 1	0 / 3 (0.00%) 0 0 / 3 (0.00%) 0	0 / 3 (0.00%) 0 0 / 3 (0.00%) 0
Respiratory, thoracic and mediastinal disorders Bronchiectasis subjects affected / exposed occurrences (all) Cough subjects affected / exposed occurrences (all) Dyspnoea subjects affected / exposed occurrences (all) Epistaxis subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0 0 / 3 (0.00%) 0 0 / 3 (0.00%) 0 0 / 3 (0.00%) 0	0 / 3 (0.00%) 0 0 / 3 (0.00%) 0 0 / 3 (0.00%) 0 1 / 3 (33.33%) 1	0 / 3 (0.00%) 0 0 / 3 (0.00%) 0 0 / 3 (0.00%) 0 1 / 3 (33.33%) 1
Psychiatric disorders Depression subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Investigations Blood bilirubin increased subjects affected / exposed occurrences (all) Blood creatinine increased subjects affected / exposed occurrences (all) Blood glucose increased	0 / 3 (0.00%) 0 0 / 3 (0.00%) 0 0	0 / 3 (0.00%) 0 0 / 3 (0.00%) 0 0	0 / 3 (0.00%) 0 0 / 3 (0.00%) 0 0

subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	1 / 3 (33.33%) 1
Blood triglycerides increased subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Intraocular pressure decreased subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Intraocular pressure increased subjects affected / exposed occurrences (all)	1 / 3 (33.33%) 3	1 / 3 (33.33%) 1	2 / 3 (66.67%) 4
Lymphocyte count decreased subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Neutrophil count increased subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	1 / 3 (33.33%) 1
Visual field tests abnormal subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Vitamin d decreased subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
White blood cell count increased subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Injury, poisoning and procedural complications			
Corneal abrasion subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Dysphotopsia subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	1 / 3 (33.33%) 1
Eye contusion			

subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Muscle rupture			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Ocular procedural complication			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Post procedural discomfort			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Post procedural inflammation			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Post-traumatic neck syndrome			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Post-traumatic pain			
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Procedural pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Skin laceration			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Suture related complication			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Cardiac disorders			
Atrial fibrillation			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Palpitations			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0

Nervous system disorders			
Dizziness			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Headache			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Paraesthesia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Tunnel vision			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Visual field defect			
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	1 / 3 (33.33%)
occurrences (all)	0	1	1
Ear and labyrinth disorders			
Eustachian tube dysfunction			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Eye disorders			
Aniseikonia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Anterior chamber cell			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	2
Anterior chamber flare			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Anterior chamber inflammation			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Asthenopia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Blepharitis			

subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Blindness transient			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Cataract			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Cataract subcapsular			
subjects affected / exposed	1 / 3 (33.33%)	1 / 3 (33.33%)	0 / 3 (0.00%)
occurrences (all)	1	1	0
Choroidal detachment			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Chromatopsia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Conjunctival haemorrhage			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Conjunctival hyperaemia			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Conjunctival irritation			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Conjunctival oedema			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Corneal deposits			
subjects affected / exposed	1 / 3 (33.33%)	1 / 3 (33.33%)	0 / 3 (0.00%)
occurrences (all)	1	1	0
Cystoid macular oedema			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Delayed light adaptation			

subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Detachment of macular retinal pigment epithelium			
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Diplopia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Dry eye			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Dyschromatopsia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Eye inflammation			
subjects affected / exposed	1 / 3 (33.33%)	2 / 3 (66.67%)	0 / 3 (0.00%)
occurrences (all)	1	3	0
Eye pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Eye pruritus			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Eyelid oedema			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Eyelid ptosis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Foreign body sensation in eyes			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Hypotony of eye			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1

Iridocyclitis			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Iritis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Lacrimation increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Lenticular pigmentation			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Macular fibrosis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Maculopathy			
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Metamorphopsia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Noninfective retinitis			
subjects affected / exposed	1 / 3 (33.33%)	1 / 3 (33.33%)	3 / 3 (100.00%)
occurrences (all)	1	2	5
Ocular discomfort			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Ocular hypertension			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Photophobia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Posterior capsule opacification			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1

Retinal artery embolism			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Retinal cyst			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Retinal degeneration			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Retinal deposits			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Retinal fovea disorder			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Retinal haemorrhage			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Retinal infiltrates			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Retinal oedema			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Retinal tear			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Retinal thickening			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Retinoschisis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Scleritis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0

Subretinal fluid			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Vision blurred			
subjects affected / exposed	1 / 3 (33.33%)	1 / 3 (33.33%)	1 / 3 (33.33%)
occurrences (all)	1	1	1
Visual acuity reduced			
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Visual impairment			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Vitreous cells			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Vitreous detachment			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Vitritis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal disorders			
Dyspepsia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Nausea			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Stomatitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Vomiting			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Skin and subcutaneous tissue disorders			

Acne			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Erythema			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Night sweats			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Rash			
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Urticaria			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal and connective tissue disorders			
Chondrocalcinosis pyrophosphate			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Muscle spasms			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Pain in extremity			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Infections and infestations			
Bursitis infective			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Conjunctivitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Ear infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Gastroenteritis			

subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Hypopyon			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Infected dermal cyst			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Influenza			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Lower respiratory tract infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Nasopharyngitis			
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Upper respiratory tract infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	4
Urinary tract infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Metabolism and nutrition disorders			
Hyperglycaemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0

Non-serious adverse events	Part 2: Untreated	Part 2: BIIB112 Low Dose	Part 2: BIIB112 High Dose
Total subjects affected by non-serious adverse events			
subjects affected / exposed	5 / 9 (55.56%)	11 / 11 (100.00%)	12 / 12 (100.00%)
Vascular disorders			
Hot flush			
subjects affected / exposed	0 / 9 (0.00%)	0 / 11 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Hypertension			

subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	1 / 11 (9.09%) 1	0 / 12 (0.00%) 0
Surgical and medical procedures Tooth extraction subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	1 / 11 (9.09%) 1	0 / 12 (0.00%) 0
Immune system disorders Multiple allergies subjects affected / exposed occurrences (all) Seasonal allergy subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0 0 / 9 (0.00%) 0	0 / 11 (0.00%) 0 0 / 11 (0.00%) 0	1 / 12 (8.33%) 1 0 / 12 (0.00%) 0
Respiratory, thoracic and mediastinal disorders Bronchiectasis subjects affected / exposed occurrences (all) Cough subjects affected / exposed occurrences (all) Dyspnoea subjects affected / exposed occurrences (all) Epistaxis subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0 2 / 9 (22.22%) 2 0 / 9 (0.00%) 0 0 / 9 (0.00%) 0	0 / 11 (0.00%) 0 0 / 11 (0.00%) 0 0 / 11 (0.00%) 0 0 / 11 (0.00%) 0	1 / 12 (8.33%) 1 0 / 12 (0.00%) 0 1 / 12 (8.33%) 1 0 / 12 (0.00%) 0
Psychiatric disorders Depression subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 11 (0.00%) 0	1 / 12 (8.33%) 1
Investigations Blood bilirubin increased subjects affected / exposed occurrences (all) Blood creatinine increased	0 / 9 (0.00%) 0	1 / 11 (9.09%) 1	0 / 12 (0.00%) 0

subjects affected / exposed	0 / 9 (0.00%)	1 / 11 (9.09%)	0 / 12 (0.00%)
occurrences (all)	0	2	0
Blood glucose increased			
subjects affected / exposed	0 / 9 (0.00%)	1 / 11 (9.09%)	0 / 12 (0.00%)
occurrences (all)	0	1	0
Blood triglycerides increased			
subjects affected / exposed	0 / 9 (0.00%)	1 / 11 (9.09%)	0 / 12 (0.00%)
occurrences (all)	0	1	0
Intraocular pressure decreased			
subjects affected / exposed	0 / 9 (0.00%)	1 / 11 (9.09%)	0 / 12 (0.00%)
occurrences (all)	0	1	0
Intraocular pressure increased			
subjects affected / exposed	1 / 9 (11.11%)	6 / 11 (54.55%)	5 / 12 (41.67%)
occurrences (all)	1	7	7
Lymphocyte count decreased			
subjects affected / exposed	0 / 9 (0.00%)	0 / 11 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Neutrophil count increased			
subjects affected / exposed	0 / 9 (0.00%)	2 / 11 (18.18%)	4 / 12 (33.33%)
occurrences (all)	0	2	4
Visual field tests abnormal			
subjects affected / exposed	0 / 9 (0.00%)	0 / 11 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Vitamin d decreased			
subjects affected / exposed	0 / 9 (0.00%)	1 / 11 (9.09%)	0 / 12 (0.00%)
occurrences (all)	0	1	0
White blood cell count increased			
subjects affected / exposed	0 / 9 (0.00%)	1 / 11 (9.09%)	2 / 12 (16.67%)
occurrences (all)	0	1	2
Injury, poisoning and procedural complications			
Corneal abrasion			
subjects affected / exposed	0 / 9 (0.00%)	0 / 11 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Dysphotopsia			

subjects affected / exposed	0 / 9 (0.00%)	0 / 11 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Eye contusion			
subjects affected / exposed	0 / 9 (0.00%)	0 / 11 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Muscle rupture			
subjects affected / exposed	0 / 9 (0.00%)	0 / 11 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Ocular procedural complication			
subjects affected / exposed	0 / 9 (0.00%)	0 / 11 (0.00%)	2 / 12 (16.67%)
occurrences (all)	0	0	2
Post procedural discomfort			
subjects affected / exposed	0 / 9 (0.00%)	0 / 11 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Post procedural inflammation			
subjects affected / exposed	0 / 9 (0.00%)	0 / 11 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Post-traumatic neck syndrome			
subjects affected / exposed	0 / 9 (0.00%)	0 / 11 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Post-traumatic pain			
subjects affected / exposed	0 / 9 (0.00%)	0 / 11 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Procedural pain			
subjects affected / exposed	0 / 9 (0.00%)	1 / 11 (9.09%)	2 / 12 (16.67%)
occurrences (all)	0	1	2
Skin laceration			
subjects affected / exposed	1 / 9 (11.11%)	0 / 11 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Suture related complication			
subjects affected / exposed	0 / 9 (0.00%)	0 / 11 (0.00%)	5 / 12 (41.67%)
occurrences (all)	0	0	5
Cardiac disorders			
Atrial fibrillation			
subjects affected / exposed	1 / 9 (11.11%)	0 / 11 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0

Palpitations subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 1	0 / 11 (0.00%) 0	0 / 12 (0.00%) 0
Nervous system disorders			
Dizziness subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 11 (0.00%) 0	1 / 12 (8.33%) 1
Headache subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	2 / 11 (18.18%) 3	1 / 12 (8.33%) 2
Paraesthesia subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 11 (0.00%) 0	1 / 12 (8.33%) 1
Tunnel vision subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 11 (0.00%) 0	1 / 12 (8.33%) 1
Visual field defect subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 11 (0.00%) 0	1 / 12 (8.33%) 1
Ear and labyrinth disorders			
Eustachian tube dysfunction subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 11 (0.00%) 0	0 / 12 (0.00%) 0
Eye disorders			
Aniseikonia subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	1 / 11 (9.09%) 1	1 / 12 (8.33%) 1
Anterior chamber cell subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	5 / 11 (45.45%) 5	6 / 12 (50.00%) 8
Anterior chamber flare subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 11 (0.00%) 0	3 / 12 (25.00%) 3
Anterior chamber inflammation subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	2 / 11 (18.18%) 2	0 / 12 (0.00%) 0
Asthenopia			

subjects affected / exposed	0 / 9 (0.00%)	0 / 11 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Blepharitis			
subjects affected / exposed	0 / 9 (0.00%)	0 / 11 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Blindness transient			
subjects affected / exposed	0 / 9 (0.00%)	1 / 11 (9.09%)	0 / 12 (0.00%)
occurrences (all)	0	1	0
Cataract			
subjects affected / exposed	1 / 9 (11.11%)	3 / 11 (27.27%)	3 / 12 (25.00%)
occurrences (all)	1	4	3
Cataract subcapsular			
subjects affected / exposed	0 / 9 (0.00%)	1 / 11 (9.09%)	1 / 12 (8.33%)
occurrences (all)	0	1	1
Choroidal detachment			
subjects affected / exposed	0 / 9 (0.00%)	0 / 11 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Chromatopsia			
subjects affected / exposed	0 / 9 (0.00%)	0 / 11 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Conjunctival haemorrhage			
subjects affected / exposed	0 / 9 (0.00%)	6 / 11 (54.55%)	9 / 12 (75.00%)
occurrences (all)	0	7	11
Conjunctival hyperaemia			
subjects affected / exposed	0 / 9 (0.00%)	1 / 11 (9.09%)	1 / 12 (8.33%)
occurrences (all)	0	1	2
Conjunctival irritation			
subjects affected / exposed	0 / 9 (0.00%)	0 / 11 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Conjunctival oedema			
subjects affected / exposed	0 / 9 (0.00%)	1 / 11 (9.09%)	0 / 12 (0.00%)
occurrences (all)	0	2	0
Corneal deposits			
subjects affected / exposed	0 / 9 (0.00%)	0 / 11 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Cystoid macular oedema			

subjects affected / exposed	0 / 9 (0.00%)	2 / 11 (18.18%)	4 / 12 (33.33%)
occurrences (all)	0	2	4
Delayed light adaptation			
subjects affected / exposed	0 / 9 (0.00%)	0 / 11 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Detachment of macular retinal pigment epithelium			
subjects affected / exposed	0 / 9 (0.00%)	0 / 11 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Diplopia			
subjects affected / exposed	0 / 9 (0.00%)	0 / 11 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Dry eye			
subjects affected / exposed	0 / 9 (0.00%)	0 / 11 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Dyschromatopsia			
subjects affected / exposed	0 / 9 (0.00%)	1 / 11 (9.09%)	0 / 12 (0.00%)
occurrences (all)	0	1	0
Eye inflammation			
subjects affected / exposed	0 / 9 (0.00%)	1 / 11 (9.09%)	2 / 12 (16.67%)
occurrences (all)	0	1	3
Eye pain			
subjects affected / exposed	0 / 9 (0.00%)	2 / 11 (18.18%)	2 / 12 (16.67%)
occurrences (all)	0	2	6
Eye pruritus			
subjects affected / exposed	0 / 9 (0.00%)	0 / 11 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Eyelid oedema			
subjects affected / exposed	0 / 9 (0.00%)	0 / 11 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Eyelid ptosis			
subjects affected / exposed	0 / 9 (0.00%)	0 / 11 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Foreign body sensation in eyes			
subjects affected / exposed	0 / 9 (0.00%)	1 / 11 (9.09%)	2 / 12 (16.67%)
occurrences (all)	0	1	2

Hypotony of eye			
subjects affected / exposed	0 / 9 (0.00%)	0 / 11 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Iridocyclitis			
subjects affected / exposed	0 / 9 (0.00%)	0 / 11 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Iritis			
subjects affected / exposed	0 / 9 (0.00%)	2 / 11 (18.18%)	2 / 12 (16.67%)
occurrences (all)	0	2	3
Lacrimation increased			
subjects affected / exposed	0 / 9 (0.00%)	0 / 11 (0.00%)	2 / 12 (16.67%)
occurrences (all)	0	0	2
Lenticular pigmentation			
subjects affected / exposed	0 / 9 (0.00%)	0 / 11 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Macular fibrosis			
subjects affected / exposed	0 / 9 (0.00%)	0 / 11 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Maculopathy			
subjects affected / exposed	0 / 9 (0.00%)	0 / 11 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Metamorphopsia			
subjects affected / exposed	0 / 9 (0.00%)	1 / 11 (9.09%)	4 / 12 (33.33%)
occurrences (all)	0	1	4
Noninfective retinitis			
subjects affected / exposed	0 / 9 (0.00%)	1 / 11 (9.09%)	3 / 12 (25.00%)
occurrences (all)	0	1	3
Ocular discomfort			
subjects affected / exposed	0 / 9 (0.00%)	2 / 11 (18.18%)	2 / 12 (16.67%)
occurrences (all)	0	2	2
Ocular hypertension			
subjects affected / exposed	0 / 9 (0.00%)	0 / 11 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	2
Photophobia			
subjects affected / exposed	0 / 9 (0.00%)	0 / 11 (0.00%)	2 / 12 (16.67%)
occurrences (all)	0	0	2

Posterior capsule opacification subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 1	0 / 11 (0.00%) 0	0 / 12 (0.00%) 0
Retinal artery embolism subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	1 / 11 (9.09%) 1	0 / 12 (0.00%) 0
Retinal cyst subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	1 / 11 (9.09%) 1	0 / 12 (0.00%) 0
Retinal degeneration subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 11 (0.00%) 0	1 / 12 (8.33%) 2
Retinal deposits subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 11 (0.00%) 0	2 / 12 (16.67%) 2
Retinal fovea disorder subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 11 (0.00%) 0	1 / 12 (8.33%) 1
Retinal haemorrhage subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	1 / 11 (9.09%) 1	2 / 12 (16.67%) 2
Retinal infiltrates subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 11 (0.00%) 0	0 / 12 (0.00%) 0
Retinal oedema subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 11 (0.00%) 0	0 / 12 (0.00%) 0
Retinal tear subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 11 (0.00%) 0	2 / 12 (16.67%) 2
Retinal thickening subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 11 (0.00%) 0	1 / 12 (8.33%) 1
Retinoschisis subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	1 / 11 (9.09%) 1	0 / 12 (0.00%) 0

Scleritis			
subjects affected / exposed	0 / 9 (0.00%)	1 / 11 (9.09%)	0 / 12 (0.00%)
occurrences (all)	0	1	0
Subretinal fluid			
subjects affected / exposed	0 / 9 (0.00%)	2 / 11 (18.18%)	3 / 12 (25.00%)
occurrences (all)	0	2	3
Vision blurred			
subjects affected / exposed	1 / 9 (11.11%)	1 / 11 (9.09%)	4 / 12 (33.33%)
occurrences (all)	1	1	7
Visual acuity reduced			
subjects affected / exposed	0 / 9 (0.00%)	1 / 11 (9.09%)	3 / 12 (25.00%)
occurrences (all)	0	1	3
Visual impairment			
subjects affected / exposed	0 / 9 (0.00%)	1 / 11 (9.09%)	3 / 12 (25.00%)
occurrences (all)	0	1	4
Vitreous cells			
subjects affected / exposed	0 / 9 (0.00%)	1 / 11 (9.09%)	4 / 12 (33.33%)
occurrences (all)	0	1	4
Vitreous detachment			
subjects affected / exposed	0 / 9 (0.00%)	0 / 11 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Vitritis			
subjects affected / exposed	0 / 9 (0.00%)	0 / 11 (0.00%)	5 / 12 (41.67%)
occurrences (all)	0	0	6
Gastrointestinal disorders			
Dyspepsia			
subjects affected / exposed	0 / 9 (0.00%)	1 / 11 (9.09%)	0 / 12 (0.00%)
occurrences (all)	0	1	0
Nausea			
subjects affected / exposed	0 / 9 (0.00%)	1 / 11 (9.09%)	2 / 12 (16.67%)
occurrences (all)	0	1	2
Stomatitis			
subjects affected / exposed	0 / 9 (0.00%)	0 / 11 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Vomiting			

subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	1 / 11 (9.09%) 1	1 / 12 (8.33%) 1
Skin and subcutaneous tissue disorders			
Acne			
subjects affected / exposed	0 / 9 (0.00%)	0 / 11 (0.00%)	3 / 12 (25.00%)
occurrences (all)	0	0	4
Erythema			
subjects affected / exposed	0 / 9 (0.00%)	0 / 11 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Night sweats			
subjects affected / exposed	0 / 9 (0.00%)	0 / 11 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Rash			
subjects affected / exposed	0 / 9 (0.00%)	0 / 11 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Urticaria			
subjects affected / exposed	0 / 9 (0.00%)	0 / 11 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal and connective tissue disorders			
Chondrocalcinosis pyrophosphate			
subjects affected / exposed	0 / 9 (0.00%)	0 / 11 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Muscle spasms			
subjects affected / exposed	0 / 9 (0.00%)	0 / 11 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Pain in extremity			
subjects affected / exposed	0 / 9 (0.00%)	1 / 11 (9.09%)	0 / 12 (0.00%)
occurrences (all)	0	1	0
Infections and infestations			
Bursitis infective			
subjects affected / exposed	1 / 9 (11.11%)	0 / 11 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Conjunctivitis			
subjects affected / exposed	0 / 9 (0.00%)	1 / 11 (9.09%)	0 / 12 (0.00%)
occurrences (all)	0	1	0
Ear infection			

subjects affected / exposed	0 / 9 (0.00%)	1 / 11 (9.09%)	0 / 12 (0.00%)
occurrences (all)	0	1	0
Gastroenteritis			
subjects affected / exposed	0 / 9 (0.00%)	0 / 11 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Hypopyon			
subjects affected / exposed	0 / 9 (0.00%)	1 / 11 (9.09%)	0 / 12 (0.00%)
occurrences (all)	0	1	0
Infected dermal cyst			
subjects affected / exposed	0 / 9 (0.00%)	1 / 11 (9.09%)	0 / 12 (0.00%)
occurrences (all)	0	1	0
Influenza			
subjects affected / exposed	0 / 9 (0.00%)	0 / 11 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Lower respiratory tract infection			
subjects affected / exposed	0 / 9 (0.00%)	1 / 11 (9.09%)	0 / 12 (0.00%)
occurrences (all)	0	2	0
Nasopharyngitis			
subjects affected / exposed	0 / 9 (0.00%)	2 / 11 (18.18%)	0 / 12 (0.00%)
occurrences (all)	0	3	0
Upper respiratory tract infection			
subjects affected / exposed	0 / 9 (0.00%)	2 / 11 (18.18%)	0 / 12 (0.00%)
occurrences (all)	0	2	0
Urinary tract infection			
subjects affected / exposed	1 / 9 (11.11%)	0 / 11 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Metabolism and nutrition disorders			
Hyperglycaemia			
subjects affected / exposed	1 / 9 (11.11%)	1 / 11 (9.09%)	0 / 12 (0.00%)
occurrences (all)	1	1	0

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
01 December 2016	Updated exclusion criteria to include time frame (3 months) within which subjects were to be compliant with the use of barrier contraception.
26 May 2017	Updated inclusion criteria for BCVA in maximum tolerated dose (MTD) cohort to allow inclusion of a wider study population in this cohort. LLVA and full field stimulus threshold added as additional assessments, in order to provide additional data to measure changes in disease progression over time. Removed microperimetry assessment at visit 4 because utility of the assessment at this timepoint was expected to be low. Updated schedule of procedures to include triplicate testing at screening/baseline, year 1, and early termination (ET) visit for EDTRS BCVA, LLVA, microperimetry, and visual fields. Triplicates were added to improve data quality by mitigating potential learning effects and providing a measure of test-retest variability. Added a corticosteroid compliance review to clarify that corticosteroid compliance would be monitored. Screening/baseline visit timing changed from within 4 weeks of visit 2 (± 2 weeks) to within 8 weeks of visit 2 (± 2 weeks) in order to provide more flexibility in scheduling subsequent visits.
15 December 2017	Study design updated to confirm assessment of Cohort 4 (1×10^{11} vg) as standard, with potential Cohorts 5 (2.5×10^{11} vg) and 6 (5×10^{11} vg) to allow wider dose exploration, if appropriate. Study design updated to include additional visits 10 (Month 18) and 11 (Year 2) to allow longer duration of post-treatment follow-up (24 months in total), in line with feedback from regulatory agencies. Updated MTD cohort eligibility criteria to include subjects ≥ 10 years of age, to allow inclusion of a wider study population in this cohort. Updated eligibility criteria to specify that ellipsoid zone (EZ) at screening must be within the borders of the spectral domain optical coherence tomography (SD-OCT) scan, to ensure that subjects have active disease within the macular region (without which the central reading center was unable to adequately grade the SD-OCT images which would negatively impact secondary study endpoints). DLT definition updated to exclude events related to the surgical procedure, to ensure only genuine cases of DLTs were identified and reported. Removed several study assessments from specific visits, e.g., blood pressure and pulse (visits 5, 9, and ET), viral shedding (visit 6), fundus autofluorescence (Visit 4), triplicate microperimetry and visual field assessments (visits 9 and ET). Following feedback from the central reading center and several study sites, the utility of the assessments at these specific timepoints was considered low.
16 January 2018	Updated inclusion criteria to clarify and allow the consent of male subjects ≥ 10 years who would require parental permission and subject assent (if applicable). Exclusion criteria (use of contraception method) was clarified for male subjects ≥ 10 years to include "if applicable". Removal of the following study procedures at visits 5, 11, and ET: blood pressure and pulse; collection of safety blood samples.
18 May 2018	Added the expansion of an active-control cohort of subjects in Part II to occur concurrently with the expansion of the MTD cohort in a randomized, double-masked fashion, in order to provide greater efficacy information through a comparison of low- and high-dose outcomes. Clarified the consent procedures for subjects under 10 years of age. Removed assessments of LLVA, blood pressure, pulse, and safety blood sampling at various visits as there was no rationale for the assessments and it lessened the burden on the site. Clarified the primary endpoint in Part I regarding the incidence of DLTs and AEs. Specified timepoints for the secondary endpoints for precision of analysis. Cohorts 5 and 6 in part I altered from optional to protocol-defined due to a lack of DLTs observed in the ongoing study cohorts 1 to 4. Specified that if DLTs were observed in cohort 5, no escalation to cohort 6 would occur.

16 November 2018	Clarified that dose 5 and 3 from part I were now defined as high (2.5×10^{11} vg) and low (5×10^{10} vg) dose arms in Part II, based on rationale that these were most likely to define safety and efficacy. Added a third untreated arm to better establish efficacy and safety of gene therapy. Specified that subjects were to be randomized in a 1:1:1 allocation, with double masking to dose in treated arm, and masked assessments of efficacy. Study duration shortened to 12 months of follow-up for part II dose expansion because a long-term follow up study was initiated to continue follow-up of AAV8 RPGR-treated subjects from 12 months out to 5 years. Phase 1 subjects were still followed for 24 months and then also invited to participate in long-term study. Endpoints and inclusion criteria separated for parts I and II to improve clarity. Endpoints were also updated for both parts I and II. Added microperimetry at 3 months as an efficacy endpoint in part II. Added an inclusion range for microperimetry to part II to assure inclusion of subjects with modifiable disease and avoid inclusion of those with microperimetry values subject to ceiling effects. Removed reading test, color vision, and full field stimulus threshold assessments due to the excessive burden of study visits on subjects, and limited value of these assessments in understanding both disease and effects of the treatment. Modified steroid regimen to improve safety and to prevent potential inflammatory response to therapy. A standardized adult dose was selected, the taper lengthened, and a 2-month visit added to assess participants at the end of the steroid therapy. A standardized adult dose was selected, taper lengthened, and a 2-month visit added to assess subjects at the end of the steroid therapy. Added information of the procedures related to unmasking in compliance with good clinical practices (GCP). Serious adverse events (SAE) reporting changed from within 7 days to immediately, per regional recommendations.
10 December 2018	Clarified the procedures and requirements for assessments performed at each visit compared with the schedule of study procedures: Added footnotes for BCVA assessment, immunogenicity sampling, and corticosteroid review to the in-text footnotes and schedule of study procedures; Removed fundus photography from visits 6 and 7; Removed viral shedding assessment from visit 6; Added autofluorescence assessment to the unscheduled visit.
18 December 2018	Modified the unmasking information to adhere more closely to good clinical practice (GCP). Added mobility test to the early termination (ET) visit list of procedures, to be conducted if feasible.
08 March 2019	Changed the date from which subjective ophthalmic assessments were made by a masked assessor from Month 1 (visit 5) to Month 3 (visit 6), to ensure that any residual signs or symptoms related to the procedure had completely resolved and did not unmask the assessor. Corrected a typographical error in the doses during the steroid tapering regimen.
14 August 2019	Added an administrative interim analysis after all part II subjects completed 3 months of post treatment follow-up, to enable continued alignment with regulatory agencies on the acceptability of the approach taken in evaluating the safety and efficacy of AAV8 RPGR. Modified the following inclusion and exclusion criteria. Removed the requirement that participants have a measurable EZ on optical coherence imaging, to allow the broader study of XLRP participants without a measurable EZ. Documentation of a positive genetic screen updated to specify that a pathogenic mutation must have been present for clarification of test results from genetic screening. Specified that participants must achieve a BCVA \geq 34 letters in both eyes and not just the study eye, to exclude monocular participants or participants with very poor vision in the fellow eye. Updated criteria to exclude participants who were unsuitable candidates for surgery for any reason. Improved the study masking language and descriptions of the specific assessments that must be conducted in a masked fashion. Added a description of the maintenance of masking of study teams during the interim analysis (IA) proceedings. Removed adaptive optics-optical coherence tomography (AO-OCT) assessments due to lack of operational feasibility. Changed some statistical analyses and endpoints. Updated the protocol template language regarding safety assessments to include better definitions of SAEs and reporting of SAEs, consistent with other protocols. Better defined the SAE of vision loss post treatment, particularly regarding the timing. Added a description of the DMC for Part II.

10 October 2019	Increased the maximum time period between the baseline/screening visit and the day of surgery (visit 2) from 8 weeks to 12 weeks, to provide operational flexibility for the sites and investigators and to minimize subject burden.
01 October 2020	Reduced the sample size to 29 subjects; study drug expired at the end of September 2019, and it was not possible to extend the shelf-life or use a new drug supply without causing significant delay to the study. This change resulted in multiple updates throughout the study design and statistical analyses sections of the protocol. Removed the requirement for an IA because it was no longer deemed necessary. Removed month 9 from the timepoints at which the endpoint of fundus autofluorescence was assessed (in both parts I), because it was added in error. Updated Part II secondary endpoints to separate the central 16-loci microperimetry mean change from baseline from the 68-loci microperimetry mean change from baseline. More granularity was needed for this endpoint as multiple analysis were to be conducted on this measure. Removed months 1, 2, and 9 timepoints from the part II endpoints of visual field since this is in error given that they are not collected at these timepoints. Added the timepoints for microperimetry and safety and secondary efficacy assessments in the description of study design with the schedule of assessments table. Added text providing instructions in case of missed final visits. Corrected the no observed adverse effect level (NOAEL) from greater than to equal to 3.54×10^9 vg/eye. Updated text to clarify that efficacy assessments were only masked at certain timepoints, not throughout the study. Clarified the definition of the end of study.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported

Online references

<http://www.ncbi.nlm.nih.gov/pubmed/32094925>